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ABSTRACT 
 Vibrio vulnificus is a marine bacterium capable of causing severe and fatal illness in 
susceptible people.  The primary virulence factor is a capsular polysaccharide (CPS) that allows 
the bacteria to evade the host immune system.  Two phenotypic forms were previously known to 
exist, opaque (virulent) and translucent (avirulent), and had been shown to undergo spontaneous 
phase variation, each switching to the other phenotype.  Provided here is the first report of a third 
phenotype, rugose.  The rugose variant is dry and wrinkled compared to the smooth colony 
morphology of the opaque and translucent forms.  Both opaque and translucent strains produce 
rugose variants that are similar in some ways, but show important differences between the two.  
Rugose V. vulnificus produce copious amounts of rugose exopolysaccharide (EPS) that allows 
them to form well-defined biofilms in attachment to glass, as a pellicle on the surface of broth, 
and as a 3-dimensional colony of distinct architecture.  The rugose forms survived better in 
normal human serum than did their opaque and translucent parents, while only the translucent 
parent and its rugose variant survived exposure to chlorine.  It is proposed that opaque-derived 
rugose variants also produce CPS, in addition to EPS, and that it is the CPS that actually confers 
susceptibility to chlorine.  Five genes associated with CPS and/or EPS production were 
expressed by all phase variants at all points of the life cycle.  Also reported here is a group of 
genes, the rugose gene cluster, differentially expressed by the three phenotypes.  Opaque and 
translucent forms expressed genes in this cluster at low levels or not at all, while the rugose 
variants expressed all of these genes at higher levels throughout exponential growth.  As biofilms 
have been shown to protect bacteria from adverse environmental conditions and the rugose 
variants produce robust biofilms, this form may contribute to the survival of this bacteria in its 
natural environment.  Future study of these genes should provide insight into the expression and 
 x
regulation of the rugose phenotype and the resulting biofilms, as well as survival and virulence 
of V. vulnificus.     
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CHAPTER 1: 
 
INTRODUCTION 
 1
 Vibrio vulnificus, an opportunistic human pathogen, is a Gram-negative, motile 
bacterium that is found in both estuarine and marine environments around the world.  When first 
reported,  it was placed in the genus Beneckea based on DNA hybridization, G+C content of 45 
to 48%, and the presence of a single, sheathed, polar flagellum (1.68).  After being isolated from 
clinical samples and differentiated from Vibrio parahaemolyticus, it was referred to as the “L+” 
or “lactose-positive Vibrio” until given its current name [vulner (L), wound] in 1979 (1.24).   
This organism is found as a contaminant in oysters as well as other seafood and is 
capable of causing a rapidly fulminating primary septicemia [reviewed by Haq et al. (1.31)] 
when raw seafood, especially oysters, is consumed by individuals with a predisposing health 
condition. Liver disease, alcoholism, diabetes, hemochromatosis, or a compromised immune 
system are conditions that will place a person at particular risk of developing a septicemia that 
can be fatal within 48 hours in approximately 50% of the cases.   A second serious illness, 
wound infections [reviewed by Oliver (1.59)], can result when a wound comes in contact with 
contaminated sea water or shellfish.  These infections can progress quickly and may require 
surgical debridement or amputation of the affected limb unless treatment is initiated promptly.  
Gastroenteritis, characterized by vomiting and diarrhea, is a less severe medical condition that 
can result from the ingestion of seafood containing this bacterium.  In this illness, the bacteria 
can be isolated from stool samples but not from blood.  Overall, V. vulnificus infections do not 
occur as often as those caused by other Vibrio species, but this bacterium causes the majority of 
fatalities associated with seafood consumption in the United States (1.9, 1.53). 
 In addition to isolation from clinical cases, V. vulnificus has been isolated from coastal 
waters around the world, sediment, seafood including crustaceans and mollusks, and in 
association with plankton [reviewed by Pruzzo et al. (1.63)].  While found throughout the 
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warmer months of the year, this organism has been reported to be almost undetectable in 
seawater during the cooler months (1.45, 1.62, 1.98).  There are several reports that when water 
temperatures drop below 10oC, V. vulnificus can enter a “viable but non-culturable” (VBNC) 
state [reviewed by Oliver (1.58) and Rice et al. (1.70)].  Questions have arisen as to whether the 
VBNC state is a true part of the life cycle, as is sporulation in Gram-positive bacteria, or if it is 
instead an indicator of impending death.  Cells in the VBNC state will not grow on media that 
normally support the growth of V. vulnificus, but they do retain identifiable indications that they 
are still metabolically active.  Also, resuscitation of VBNC cells has been reported, both upon 
temperature upshift in vitro as well as when passaged through mice pre-treated with 
supplemental iron.  The apparent ability of these VBNC cells to resuscitate after entry into a host 
is troubling, especially where food safety and public health are concerned (1.58, 1.63, 1.70).   
V. vulnificus strains have been classified using traditional and molecular methods in 
attempts to distinguish virulent strains from avirulent strains.  Traditional characterizations 
include biotypes, capsular polysaccharide (CPS) serotypes and carbotypes, and lipopoly-
saccharide (LPS; O-antigen) serotypes.  Molecular characterizations include ribotyping, pulsed-
field gel electrophoresis (PFGE) for DNA fingerprinting, multilocus enzyme electophoresis 
(MLEE), multilocus sequence typing (MLST), polymerase chain reaction (PCR) of 16S rRNA 
gene sequences, and randomly amplified polymorphic DNA (RAPD) PCR (1.8, 1.29, 1.30, 1.72).   
Biotype 1 strains are indole positive, express numerous LPS types (1.48), show at least 
66 MLST types (1.8), and are pathogenic in humans.  Biotype 2 strains are indole negative, 
express a single LPS type [serovar E (1.6)], show only four MLST types (1.8), and are 
pathogenic in eels primarily, but do infect humans on occasion.  Biotype 3 strains, recently 
isolated from people who had handled or eaten St. Peter’s fish (Tilapia spp.) in Israel (1.7), are 
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indole positive, lactose, cellobiose, citrate, and salicin negative (biotypes 1 and 2 are positive for 
these four tests), show only one MLST type, and are reported to be genetically identical hybrids 
of biotype 1 and biotype 2 (1.8).   
Attempts to classify biotype 1 strains by CPS type have been hampered by the large 
number of highly variable CPS types reported: 94 different carbotypes from 120 strains (1.12, 
1.33) and at least ten different serotypes (1.79).  Similarly, LPS types of biotype 1 strains show 
considerable variation.  Martin and Siebeling (1.48) devised a limited monoclonal antibody 
serotyping system that recognized five distinct LPS types and one hybrid type.  When this 
system was used to type a large number of strains from environmental, retail, and clinical 
sources, 39 to 59% of the samples could not be typed, indicating a high degree of variation in 
LPS types among V. vulnificus isolates (1.107).  Interestingly, clinical isolates were typed with 
the highest frequency and a large percentage of them showed the same serotype.  It was 
suggested that strains expressing this serotype may be better adapted to the human host and thus 
more virulent (1.107).  While oysters have been shown to yield a plethora of different strains of 
V. vulnificus (1.11, 1.36, 1.89), only single strains have been isolated from blood samples from 
individual patients, suggesting that some strains are more virulent than others (1.36).   
Molecular characterizations have provided more information for grouping strains, 
sometimes too much.  PFGE has been shown to be too discriminating by producing such a large 
number of different restriction patterns that it is difficult to group strains (1.11, 1.89).  
Ribotyping showed the presence of four distinct groups into which strains could be placed with 
one group containing very few clinical strains, suggesting a possible relationship between 
ribotypes and virulence (1.89).  PCR and restriction digestion have been used to determine 
differences in the 16S rRNA genes of clinical and environmental isolates.  The majority of 
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environmental strains were placed in group A while the majority of clinical strains were placed 
in group B, suggesting a link between this 16S rDNA sequence and virulence (1.55).  Recently, 
RAPD PCR was used to show that specific RAPD profiles are correlated with either 
environmental (E) or clinical (C) strains and suggest the presence of two genotypes in V. 
vulnificus, one of which is an indicator of virulence.  Also, the category in which a strain was 
placed based on its RAPD profile matched the same category based on its 16S rDNA profile 
(1.72).  However, these studies do not suggest that all clinical strains are virulent while all 
environmental strains are avirulent; to the contrary, no difference in virulence between the two 
groups in the iron-overload mouse model has been shown (1.22, 1.84).  Consequently, a rapid 
and sensitive test to distinguish between virulent and avirulent strains in oysters and other 
seafood is still needed for the protection of the consumer as well as the seafood industry.     
V. vulnificus produces a multitude of pathogenicity factors [reviewed by Gulig et al. 
(1.29), Linkous and Oliver (1.46), and Strom and Paranjpye (1.87)] including numerous secreted 
proteins, an RTX toxin, a flagellum and pili that aid in attachment, siderophores to aid in the 
acquisition of iron, and CPS.  The secreted proteins include hemolysin/cytolysin, protease, 
metalloprotease, mucinase, lipase, chondroitinase, hyaluronidase, DNase, esterase, and sulfatase; 
none has been shown to be the single factor required for virulence.  The RTX toxin is cytotoxic 
in cell culture, but there are conflicting reports on its toxicity to mice (1.29).  Flagellar mutants 
show decreased systemic virulence, but some are still capable of causing skin infections (1.29, 
1.42, 1.44).  Pili mutants show decreased virulence, but as they also do not produce protease, 
hemolysin/cytolysin, and chitinase, the contribution of pili to virulence is still undetermined 
(1.29, 1.60).  Some of the predisposing conditions in susceptible hosts result in elevated serum 
iron levels and siderophores are used by V. vulnificus to collect iron that assists with growth in 
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the host (1.29, 1.80).  CPS is the pathogenicity factor that has been shown to affect the survival 
of V. vulnificus in the human host most directly, presumably by allowing cells expressing CPS to 
evade complement-mediated lysis and phagocytosis by host immune cells (1.28, 1.29, 1.43, 1.81, 
1.106).      
 Many bacterial species exhibit the phenomenon of phase variation, which is the 
reversible switching from one phenotype to another [extensively reviewed by van der Woude 
and Bäumler (1.91) and Salaün et al. (1.77)].  The variation may be completely “on/off” or there 
may be varying degrees of expression of the phenotype in question.  Numerous phenotypes have 
been reported to phase vary including colony morphology, opacity, expression of capsule, 
lipopolysaccharide (LPS), lipooligosaccharide (LOS), fimbriae, pili, flagella, outer membrane 
proteins (OMP), DNA restriction-modification (R/M) systems, and regulatory proteins.  These 
products of phase variation may be exhibited outside the cell or retained in its interior.  Different 
genetic mechanisms may be used (such as inversions, insertions, variable numbers of repeated 
sequences, slipped-strand mispairing, or homologous recombination) to result in the alternate 
phenotype being maintained in the population at a low level.  The presence of different 
phenotypes allows the population to adapt when environmental conditions change.  In the case of 
a pathogen invading a host, when an immune response has been mounted against one antigen, 
cells exhibiting an alternate form of the trait will survive and the infection will continue.  
However, if deletions occur, the switching is no longer reversible or variable and may result in a 
reduced adaptive capability of the population (1.77, 1.91).   
A related phenomenon, antigenic variation, occurs when different cells in a population 
exhibit different forms of cell wall epitopes or other external structures so that there are multiple 
distinct antigenic forms at one time in the population.  The primary difference between phase 
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variation and antigenic variation is that the former is considered reversible while the latter may 
or may not be reversible, depending on the mechanism behind it.  Antigenic variation can occur 
by mechanisms that result in phase variation of gene expression or it can be the result of gene 
conversion.  Examples of antigenically varied structures include the S-layer proteins of 
Campylobacter fetus and lipoproteins of Borrelia burgdorferi, while Type IV pilin in Neisseria 
spp. is both phase and antigenically variable (1.35, 1.77, 1.91).   
Phase variation usually occurs at a high frequency of approximately one in 103 cells per 
generation, or greater, while spontaneous mutations generally occur in bacteria at a rate of one in 
108 cells per generation (1.77, 1.91).  Each change in one gene related to a phase variable 
phenotype will result in the existence of two possible genotypes and possibly, two phenotypes, in 
the population.  Considering that there may be numerous genes contributing to each or to 
different phase variable phenotypes, there can be large numbers of possible genotypes 
contributing to the resulting phenotypes.  For example, Haemophilus influenzae has 18 genes 
currently identified as phase variable resulting in the hypothetical ability to produce 218 
genotypes and Neisseria gonorrhoeae contains an estimated 74 or more phase variable genes, 
capable of generating a possible 274 genotypes.  These immense numbers show the potential of 
bacteria to adjust to changing environments as well as to evade the human host’s immune system 
(1.77).   
Phase variation in many bacterial species is identified primarily by noticing visible 
changes in colony morphology.  Phases are referred to as opaque or translucent, smooth or 
wrinkled or rough, and mucoid or dry.  In V. vulnificus, opaque (O) colony morphology is 
correlated with the presence of CPS and virulence in an iron-overload mouse model, while 
reduced or no CPS results in a translucent (T) colony morphology and avirulence in this mouse 
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model (1.29).  Different levels of CPS expression correlated with different levels of opacity and 
translucence have been documented (1.100, 1.101, 1.106), while transposon mutagenesis 
insertions have produced translucent strains that express no CPS (1.67, 1.100, 1.101, 1.108).  
Opaque strains of V. vulnificus spontaneously switch to the translucent phenotype at frequencies 
of 10-5 or higher (1.40, 1.81, 1.101, 1.106).  The reverse switch, from translucent to opaque, also 
has been reported to occur at frequencies higher than expected for spontaneous mutation.  
Curiously, the opaque to translucent switch has been reported more often than the translucent to 
opaque switch, suggesting that in some translucent strains, the ability to switch back to the 
opaque form may have been lost or impaired (1.40, 1.81, 1.101, 1.106).   
An epimerase gene (wcvA) essential for CPS expression and virulence in V. vulnificus 
1003 has been identified (1.108), but no mechanism was suggested for the opaque to translucent 
switch.   A similar epimerase gene (wbpP) was recently described as essential for CPS 
expression and virulence in strain ATCC 29307, another clinical isolate (1.61).  A group 1-like 
CPS operon containing the wzaVv, wzbVv, and wzcVv genes, has been identified in V. vulnificus 
M06-24/O (also a clinical isolate) and shows characteristics similar to those of Escherichia coli 
group 1 CPS operons (1.15, 1.97, 1.99).  These operons contain highly conserved genes and 
produce polycistronic transcripts while the polysaccharides manufactured by the products of 
these operons are generally composed of uronic acid sugars and are constitutively produced.  The 
wzaVv operon was reported to contain multiple short sequence repeats (SSR) in its promoter 
region as well as between some of the genes, suggesting deletion as a possible mechanism for 
genetic control of the opaque to translucent switch (1.15).  A more extensive transposon 
mutagenesis study in strain 1003 resulted in the identification of four loci containing genes 
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potentially associated with CPS expression (1.82), but no possible mechanisms for control of the 
switch were suggested.  
All Vibrio spp. studied to date show the presence of two circular chromosomes, with 
chromosome I larger than chromosome II and a total genome size between 4 Mb and 5.26 Mb 
that varies both between species and among strains of the same species (1.16, 1.34, 1.41, 1.47, 
1.57, 1.76, 1.88, 1.90, 1.102).  The recently sequenced genome of V. vulnificus YJ016 contains 
the same wzaVv operon found in strain M06-24/O and surprisingly, also contains two additional 
similar operons of limited identity in different locations, one of which is on the smaller 
chromosome (1.16).  The other sequenced strain of V. vulnificus in the database, CMCP6, 
contains at least one copy of the same operon (1.41).  In strain YJ016, the wzaVv operon 
possesses direct repeat sequences upstream of wzaVv, between genes in the operon, and shows 
additional repeats at the end of the operon.  Not only are these repeats possible locations for 
slipped strand mispairing during transcription, they are also possible sites for the deletion of part 
or all of this region as suggested for strain M06-24/O.  Interestingly, wcvA from strain 1003 is 
missing from the genome of strain YJ016 and only two of the genes identified in the later study 
of strain 1003 are present in the genome of strain YJ016, while wbpP from strain ATCC 29307 
shows only limited identity to any CPS gene in strain YJ016 or strain CMCP6.  Considering the 
large number of CPS types identified (1.12, 1.33), it is not surprising that all strains do not 
contain the same genes for CPS expression.   
In addition to similarities and differences in some characteristics of their genomes, the 
sequencing of multiple Vibrio spp. genomes has revealed a particular genomic characteristic 
shared by all members of this genus, a super-integron (SI).  Super-integrons are large (29 Kb to > 
100 Kb) islands of gene cassettes in the genomes of numerous bacterial species (1.75), but were 
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first identified in Vibrio cholerae (1.18).  All SIs show the same organization: an integrase gene 
(int), an attI site, and large numbers of gene cassettes.  The integrase gene is located at the 5’ end 
of the SI in opposite orientation to the cassettes and contains a strong promoter for expression of 
cassette genes.  The attI site, where new cassettes are integrated into the SI, is located between 
the int gene and the first cassette.  Gene cassettes consist of a gene with an imperfect direct 
repeat at the 3’ end.  The direct repeats belong to a family of repeats termed 59-base elements 
(59-be) and contain the ‘core site’, GTTRRY, which serves as an attC recognition site for the SI 
integrase (1.74).  After a cassette is integrated into the SI, it is bordered by the imperfect direct 
repeats, each containing a core site, on either side of the gene; these core sites can be the location 
for recombination.  Cassettes are first added to the SI at the attI site, but can be excised from any 
location within the array using available attC sites, and excised cassettes can be reinserted at the 
attI site, changing their location in the array and the likelihood the gene will be expressed (1.73).   
 The existence of SIs was first hinted at with the descriptions of multiple copies of 123 bp 
(1.56) and 124 bp (1.5) direct repeats associated with virulence factor genes in V. cholerae.  The 
term “mega-integron” was proposed when it was determined that the repeat region contained a 
minimum of 80 copies of the direct repeats, termed VCRs (V. cholerae repeats) and was located 
within a 200 Kb region of the chromosome (1.18).  The organization of this region was similar to 
the structure of antibiotic resistance integrons, each with an integrase gene, an attI site, generally 
fewer than 10 gene cassettes (each bordered by 59-bes) usually encoding antibiotic resistance,  
and all located on plasmids; these mobile genetic elements were named after their function, 
“DNA integration elements” (1.85).  Mazel et al. (1.50) coined the term “super-integron” in 
relation to the large size of the V. cholerae integron, which was later termed a “chromosomal 
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integron”  based on its location in the small chromosome of V. cholerae (1.17, 1.34), but the 
super-integron name has been used more extensively.     
 While all of the Vibrio spp. studied to date contain an SI, several SIs have recently been 
compared and have been shown to vary widely in size and cassette composition (1.10).  Most 
cassettes found in one species are not found in other species or even in different strains of the 
same species.  In fact, the SIs from the two sequenced strains of V. vulnificus are different 
enough that computer alogorithms identify each of them as missing from the other genome (1.64, 
1.92).  Regardless of their differences, each SI has the ability to function as a gene capture 
system (1.73), providing a possible mechanism for the transfer of genes from one organism to 
another.    
V.  cholerae, the etiological agent of cholera, is a relative of V. vulnificus.  The 
nonencapsulated O1 strains of V. cholerae have been responsible for six pandemics of the 
diarrheal disease cholera.  The current, seventh pandemic has been caused not only by the O1 
strains but also by O139 strains, which do produce CPS (1.19, 1.38, 1.39, 1.53, 1.95).  Both the 
nonencapsulated and encapsulated strains are referred to as having a smooth colony morphology 
and they show varying levels of opacity and translucence (1.25).  V. cholerae also exhibits a 
third colony morphology phenotype, rugose.  Described in the 1930’s (1.96), rugose (R) variants 
arise in both the O1 El Tor biotype and non-O1 V. cholerae strains, including the encapsulated 
O139 (1.54).  Rugose colonies appear wrinkled and dry compared to the smooth and mucoid 
phenotypes of non-rugose strains and are typically obtained after extended growth of cells in a 
minimal medium or under prolonged starvation conditions.   
It has been suggested that the rugose phenotype may confer a protective advantage to V. 
cholerae under adverse environmental conditions (1.3, 1.52, 1.54, 1.69, 1.93, 1.105) and it was 
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recently reported that rugose variants were actually protected from grazing by protozoans 
compared to smooth strains (1.49).  Also, the presence of rugose variants during infection may 
enhance the virulence of smooth strains by assisting in colonization of the host intestine (1.66).   
Rugose variants produce copious amounts of extracellular polysaccharide [EPS; also 
specifically known as rEPS, rugose EPS (3) or EPSETr, EPS El Tor rugose (1.105)].  Bacteria 
produce many different forms of EPS, some of which are attached to the cell wall and others 
which are secreted and show no attachment to the cell wall.  CPS is another form of EPS and has 
been shown to be covalently linked to the cell surface (1.71).  Even though CPS is attached, 
portions of it distal to the cell wall can be broken off and released into the environment, 
contributing to the total unlinked EPS surrounding the cell (1.20).   
The production of such large amounts of EPS contributes to the ability of rugose strains 
to form robust biofilms.  Biofilms are an accumulation of cells encased in an exopolymeric 
matrix produced by the cells and are usually attached to a surface (1.23, 1.78).  In biofilm 
formation, flagella are used for the initial attachment to and movement over a surface, while pili 
may be required in some bacteria.  As the bacteria attach in larger numbers, a monolayer is 
formed followed by continued cell accumulation to produce microcolonies.  At this stage, cells 
cease expression of flagella and increase expression of EPS with large amounts encasing the 
cells in the growing biofilm.  Cells growing within a biofilm have been shown to be more 
resistant to antibiotics and the host immune response.  They are also more likely than planktonic 
cells to acquire genes through horizontal gene transfer [HGT] (1.21, 1.27, 1.83, 1.86, 1.94).  
Both smooth and rugose V. cholerae attach to and grow on the chitin exoskeletons of aquatic 
crustaceans (1.4, 1.14).  While no Vibrio spp. have been reported previously to be naturally 
competent in the uptake of foreign DNA, it was shown recently that during growth on chitin, V. 
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cholerae was induced to become naturally transformable.  Cells growing on crab shells not only 
took up exogenous DNA added during the experiments, but also transferred DNA containing 
selectable markers to recipients who originally did not contain those markers (1.51).  Thus, this 
study showed a scenario for HGT likely to occur in the natural habitat of this organism.   
Numerous genes associated with the production of rugose EPS and biofilms have been 
identified in V. cholerae.  These include two vps (Vibrio polysaccharide) operons [vpsI and vpsII 
(1.2, 1.105)], additional unlinked genes between the two operons (1.2, 1.26), several genes 
encoding regulator proteins (1.13, 1.32, 1.37, 1.65, 1.103), two genes (epsDE) in an extracellular 
protein secretion (type II) operon (1.1), as well as several genes involved in the synthesis of LPS 
or other polysaccharides (1.2, 1.65, 1.105).  Also, a recent in-depth gene expression study 
explored the complex relationship between the structural genes for rugose EPS and their various 
regulators (1.104). 
With the increase in the number to five of Vibrio spp. genomes completely sequenced [V. 
cholerae N16961 (1.34), V. vulnificus YJ016 (1.16) and CMCP6 (1.41), V. parahaemolyticus 
RIMD2210633 (1.47), and V. fischeri ES114 (1.76)] and 13 in progress [V. alginolyticus 12G01; 
V. angustum S14; V. campbelli AND4;  V. cholerae O395, MO10, V51, V52, RC385; V. lentus 
MEL32; V. salmonicida LFI1238; Vibrio sp. Ex25; Vibrio sp. MED222; and V. splendidus 
12B01 (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi)], it will soon be possible to 
determine how widespread the genes for CPS and EPS are in this ubiquitous genus.  It will also 
be possible to determine the conservation of these gene sequences and their order between the 
different species and among strains of the same species, both pathogens and non-pathogens.   
In this work, the results of several studies on phase variants of V. vulnificus are reported.  
In Chapter 2, repetitive sequences and genes associated with a super-integron in different phase 
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variants and the possible connection of one gene with CPS expression are described.  In Chapter 
3, a new phenotype for V. vulnificus, the rugose variant, is described and characterized.  The 
rugose variants derived from opaque and translucent parents look similar, but they also exhibit 
certain distinct characteristics.   In Chapter 4, the results of a study on differential gene 
expression among phase variants are reported and genes whose expression is elevated in or 
specific to the rugose variants are identified.  
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INTRODUCTION 
 Vibrio vulnificus is a marine bacterium that has been reported as the cause of the majority 
of deaths related to seafood consumption in the United States.  It is capable of causing a rapidly 
fulminating septicemia after the ingestion of contaminated raw oysters by susceptible individuals 
and death can occur within 48 hours.  Infection can also occur by contact of a pre-existing wound 
with contaminated seawater and may result in amputation if medical intervention does not occur 
in a timely fashion.  Individuals who are especially susceptible include those with liver disease, 
diabetes, immune dysfunction, or elevated serum iron levels (2.7, 2.22, 2.32, 2.35, 2.58).   
 Many V. vulnificus isolates produce colonies that show a smooth, mucoid, and opaque 
appearance on solid media as a result of the production of a polysaccharide capsule (2.2, 2.19), 
with some undergoing phase variation and spontaneously producing translucent (T) variants 
(2.65, 2.73) when cultured in the laboratory.  The capsule has been shown to be a major 
virulence factor, presumably protecting the bacteria from complement and phagocytic cells of 
the host immune system (2.17, 2.28, 2.55, 2.69).  Opaque strains have been shown to be virulent 
while translucent strains are avirulent in an iron-supplemented mouse model (2.17, 2.55, 2.69, 
2.73).  The different phenotypes produce varying amounts of capsular polysaccharide [CPS] 
(2.65, 2.67, 2.69), suggesting there are different degrees of opacity and translucence as reported 
for Vibrio cholerae (2.16).  Transposon mutagenesis has produced strains that express no CPS 
(2.43, 2.65, 2.67, 2.73).   
 Phase variation, as illustrated by the switch from opaque to translucent colony 
morphology, is a phenomenon common in bacteria that is often reversible and results in the 
differential expression of genes in the phase variants (2.60).  Phase variation can occur by many 
mechanisms including: 1) slipped strand mispairing (SSM) where short sequence repeats are not 
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aligned properly during DNA replication resulting in an increase or decrease of the number of 
repeats; 2) recombination between regions of the DNA that show homology between 50 base 
pairs (bp) or more; 3) site-specific recombination that can result in inversions, deletions, or 
insertions of DNA such as those produced by recombinase, integrase, and transposase enzymes.  
Phase variation can also occur as a result of differential gene regulation (2.60).   
While the exact mechanism for the phenotypic switch in V. vulnificus has not been 
determined, both phenotypes have been reported to switch spontaneously to the opposite 
phenotype at frequencies greater than expected for spontaneous mutation.  However,  the 
translucent to opaque switch has been seen less often (2.24, 2.55, 2.67, 2.69).   
 In an attempt to identify genes associated with CPS production and a possible 
mechanism behind phase variation in V. vulnificus, a previous study resulted in the generation of 
translucent transposon mutants of V. vulnificus 1003(O) and the characterization of one of the 
mutants, ABZ1(T) (2.72, 2.73).  While one gene, wcvA, was identified as essential for CPS 
expression, the sequence did not suggest any possible mechanism for phase variation.  
Preliminary studies on another mutant, GMB4(T), revealed the presence of an insertion 
sequence, a homolog of  IS492 (2.56).  IS492 has been shown to control the expression of 
extracellular polysaccharide (EPS) by the precise insertion and excision of the insertion sequence 
into and out of the eps gene of Pseudoalteromonas atlantica (2.4, 2.5, 2.40).  Subsequent 
analysis revealed the presence of a super-integron (SI) in V. vulnificus.   
Super-integrons are large genetic islands containing numerous gene cassettes.  They have 
been found in the genomes of multiple bacterial species and all SIs show the same organization: 
an integrase gene (int), an attI site, and large numbers of gene cassettes.  Cassettes contain attC 
sites located in direct repeat sequences that flank the cassettes and serve as recognition sites for 
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the integrase.  New cassettes are inserted at the attI site but may be excised from the SI and 
reinserted back at the attI site.  SIs have been shown to function as gene capture systems (2.13, 
2.46, 2.47, 2.49). 
The current study was undertaken to further characterize GMB4(T), to determine if the 
IS492 homolog influences CPS expression, to sequence the transposon-containing region of 
GMB4(T), and to identify the gene interrupted by the transposon and its potential role in CPS 
expression in V. vulnificus. 
MATERIALS AND METHODS 
Bacterial Strains and Growth Conditions.  All strains and plasmids are listed in Table 
2.1.  The encapsulated, opaque clinical strain V.  vulnificus 1003(O) and a spontaneous 
translucent variant, BG(T1), were the primary strains studied.  Both opaque and translucent 
phenotypes of ten capsular serotypes of V. vulnificus (2.31, 2.54) were studied for comparison 
purposes.  A nonencapsulated transposon mutant of 1003(O), designated GMB4(T), was 
identified previously (2.72) and described subsequent to the current study (2.56).  All Vibrio spp. 
cells were grown in heart infusion broth (Difco) supplemented to 2% NaCl (HI) at 37oC for 18 h 
with shaking at 200 rpm, unless otherwise stated.  For growth on solid media, 18 g of agar 
(Difco) were added per liter of HI.  Plates were incubated at 37oC unless indicated otherwise.   E. 
coli cells were grown in Luria-Bertani (LB) broth at 37oC for 18 h with shaking at 200 rpm or on 
LB plates containing 18 g agar per liter, unless otherwise stated.  Kanamycin (50 μg/ml), 
ampicillin (100 μg/ml), tetracycline (15μg/ml), carbenicillin (50 μg/ml), chloramphenicol (25 
μg/ml), and apramycin (200 μg/ml) were used when appropriate.   
Genomic and Plasmid DNA Methods.  Genomic DNA from V. vulnificus 1003(O) was 
extracted as described (2.72), a modification of a previously described method (2.9).  This  
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TABLE 2.1. Bacterial strains and plasmids used in this study. 
   
   
Strain Isolation and characterizationa Reference(s) or 
source 
   
   
Vibrio vulnificus 1003   
1003(O) Wound isolate, opaque, encapsulated, virulent; 
designated as wild type, smooth; CPS serotype 9, 
LPS serotype unk.;  Colr
(2.31, 2.54) 
BG(T1) Spontaneous translucent derivative of 1003(O), 
smooth 
This study 
GMB4(T) Translucent, avirulent; mini-Tn10 insertion in 
ORF4 of 1003(O) super-integron region, smooth; 
previously ABZ44(T); Kanr
(2.56, 2.72) 
V. vulnificus   
C7184(O)b Blood isolate, opaque, smooth; CPS serotype 1, 
LPS serotype 3 
(2.66) 
C7184(T) Spontaneous translucent derivative of C7184(O), 
smooth 
Laboratory 
collection 
1010(O) Blood isolate, opaque, smooth; CPS serotype 2, 
LPS serotype unk 
(2.31, 2.54) 
1010(T) Spontaneous translucent derivative of 1010(O), 
smooth 
Laboratory 
collection 
1014(O) Source unk, opaque, smooth; CPS serotype 3, LPS 
serotype 2 
(2.31, 2.54) 
1014(T) Spontaneous translucent derivative of 1014(O), 
smooth 
Laboratory 
collection 
1007(O) Blood isolate, opaque, smooth; CPS serotype 4, 
LPS serotype O1 
(2.31, 2.54) 
1007(T) Spontaneous translucent derivative of 1007(O), 
smooth 
Laboratory 
collection 
1657(O) Wound isolate, opaque, smooth; CPS serotype 5, 
LPS serotype 1 
(2.31, 2.54) 
1657(T) Spontaneous translucent derivative of 1657(O), 
smooth 
Laboratory 
collection 
1866(O) Blood isolate, opaque, smooth; CPS serotype 6, 
LPS serotype O1/O5 
(2.31, 2.54) 
1866(T) Spontaneous translucent derivative of 1866(O), 
smooth 
Laboratory 
collection 
1002(O) Blood isolate, opaque, smooth; CPS serotype 7, 
LPS serotype O1 
(2.31, 2.54) 
1002(T) Spontaneous translucent derivative of 1002(O), 
smooth 
Laboratory 
collection 
 
 28
Table 2.1.  continued 
 
   
549(O) Blood isolate, opaque, smooth; CPS serotype 8, 
LPS serotype 2 
(2.31, 2.54) 
549(T) Spontaneous translucent derivative of 549(O), 
smooth 
Laboratory 
collection 
938(O) Eel isolate, opaque, smooth; CPS serotype 9, LPS 
serotype 4 
(2.31, 2.54) 
938(T) Spontaneous translucent derivative of 938(O), 
smooth 
Laboratory 
collection 
1456(O) Source unk, opaque, smooth; CPS serotype 10, LPS 
serotype 1 
(2.31, 2.54) 
1456(T) Spontaneous translucent derivative of 1456(O), 
smooth 
Laboratory 
collection 
V.  cholerae   
O139 Opaque, encapsulated, smooth, serotype O139 Laboratory 
collection 
El Tor Africa Opaque, smooth, serotype O1 Laboratory 
collection 
5875 La El Tor Opaque, smooth, serotype O1 Laboratory 
collection 
ATCC14035 Opaque, smooth, serotype O1, Classical, Ogawa Laboratory 
collection 
V.  parahaemolyticus 
17802 
Opaque, smooth Laboratory 
collection 
Escherichia coli 
DH5Αmcr F- endA1 supE44 thi-1 λ- recA1 gyrA96 relA1 deoR 
Δ(lacZYA-argF)U169 φ80dlacZΔM15 mcrA 
Δ(mrr hsdRMS mcrBC) 
(2.18) 
S17-1 recA derivative of E. coli 294 (F- thi pro hsdR) 
carrying a modified derivative of IncPα plasmid 
pRP4 (Ampr Tetr Kanr), Tpr
(2.53) 
NovaBlue endA1 hsdR17 (rK12- mK12+) supE44 thi-1 recA1 
gyrA96 relA1 lac F’[proA+B+ 
lacIqZΔM15::Tn10] (Tetr) 
Novagen 
Max Efficiency  
STBL2 
F- mcrA Δ(mcrBC hsdRMS mrr) recA1 lon gyrA96 
thi supE44 relA1 λ- Δ(lac proAB) 
Invitrogen 
SURE® 2 e14- (McrA-) Δ(mcrCB hsdSMR mrr)171 endA1 
supE44 thi-1 gyrA96 relA1 lac recB recJ sbcC 
umuC::Tn5 (Kanr) uvrC [F’ proAB 
lacIqZΔM15Tn10 (Tetr) Amy (Camr) 
Stratagene 
Plasmids   
p44XBS pBluescript SK(-) containing insert of V. vulnificus 
GMB4(T) genomic DNA with transposon 
insertion in ORF4 cloned at the XbaI site; Kanr
(2.56, 2.72) 
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TABLE 2.1.  continued 
 
   
pUC19 High-copy number cloning vector; α-lac/MCS; 
Ampr
(2.68) 
pSTBlue1 High-copy number cloning vector; α-lac/MCS; 
Ampr, Kanr
Novagen 
pBBR1MCS Broad host range, medium-copy number cloning 
vector; Camr
(2.27) 
pBBR1MCS-4 Ampr derivative of pBBR1MCS (2.26) 
pRK2013 Self transmissible plasmid, contains RK2 transfer 
genes cloned into a ColE1 replicon; used as a 
helper plasmid; Kanr
(2.15)  
pOJ446 Source of oriT; E. coli – Streptomyces shuttle 
cosmid; Aprr
(2.6) 
pBG5.2 pSTBlue-1 containing 5.2 Kb PfuTurbo PCR 
product; Ampr, Kanr
This study 
pBG5.2b pBBR1MCS containing 5.2 Kb PfuTurbo PCR 
product at the BamHI and XbaI sites; Camr
This study 
pBG5.2c pBBR1MCS-4 containing 5.2 Kb PfuTurbo PCR 
product at the BamHI and XbaI sites; Ampr
This study 
pBG5.2d pBG5.2 containing the oriT from pOJ446 at the 
PstI cloning site; Ampr, Kanr
This study 
pBG-ORF4 pBBR1MCS containing 1.8 Kb PfuTurbo PCR 
product at the BamHI and XbaI sites ; Camr
This study 
   
 
a Colr, colistin resistance; Kanr, kanamycin resistance; Tetr, tetracycline resistance; Tpr, 
trimethoprim resistance; Camr, chloramphenicol resistance; Ampr, ampicillin resistance; Aprr, 
apramycin resistance; unk., unknown. 
b V. vulnificus strains are listed in order of their CPS serotype, 1 through 10. 
 
 
method was further modified for large-scale extraction as follows.  Isolated colonies were used 
to inoculate 3 ml HI broth cultures that were incubated overnight.  The next day, cultures were 
diluted 1:100 into 100 ml HI broth and incubated overnight.  Cells were pelleted and then 
resuspended in 1 M NaCl, then centrifuged again to pellet the cells.  Then, this step was 
repeated.  The resulting pellet was resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, 
pH 8.0), after which 0.07 vol of pronase (20 mg/ml) (Sigma) and 0.05 vol of 10% sodium 
dodecyl sulfate (SDS) were added.  The tubes were inverted gently to mix the contents and then 
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incubated 1.5 h in a 56oC water bath.  After incubation, 5 M NaCl was added to give a final 
concentration of 0.7 M NaCl; then the tubes were inverted gently to mix the contents and 
incubated for 30 min in a 65oC water bath.  After the second incubation, the solution in each tube 
was divided equally into 2 tubes.  One volume phenol/chloroform/isoamyl alcohol (25:24:1) was 
added to each tube and they were centrifuged at 12,000 × g for 15 min.  Aqueous layers were 
transferred to clean tubes and the extraction was repeated using phenol/chloroform/isoamyl 
alcohol (0.7 volume). The aqueous layers were then ethanol precipitated as described (2.50), and 
DNA pellets were allowed to dry overnight.  The DNA was rehydrated with sterile H2O and the 
tubes were incubated in a 50oC water bath for 1 h after which Ribonuclease A (RNase A, Sigma) 
was added to a final concentration of 1 μg/ml and the samples were incubated for 30 min at 
37oC.  After incubation, 7.5 M ammonium acetate (0.7 volume) was added to each tube and 
samples were extracted again with an equal volume of phenol/chloroform/isoamyl alcohol.  This 
extraction was repeated as necessary and then followed by ethanol precipitation, drying, and 
rehydration in sterile H2O.  For smaller scale isolations, genomic DNA was extracted from 
strains of other Vibrio spp. using the PureGene DNA Isolation Kit (Gentra Systems) as directed 
by the manufacturer.  All DNA samples were stored at –20o C.    
 Concentration of DNA samples was estimated by determination of the 260/280 
absorbance ratio (2.50) as well as by agarose gel electrophoresis.  DNA samples were subjected 
to an autodigestion reaction to confirm the absence of nucleases prior to restriction enzyme 
digestion.  Approximately 200 ng of DNA were diluted to 4.5 µl with nuclease-free H2O 
(Sigma), 0.5 µl of 10X restriction enzyme buffer (New England Biolabs) were added, and the 
reaction was incubated at 37oC overnight.  Reactions were subjected to agarose gel 
 31
electrophoresis to determine integrity of the DNA.  If the DNA was degraded, stored samples 
were further purified and ethanol precipitated.  
 Plasmids were isolated using the QIAprep Spin Mini Prep Kit (QIAGEN), following the 
manufacturer’s protocol.  Medium and low-copy plasmids were isolated using the Hi-Speed Midi 
Kit (QIAGEN) following the kit instructions. Multiple samples of the same low-copy plasmid 
were pooled and ethanol precipitated.  Plasmid DNA concentration was estimated as described 
for genomic DNA.   
 DNA Sequencing.  Sequencing of the 6.2 Kb XbaI insert of p44XBS (2.72) began with 
the T3 and T7 primers.  Subsequent primers were designed using the program Primer Design, v.2 
(Scientific and Educational Software) and synthesized by Gene Lab at the Louisiana State 
University School of Veterinary Medicine or MWG Biotech, Inc.  An additional 200 bp on the 5’ 
end of the insert was determined by sequencing genomic DNA.  Sequencing reactions used the 
ABI PRISM Big Dye-labeled terminators chemistry (PE Applied Biosystems) and sequencing 
was conducted on an ABI PRISM 310 Genetic Analyzer.  Sequences were analyzed with the 
program Clone Manager 5 (Scientific and Educational Software) and submitted to a Basic Local 
Alignment Search Tool [BLAST (2.1)] search of relevant databases to determine nucleotide and 
amino acid identity/similarity.  Alignment of nucleotide sequences was done using the program 
Align Plus, v. 2.0 (Scientific and Educational Software).  The complete nucleotide sequence for 
ORF4 is available from GenBank under accession number AY676134.   
  PCR Methods.  Digoxigenin (DIG)-labeled probes were synthesized using the PCR DIG 
Probe Synthesis Kit (Boehringer).  Primers (Table 2.2) were designed as described above. Each  
50 μl PCR reaction for probe synthesis was prepared following protocols supplied by the 
manufacturer, except that dimethyl sulfoxide (DMSO) was added to each reaction to a final  
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TABLE 2.2.  Primers used in this study. 
 
 
Primer Name Sequencea Reference or 
source 
 
 
IS492-For 5’-CCGTATCAACGCCGACATTA-3’ A. B. Smithb
IS492-Rev 5’-GTTCGATTGAACGCTGGCTC-3’ A. B. Smithb
VVR-For 5’-TAACAAAGCGTTCAAGAGGGAC-3’ This study 
VVR-Rev 5’-TAACGCCGCGTTAAGGGG-3’ This study 
2066-Ext 5’-TCGTACCATCGAAGAGCCAA-3’ This study 
2272-Rev 5’-GCCACCAATTCGTAAGTACA-3’ This study 
Var1-For1 5’-GCCGGATCCGGCCCAGAAGACTATTCGAG-3’ This study 
Var1-For2 5’-GCCGGATCCGTTATCGGTCTCTCAATAGAGGAG-3’ This study 
Var1-Rev 5’-GGCTCTAGAGTCTCATTTTTCACCTGGTG-3’ This study 
Orf4-For1 5’-GCCGGATCCGCTGATGAAAAAGTGGGCTCTGGT-3’ This study 
Orf4-Rev1 5’-GGCTCTAGATATAGAAGTCTCGTGTGCCC-3’ This study 
Orf1-For1 5’-GCCGGATCCGTTAGGGCCGGCTGGATTAA-3’ This study 
Orf1-For2 5’-GCCGGATCCGCAGAATTGCAGTCATTTGG-3’ This study 
Orf1-Rev1 5’-GGCTCTAGAGGTTCTTCGCGACATATTCT-3’ This study 
Orf1-Rev2 5’-GGCTCTAGACCGGCTAACGTGAACGCTCTT-3’ This study 
   
   
a Underline represents restriction sites for BamHI (forward primers) or XbaI (reverse primers). 
b Personal communication. 
 
concentration of 0.02%.  The reactions were run on a Perkin Elmer Gene Amp 2400 and 
consisted of an initial temperature of 95oC for 5 min followed by 10 cycles of 95oC for 10 sec, 
60oC for 30 sec, and 72oC for 2 min.  Then, 20 cycles of 95oC for 10 sec, 60oC for 30 sec, and 
72oC for 2 min with a 20 sec elongation time starting with overall cycle 11 completed the 
reaction.  Amplification of the desired product was determined by agarose gel electrophoresis.
 Separate multiplex PCRs were conducted to determine the presence of an IS492 homolog 
and VVRs in several V. vulnificus strains.  Reaction constituents were essentially the same as 
mentioned above for probe synthesis except that a second set of primers for an E. coli rRNA 
gene (2.61) was included in each reaction as an internal control and DMSO was added to 10% of 
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the total reaction volume. Separate reactions were run using genomic DNA (100 ng) from both 
opaque and translucent strains of each of the 10 capsular serotypes of V. vulnificus as well as 
1003(O) and BG(T1).  PCR was also conducted using primers 2066-Ext and 2272-Rev to 
determine the prevalence of ORF4 in different strains (both opaque and translucent) of each of 
the 10 capsular serotypes of V. vulnificus as well as 1003(O), BG(T1), and GMB4(T), four 
strains of V. cholerae, and Vibrio parahaemolyticus 17802.  All PCR run conditions were the 
same as for probe synthesis and products were analyzed by agarose gel electrophoresis.   
 PCR to produce products for cloning was conducted using Pfu Turbo polymerase 
(Stratagene) following the manufacturer’s protocol.  Primers contained 5’ linker sequences for 
either BamHI (forward primer) or XbaI (reverse primer) restriction sites (Table 2.2).  PCR 
products were verified by agarose gel electrophoresis, purified using the QIAquick PCR 
Purification Kit (QIAGEN) following the manufacturer’s protocol, and stored at –20o C.    
 Southern Hybridization.  Restriction enzyme digestions of genomic DNA followed 
established protocols (2.50).  For use in Southern hybridization, a 50 μl digest containing 
approximately 7 μg of genomic DNA was electrophoresed on a 0.8% agarose gel at 20 V for 24 
h, after which the gel was stained with ethidium bromide and visualized using an Eagle Eye II 
(Stratagene).  The procedure for capillary blotting and Southern hybridization was as described 
(2.50).  Hybridization with the DIG-labeled probe and development of the blot followed the 
protocols of the manufacturer.   
 Pulsed-field Gel Electrophoresis (PFGE).  Agarose plugs of V. vulnificus and V. 
cholerae strains for PFGE were prepared as described (2.23).  Restriction enzyme digestion of 
plugs was as described (2.51).  Electrophoresis was done in a CHEF-DR III system (Bio-Rad) 
with the following conditions:  14oC, 6 V/cm, with an initial switch time of 1 sec and a final 
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switch time of 60 sec, an included angle of 120o, and a run time of 20 h.  For PFGE of 
undigested chromosomal DNA, plugs were loaded into the gel without restriction enzyme 
digestion with electrophoresis at 14oC, 3 V/cm, initial and final switch times of 500 sec each, 
included angle of 106o, and a run time of 48 h.  After electrophoresis, each gel was stained with 
ethidium bromide and visualized under UV light.  In preparation for vacuum blotting, the gel 
was placed in a GS Gene Linker UV Chamber (Bio-Rad) and the DNA was nicked by exposure 
to 254 nm UV light.  Vacuum blotting onto a Zeta-Probe GT nylon membrane (Bio-Rad) was 
carried out with a Model 785 Vacuum Blotter (Bio-Rad) and the procedure for vacuum blotting 
and Southern hybridization was as suggested by the manufacturers.   
 Complementation Attempts.  V. vulnificus genomic DNA was digested with XbaI and 
electrophoresed as described for Southern hybridization.  After staining with ethidium bromide, 
fragments of the desired size were excised from the gel and purified using the QIAquick Gel 
Extraction kit (QIAGEN) following the manufacturer’s protocol.  Purified products were cloned 
into XbaI (New England Biolabs) digested and alkaline phosphatase (New England Biolabs) 
treated pUC19 and either electroporated into electroporation-competent Escherichia. coli 
DH5αMCR or transformed into chemically competent E. coli Nova Blue (Novagen) following 
manufacturer’s protocols.  Resulting transformants were screened for the presence of the desired 
insert by PCR with primers 2066-Ext and 2272-Rev (Table 2.2) following the protocol given in 
the Perfectly Blunt Cloning kit (Novagen).   
 Pfu Turbo PCR products were first cloned into pSTBlue-1 using the Perfectly Blunt 
Cloning kit (Novagen) and then transformed into E. coli Nova Blue following the manufacturer’s 
protocol.  Resulting transformants were selected by growth on LB containing carbenicillin and 
kanamycin then screened by PCR and restriction digestion of extracted plasmids.  This protocol 
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produced plasmid pBG5.2, which was positive by PCR for Var1/ORF3, ORF4, and ORF1 and 
also contained the correct size insert.  The 5.2 Kb Pfu Turbo PCR product was released from 
pBG5.2 double digested with BamHI and XbaI, cloned into double digested, gel purified 
pBBR1MCS or pBBR1MCS-4 to produce pBG5.2b and pBG5.2c, respectively, and transformed 
into E. coli Max Efficiency STBL2 (Invitrogen) or E. coli SURE® 2 (Stratagene), respectively.  
Transformants were selected by growth on LB containing the appropriate antibiotics and then 
screened as above.  Plasmid pBG5.2d was constructed by digesting pBG5.2 and pOJ446 with 
PstI, gel purifying the desired products, and ligating the oriT fragment from pOJ446 into the PstI 
site of pBG5.2.  The ligation mixture was then transformed into E. coli S17-1 as described 
(2.50).  Transformants were selected and screened as for pBG5.2.  Also, other Pfu Turbo PCR 
products were double digested with BamHI and XbaI, cloned into double digested, gel purified 
pBBR1MCS, and transformed into E. coli Max Efficiency STBL2.  Transformants were selected 
by growth on LB containing the appropriate antibiotics and then screened as above.  This 
protocol produced plasmid pBG-ORF4 which was positive by PCR for ORF4 and contained the 
correct size insert (1.8 Kb).   
 Electroporation of pBG-ORF4 into V. vulnificus GMB4(T) was attempted numerous 
times with different combinations of buffers and electroporation conditions following described 
methods (2.30, 2.34).  In addition, further attempts were made to make electroporation-
competent V. vulnificus by growing cells in HI with 0.4% glucose, 5 mM glycine betaine 
(Sigma), and 28.7 mM K2HPO4 and using a wash buffer consisting of 5 mM sodium phosphate 
buffer (pH 7.4), 1 mm CaCl2, 1 mM MgCl2, and 272 mM glucose (D. Rowe-Magnus, personal 
communication).  All other steps in the protocol were as described.  While V. vulnificus cells 
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survived all washes and electroporation, no transformants were obtained in any of the 
electroporation experiments.   
 Tri-parental conjugation was then used to attempt to complement GMB4(T).  Cultures of 
E. coli STBL2(pBG-ORF4), V. vulnificus GMB4(T), and E. coli(pRK2013) were grown and 
mixed as described (2.14) with the RP4 transfer functions provided in trans by the helper 
plasmid pRK2013.  Briefly, overnight cultures of each strain were diluted 1:100 in fresh HI 
containing appropriate antibiotics and grown to an OD600 between 0.4 and 0.8.  Cultures were 
centrifuged at 5000 × g for 10 min at room temperature to pellet the cells which were then 
resuspended in 1.5% NaCl to wash the cells and remove any remaining antibiotics.  Equal 
volumes of each resuspended culture (4 ml) were combined in a 50 ml conical tube (Corning), 
pelleted as above, and resuspended in 120 µl of HI.  Sterile nitrocellulose filters were placed on 
HI plates and 30 µl of cells were spotted onto each of four membranes.  Plates were incubated 
upright overnight at 30oC.  Each filter was then aseptically transferred to 5 ml HI in a 50 ml 
conical tube, vortexed on high to remove cells from the filter, and filters were removed from the 
tubes.  Cells were pelleted as above and resuspended in 200 µl of HI, after which half was plated 
to LB containing kanamycin and chloramphenicol and half was plated to HI containing colistin 
and chloramphenicol.  Transconjugants were then screened for the presence of the appropriate 
plasmid and PCR products as described above.  
 The next attempt involved a two-parent mating between E. coli S17-1(pBG5.2d) and V. 
vulnificus GMB4(T) as above, except that 3 vol of E. coli S17-1(pBG5.2d) were used per 1 vol 
of V. vulnificus GMB4(T).  E. coli S17-1 contains the RP4 transfer functions integrated into its 
chromosome; thus, a helper plasmid was not needed.  Transconjugants were selected on LB 
containing ampicillin and HI containing colistin and ampicillin and screened by PCR and 
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restriction digestion of extracted plasmids.  In addition, transconjugants from this set of 
experiments were screened for growth on the Vibrio-selective medium, thiosulfate citrate bile 
salts sucrose (TCBS) agar.   
RESULTS  
Genetic Organization of the Transposon Insertion Region in V. vulnificus GMB4(T).   
Figure 2.1 shows a representation of the gene order in the region surrounding the transposon 
insertion in GMB4[T] (see also Appendix Table A.1).  The 6436 bp region consists of a  
 
 
Tn Insertion
C1 C2 C3 C4 C5 C6
Var1/ORF3 ORF4 ORF1 
6436 bp
A. 
6234 bp
B.  
5.2 Kb
C. 
1.8 Kb
Transposase 
 FIGURE 2.1.  Fragment of the V. vulnificus 1003 genome showing 6436 bp of the SI 
region with ORF4 interrupted by the transposon insertion in strain GMB4(T).  C1 through C6 
represent six repetitive mini-cassettes.  Filled triangles represent VVRs; they are in the following 
arbitrary order, left to right: 9, 1, 2, 10, 8, 7, 6, 5, 4, 3.  The different sized fragments (A, B, C) 
represent different cloning and complementation attempts as described in the text.  A. XbaI 
genomic DNA fragment from V. vulnificus 1003(O) cloned into pUC19 and pSTBlue1.  B. 5.2 
Kb PfuTurbo PCR product cloned into pBBR1MCS, pBBR1MCS-4, and pSTBlue1 containing 
the oriT region from pOJ446.  C. 1.8 Kb PfuTurbo PCR product cloned into pBBR1MCS. 
 
 
transposase (an IS492 homolog), one open reading frame (ORF2; right end of transposase and 
white box) between the transposase and Var1/ORF3 and assumed to be an artifact of 
transposition, three complete ORFs (Var1/ORF3, ORF4, and ORF1), 10 imperfect direct repeat 
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sequences of 120 to 123 bp each [V.  vulnificus repeats (VVRs), filled triangles], and six larger, 
imperfect direct repetitive sequences termed mini-cassettes (boxes designated C1 through C6).  
The appearance of VVRs indicates the presence of a super-integron (SI), first identified in V. 
cholerae (2.3, 2.33).  Also shown in Figure 2.1 are the locations of the fragments (A, B, and C) 
used in later cloning and complementation experiments.   Table 2.3 lists the ORFs (except 
ORF2) from GMB4(T) and their homology to any known ORFs.   
  
TABLE 2.3.  Identification of ORFs from the SI of V. vulnificus 1003. 
      
 
 
ORF 
 
Organism 
 
Homolog/ 
function 
% Amino 
acid 
identity 
 
Accession 
number 
 
Reference 
      
      
Transposase Pseudoalteromonas  
atlantica 
Control of EPS 
expression 
72 AAA25864 (2.4) 
ORF3 V. vulnificus YJ016 Var1 homolog 92 NF_934597.1 (2.10) 
ORF4 Staphylococcus 
epidermidis 
Unknown 27 NP_765031.1 (2.70) 
ORF1 none Unknown none none None 
      
 
 
 Table 2.4 shows the nucleotide identity between the 10 VVR sequences as determined by 
pairwise alignments (see also Appendix Figures A.1, A.2, A.3, and A.4).  Those VVRs with 
identity to each other greater than 90% (bold print; copies 2, 3, 5, 7, 8, and 9) are considered true 
VVRs.  These true VVRs each show low identity to VCRs as determined by a BLAST search 
(data not shown).  Those with less than 90% identity to each other (copies 1, 4, 6, and 10) are 
considered homologs of VCRs based on high identity to VCRs as determined by a BLAST 
search (data not shown).  Restriction maps of each VVR further establish the existence of these  
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TABLE 2.4.  Nucleotide identity between 10 VVR sequences.   
 
           
VVRa    1    2    3    4    5    6    7    8    9   10 
           
           
   1 -          
   2 79 -         
   3 80 96 -        
   4 82 83 82 -       
   5 80 93 93 84 -      
   6 86 79 80 84 84 -     
   7 80 94 94 88 91 80 -    
   8 79 96 96 86 93 79 95 -   
   9 78 93 94 86 93 82 95 93 -  
  10 79 77 77 83 76 75 80 77 78 - 
 
 
a Identity was determined by pairwise alignments.  Those VVRs whose nucleotide identity is 
shown in bold print (greater than 90%) are considered true VVRs.  Those with less than 90% 
identity are considered VCR homologs.   
 
two separate categories (Appendix Table A.2).  True VVRs (copies 2, 3, 7, 8, and 9) have highly 
similar maps.  The restriction map of VVR5 is slightly less similar to the other true VVRs, but 
similar enough to place it with this group.  The remaining VVRs (copies 1, 4, 6, and10), which 
were identified as VCR homologs based on sequence identity, have highly similar maps that are 
quite different from those of the true VVRs and thus, are considered to be VCR homologs.   
 Repetitive Sequences and Phase Variation.  The presence of an IS492 homolog 
suggested that this insertion sequence might play a role in phase variation in V. vulnificus as it 
does in Pseudoalteromonas atlantica (2.4, 2.5).  Figure 2.2 shows the results of Southern 
hybridizations with a probe specific for the insertion sequence.  Multiple copies were present in 
V. vulnificus 1003 (see also Appendix Figure A.5) and fewer copies were present in four other 
strains (1014, 1657, 549, and 938) with capsule serotypes 3, 5, 8, and 9, respectively.  There was 
no apparent difference between the opaque and translucent phenotypes of any strain with respect 
 FIGURE 2.2.  Southern blots show the presence of the IS492 homolog in four of 10 CPS serotypes of V. vulnificus.  Multiple 
copies of the sequence were present in V. vulnificus 1003 (C, control) and CPS serotypes 3, 5, 8, and 9.  Strain numbers and their 
respective CPS serotypes are given in Table 2.1.  The probe used was a DIG-labeled PCR product specific for the IS492 homolog.  O, 
opaque; T, translucent; M, marker, DIG-labeled λ Hind III digest (Boehringer).  Numbers to the left of each blot refer to the size in Kb 
of the marker fragments. 
  
M  O  T     O  T    O  T     O  T     O  T    O  T 
 C          1          2          3            4          5      
Capsular Serotypes 
M  O  T     O  T    O  T     O  T     O  T    O  T 
   C          6          7           8          9         10 
Capsular Serotypes 
2.3 
23.1 
27.5 
9.4 
6.5 
4.4 
2.0 
23.1 
27.5 
9.4 
6.5 
4.4 
2.3 
2.0 
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to this sequence.  Multiplex PCR was conducted (data not shown) and confirmed the presence or 
absence of the insertion sequence as indicated by the Southern blots.  These results suggest that 
the IS492 homolog does not play a role in phase variation of CPS expression in the opaque and 
translucent strains of V. vulnificus tested here.  
 Next, it was considered that the VVR sequences might play a role in mediating phase 
variation in V. vulnificus, as they flanked ORF4 which was the site of the transposon insertion.  
Multiplex PCR revealed the presence of VVRs in both opaque and translucent phenotypes of 11 
strains (Appendix Figure A.6).  Southern hybridization with a DIG-labeled PCR product specific 
for the VVR sequence was used and both strains 1003(O) and BG(T1) showed multiple bands 
with no apparent difference between the two strains (Appendix Figure A.7).   
As the V. cholerae SI is approximately 120 Kb and contains an estimated 150 VCR gene 
cassettes (2.12), it was reasoned that the apparent SI of V. vulnificus would be equally large.  To 
determine if any difference existed between the phase variants with respect to this region, 
pulsed-field gel electrophoresis (PFGE) was conducted on V. vulnificus 1003(O) and BG(T1) 
(Figure 2.3); no difference between the restriction patterns of the two phenotypes was detected.  
Southern hybridization with the VVR-specific probe showed the SI localized on an AccI 
fragment of approximately 243 Kb and no apparent difference between opaque and translucent 
strains with respect to the location of this genomic island.  PFGE of undigested chromosomal 
DNA followed by Southern hybridization (Figure 2.4) revealed that the V. vulnificus SI is located 
on the larger of the two chromosomes, in contrast to the V. cholerae SI, which is located on the 
smaller chromosome (2.20).  Also shown in Figure 2.4 are the relative sizes of the two 
chromosomes of V. vulnificus 1003(O) and four strains of V. cholerae.  It is of interest that both 
chromosomes are larger in V. vulnificus, with the large chromosome being approximately 3.2  
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   O    T       O     T      O    T       λ 
SfiI AccI NotI 
  O    T        O    T       O    T     
 SfiI  AccI NotI 
340 
243 
146 
48.5 
Kb 
437 
631 
A B 
FIGURE 2.3.  VVRs are located in one region of the genome of V. vulnificus 1003(O) 
and BG(T1).  A. PFGE of O and T strains reveals highly similar restriction patterns.  B. Southern 
blot of the PFGE gel shows that the VVR region is located in an area of the genome no larger 
than 243 Kb, as shown in the AccI digest.  The probe used was a DIG-labeled PCR product 
specific for the VVR sequence.  λ, lambda ladder composed of concatemers of lambda c1857 
Sam7 (Bio-Rad). 
 
Mb, and the small chromosome approximately 1.8 Mb for a genome of approximately 5 Mb, 
similar to that reported for V. vulnificus strains YJ016 (2.10), CMCP6 (2.25), and RIMD2219025 
(2.38), but almost a full 1 Mb larger than that reported for V. cholerae (2.20).   
 Additional Repetitive Sequences: Mini-Cassettes.  Six mini-cassettes are shown in 
Figure 2.1 and further described in Table 2.5.  Five of the six are almost identical in length (349 
to 355 bp) and those five showed 64% to 83% identity with each other (Appendix Figure A.8; 
Table A.4).  Mini-cassette C1 is the shortest and also shows the least identity to the others (all 
below 45%; data not shown).  All have homologs in the SIs of one or both of the V. vulnificus  
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 FIGURE 2.4.  The SI of V. vulnificus 1003(O) is located on the larger of two 
chromosomes.  A. PFGE of undigested chromosomal DNA shows that V. vulnificus 1003(O) has 
two chromosomes and that both are larger than the respective chromosomes in four strains of V. 
cholerae.  B. Southern blot of the PFGE gel reveals that the SI is located on the large 
chromosome in V. vulnificus 1003(O) in contrast to its location on the small chromosome in V. 
cholerae.  The probe was a DIG-labeled PCR product specific for the VVR sequence.  M, 
marker, Hansenula wingei chromosomes (Bio-Rad); 1, V. vulnificus 1003(O); 2, V. cholerae 
O139; 3, V. cholerae El Tor Africa; 4, V. cholerae 5875 La El Tor; 5, V. cholerae ATCC 14035. 
 
 
strains that have had their genomes sequenced.  As determined by a BLAST search (data not 
shown), these mini-cassettes showed at least 90% identity to a cassette in one or both sequenced 
strains and also showed greater than 80% identity with numerous (> 10) cassettes in each strain 
in which they were identified.  Surprisingly, mini-cassette C4 showed 100% identity in its 
entirety with three SI cassettes in strain CMCP6. 
 Characterization of ORF4.  ORF4 is a gene cassette of 1870 bp, with VVR2 at the 5’ 
end and VVR10 at the 3’ end (Figure 2.1).  VVR2 is a true VVR while VVR10 is a VCR  
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TABLE 2.5.  Identification of mini-cassettes from the SI of V. vulnificus 1003. 
      
      
  % Nucleotide identityb Gene 
      
      
Cassette Size (bp)a YJ016 CMCP6 YJ016 CMCP6 
      
      
C1 260 93 none VV1874-75 None 
C2 350 97 97 VV1898 VV12518 
C3 349 90 84 VV1870 VV12454-55 
C4 355 90 100 VV1917 VV12408-09 
VV12459-60 
VV12469-70 
C5 350 93 82 VV1760 VV12484-86 
C6 354 85 90 VV1934-35 VV12491-92 
      
      
a 3’ VVR is not included in the size determination. 
b Nucleotide identity and gene numbers are given for the two strains of V. vulnificus whose 
genomes have been sequenced.  All genes are in the SIs of each strain.   
 
homolog (Table 2.4).   The ATG start codon is separated from the 3’ end of VVR2 by 39 bp.  A 
putative ribosome binding site (RBS) is located 9 bp upstream of the ATG start codon, with a 
possible promoter region upstream of the RBS.  Interestingly, the possible -35 site is located 
within the 3’ portion of VVR2, indicating that VVRs may serve to provide promoters to 
promoterless genes during cassette generation and integration as reported (2.47).  There are 54 
bp between the TAG stop codon and the 5’ end of VVR10.  The ORF itself is 1035 bp in length 
and the transposon had inserted between bases 322 and 323 of the ORF.   
 To determine the distribution of ORF4, PCR was conducted on both opaque and 
translucent strains of 10 CPS serotypes of V. vulnificus, four strains of V. cholerae, and one 
strain of V. parahaemolyticus (Table 2.1).  Primers used were 2066-Ext and 2272-Rev, which 
produced a product of 311 bp in V. vulnificus 1003(O).  A positive PCR product for ORF4 was 
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produced in only V. vulnificus 1003(O) and its derivatives, with a larger product resulting from 
GMB4(T) (Appendix Figure A.9).  No other strains of V. vulnificus, V. cholerae, or V. 
parahaemolyticus tested positive by PCR for ORF4 (data not shown), indicating that this cassette 
is unique to V. vulnificus 1003, as has been shown for other SI cassettes specific to other species 
of Vibrio (2.45).  Southern hybridization was employed to determine if there was any difference 
in the genomic location of ORF4 in 1003(O) and BG(T1).  Both the opaque and translucent 
phase variants contain one copy each of ORF4 on the same XbaI fragment, with no apparent 
difference between the two (Appendix Figure A.7).   
 Attempts to Restore Opacity to GMB4(T) through Complementation.  Several 
attempts were made to verify the necessity of ORF4 for CPS expression by providing an 
uninterrupted copy of the gene to GMB4(T) in trans.  The first attempts at cloning ORF4 
involved extracting XbaI digested genomic DNA in the 6 Kb size range (Figure 2.1 A) from an 
agarose gel, cloning these fragments into XbaI digested pUC19, and electroporating the resulting 
constructs into E. coli DH5αMCR, resulting in very few transformants, all of which were 
negative by PCR for ORF4, yet surprisingly positive for VVRs.  Next, the same population of 
constructs was introduced into E. coli NovaBlue, resulting in 164 colonies, all negative by PCR 
for ORF4 and positive for VVRs.  The possibility existed that a portion of the V. vulnificus DNA, 
containing multiple direct repeats, was being deleted by the E. coli cells.  Therefore, the same 
population of constructs was introduced into E. coli Max Efficiency STBL2, a strain marketed 
specifically for its being recombination deficient and capable of maintaining foreign DNA 
containing direct repeats or other instabilities.  Eighty colonies resulted, all of which were 
negative by PCR for ORF4 and positive for VVRs.   
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 The next approach involved generating ORF4-containing PCR products using the 
proofreading polymerase, Pfu Turbo, and cloning those products.  Primers Var1-For1 and Orf1-
Rev1 generated a PCR product of 5.2 Kb (Figure 2.1 B) and primers Orf4-For1 and Orf4-Rev1 
generated a PCR product of 1.8 Kb (Figure 2.1 C).  On the first attempt, each product was cloned 
into pSTBlue1 and transformed into E. coli NovaBlue, resulting in three sets of 26 colonies (78 
total), with each set being positive by PCR for Var1/ORF3, ORF4, or ORF1.  Also, three of the 
78 colonies that resulted were positive for all three ORFs; the plasmids were of the correct size 
and this construct was labeled pBG5.2.  This plasmid was used as the source of insert DNA for 
the construction of two additional plasmids, pBG5.2b (Kanr) and pBG5.2c (Camr).  However, 
upon introduction of these latter clones into E. coli Max Efficiency STBL2 and E. coli SURE® 2, 
respectively, no plasmids containing the intact 5.2 Kb inserts were obtained.   
 Next, pBG-ORF4 was constructed, which contained only the 1.8 Kb PCR product insert 
(Figure 2.1 C).  This plasmid was used first in the many unsuccessful attempts to electroporate 
directly into V. vulnificus GMB4(T).  pBG-ORF4 was introduced into E. coli Max Efficiency 
STBL2 by transformation; then, conjugation was attempted.  Tri-parental matings  
(quadruplicate experiments) between E. coli DH5αMCR(pRK2013),  E. coli Max Efficiency 
STBL2 (pBG-ORF4), and V. vulnificus GMB4(T) resulted in V. vulnificus transconjugants, three 
of which were positive by PCR for ORF4 but still showed a translucent phenotype, not the 
opaque phenotype that would have resulted had the mutation in ORF4 been complemented by 
the introduced gene.  A second quadruplicate set of tri-parental matings produced V. vulnificus 
transconjugants, two that were positive by PCR for ORF4 and one that showed the mutant PCR 
product, yet all were still of the translucent phenotype.  These results suggested that the 1.8 Kb 
insert was missing some necessary portion of the sequence needed to convert the translucent 
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GMB4(T) to the opaque phenotype.  Finally, pBG5.2d was constructed by the addition of an oriT 
region from pOJ446 into pBG5.2 to allow direct transfer from E. coli to V. vulnificus; it was then 
introduced into E. coli S17-1, and the resulting transformant was used in quadruplicate two-
parental matings with V. vulnificus GMB4(T).  Numerous transconjugants were obtained; all 
exhibited the appropriate antibiotic resistance, all were positive by PCR for ORF4, all contained 
plasmids of the appropriate size, and all retained the translucent phenotype.  No further attempts 
at complementation were made. 
DISCUSSION 
  The polysaccharide capsule of V. vulnificus has been shown to be a major virulence 
factor and numerous capsule chemotypes and serotypes have been identified (2.8, 2.19, 2.43, 
2.54), complicating the task of identifying the underlying mechanisms behind CPS production.  
The genetic organization of CPS/EPS genes in other pathogens has been well documented (2.44, 
2.52, 2.63, 2.64) but prior to the initiation of this study, only one gene, wcvA, had been reported 
to be necessary for CPS expression in V. vulnificus (2.73).  In this work, 6436 bp of the V. 
vulnificus genome from p44XBS [containing the insert from GMB4(T)] and genomic DNA were 
sequenced and revealed the presence of a genetic region with characteristics similar to those of 
the V. cholerae super-integron [SI] (2.33).  Among the characteristics of SIs, the presence of 
VVR repetitive sequences, gene cassettes, and an insertion sequence (the IS492 homolog) were 
shown.  Only one gene cassette, Var1/ORF3, showed homology to any known gene or gene 
product (Table 2.3).  This region also contained a gene (ORF4) interrupted by a transposon in a 
previous transposon mutagenesis experiment (2.72) and the resulting colony exhibited the 
translucent phenotype, which suggested that ORF4 was a novel gene necessary for CPS 
expression.  Subsequent to this work, a partial sequence of p44XBS was published by others 
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(2.56); the published sequence differs from that described here in some ways and those 
differences will be discussed where applicable.  
 Insertion sequences (ISs) are simple mobile genetic elements consisting of only a gene 
encoding a transposase that is flanked by inverted repeats (2.29, 2.37).  These elements are 
capable of transposition into or out of DNA molecules and if they insert into a gene, the gene 
will be disrupted; this disruption may be reversible if the IS is capable of precise excision.  IS 
insertion has been reported to result in phase variation due to the disruption of CPS/EPS genes in 
numerous bacterial species (2.21, 2.39, 2.41, 2.57, 2.71).  In addition, IS492 has been shown to 
reversibly control EPS expression in P. atlantica (2.4, 2.5).  The presence of an IS492 homolog 
in the SI region of GMB4(T) suggested this element may be related to CPS expression in V. 
vulnificus.  Southern hybridization revealed that the sequence was not present in all strains tested 
and that there was no difference between opaque and translucent variants of any strain tested 
with respect to this sequence.  The presence or absence of the IS was confirmed by PCR.  Thus, 
based on these results, it appears that the IS492 homolog plays no role in CPS expression in the 
strains tested. 
 Smith and Siebeling (2.56) also reported the presence of this IS in p44XBS as well as 
multiple copies present in the genome of 1003(O) and a different spontaneous translucent strain, 
referred to here as AZ(T) [previously 1003(T)].  Of special interest, Southern hybridization with 
a probe for the IS492 homolog showed multiple differences between 1003(O) and AZ(T) with 
respect to this IS.  Using PFGE, they reported restriction patterns of 1003(O) and AZ(T) that 
differed in only one fragment of approximately 330 Kb in 1003(O) and 260 Kb in AZ(T).  The 
IS492 probe hybridized to these different fragments and it was reported, but not shown, that a 
probe for VCR9 also hybridized to these same fragments, suggesting the IS was associated with 
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the SI.  So, while no differences were found between opaque and translucent forms of many 
strains in the current study, the possibility that this IS does play a role in the interruption and 
control of CPS expression in strain AZ(T) cannot be discounted.  Also, the same authors reported 
the presence of a five bp target sequence (ACAAG) identical to that necessary for insertion of 
IS492 in P. atlantica.  In P. atlantica , the target sequence is immediately adjacent to the inserted 
IS492 (2.40).  The same five bp sequence was identified in several locations in the sequence 
reported here, but none were immediately adjacent to the IS; however, that sequence was 
actually present in the 5’ portion of the six true VVRs, but not in any of the VCR homologs.  If 
this five bp sequence is indeed a target sequence for the IS492 homolog, its presence in VVRs 
would explain the apparent link between the SI and the IS.  Other members of the IS110 family, 
to which IS492 belongs, have been shown to insert in or near REP (repetitive extragenic 
palindromic) sequences in E. coli (2.11) and Pseudomonas putida (2.42).  It has been suggested 
that insertion into REP sequences allows the IS to propagate itself without as much harm to the 
host.  Further study would be needed to show an absolute correlation between the VVRs and the 
IS492 homolog. 
 Also of interest, V. vulnificus 1003(O), BG(T1), and AZ(T) possess many more copies of 
this IS than do the other strains tested.  While IS492 excises itself precisely and the donor DNA 
molecule is repaired (2.40), multiple copies of the IS may have arisen through multiple insertions 
in the genome.  Alternately, as some ISs are capable of transposition by a replicative mechanism 
(2.29), it is possible that the V. vulnificus IS492 homolog uses this method of transposition and 
has been present in 1003(O) and its derivatives longer than in the other strains, giving the IS 
more time to propagate additional copies of itself.  Given the lack of identical target sites at the 
insertion junction and that the amino acid identity between the two IS elements is only 72%, it is 
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suggested that the IS identified here is a novel IS and its role in CPS expression in V. vulnificus 
remains to be determined. 
 The characteristic that resulted in the initial identification of the V. cholerae SI was the 
presence of large numbers of imperfect direct repeats of 121 to 124 bp, termed VCRs, with each 
associated with a gene to form a gene cassette (2.13, 2.33, 2.36).  Ten of these repeats in V. 
vulnificus have been described here, six of which have been designated true VVRs because of 
their high nucleotide identity to each other and low identity to known VCRs.  XXRs (VVR and 
VCR homologs in other bacterial species with the XX representing the initials of the genus and 
species names) are considered to be species specific and the presence of VCR homologs in V. 
vulnificus suggests that the gene cassettes containing these repeats were generated at some time 
in V. cholerae and acquired by V. vulnificus through horizontal gene transfer (HGT) (2.45, 2.48).  
Exactly how a direct repeat sequence becomes associated with a gene to form a cassette is 
unknown.  Gene cassettes, when free and unintegrated in the SI array, are composed of the gene 
itself and the 3’ XXR; once integrated, cassettes are bordered by the repeats on both the 5’ and 3’ 
end.  Of special interest in the sequence reported here is that all three complete ORFs 
(Var1/ORF3, ORF4, and ORF1) have a VCR homolog as their 3’ repeat, suggesting that all were 
acquired through HGT.   
 All VVRs in this sequence are in the same orientation.  Smith and Siebeling (2.56) 
reported the presence of six VVRs in p44XBS, with two classed as VCR homologs and in the 
opposite orientation to the VVRs.  To date, all other XXRs  have been shown to be in the same 
orientation (2.45, 2.48, 2.59), supporting the interpretation of the p44XBS insert sequence 
reported here.  Both opaque and translucent forms of all V. vulnificus strains tested showed the 
presence of the VVRs, indicating that the SI is common in this species as it is in other Vibrio 
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spp. (2.45, 2.48).  Even though no difference was identified between strains 1003(O) and 
BG(T1) and the presence of the VVRs, there does appear to be a difference between these strains 
and strain AZ(T).  Whether the IS492 homolog, the VVRs themselves, or a combination of the 
two is the reason behind those differences remains to be determined.   
 Another form of repetitive sequence was identified in this work, the mini-cassettes.  
These small cassettes (260 to 355 bp) encode no ORFs and four of them are in tandem 
downstream of ORF4, which made sequencing of this region especially difficult and is most 
likely the reason that Smith and Siebeling (2.56) reported only a partial sequence of p44XBS that 
did not include this region.  These mini-cassettes seem to be another characteristic of SIs, as 
multiple copies of mini-cassettes are found in the SIs of several different bacteria (2.45).  Of 
special interest is that the V. vulnificus SI is on the large chromosome while that of V. cholerae is 
on the small chromosome (2.20), indicating that the position of the SI in the genomes of different 
species is not fixed, but only dependent upon the location of the int gene and its associated attI 
site.   
  A BLAST search utilizing the ORF1 sequence revealed no homology with any known 
gene or gene product.  This was not unusual in that many SI genes in other species encode 
unknown or hypothetical proteins (2.45).  This ORF remains uncharacterized.  Var1/ORF3 is a 
homolog of a gene (var1) found in Xenorhabdus nematophilus, an insect pathogen that is a 
symbiont in a nematode that is also an insect pathogen.  This gene has been shown to regulate 
stationary phase phenotypic variation in X. nematophilus with mutants retaining pathogenicity 
but unable to assist the growth of their nematode host in the parasitized insect host (2.62).  As 
this gene did not affect the ability of X. nematophilus to be pathogenic, ORF4, the gene disrupted 
by the transposon insertion, was chosen for further study.   
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 A translucent variant with ORF4 disrupted by the transposon and the lack of significant 
identity between ORF4 and any known gene or gene product suggested that ORF4 was a novel 
gene involved in CPS expression.  The fact that only 1003(O) and its derivatives harbor ORF4 is 
not unexpected, given the large number of different CPS types in V. vulnificus, as well as the 
report that many SI cassettes are species specific, regardless of the ancestry of the repeat 
sequence (2.45).  While other genes involved in pathogenesis [heat-stable enterotoxin (sto) and 
mannose-fucose resistant hemagglutinin (mrhB)] have been identified in the V. cholerae SI, 
neither is related to CPS expression (2.3, 2.36).   
 Definitive evidence for the role of ORF4 in CPS expression could only be acquired 
through complementation of the disrupted gene.  All complementation attempts that produced 
transformants or transconjugants used a PCR-generated uninterrupted copy of ORF4 and 
surrounding sequence.  The initial 5.2 Kb product in pBG5.2 was the source of the insert for 
subsequent clones pBG5.2b and pBG5.2c.  Transformations of E. coli using these two plasmids 
produced antibiotic-resistant transformants: some from which no plasmids could be isolated, 
indicating integration of the plasmid into the chromosome, and many more that yielded plasmids 
smaller than the original.  These transformants were also negative by PCR for the ORFs; together 
with the smaller plasmid size, this indicated deletions in the insert.  These deletions were not 
completely unexpected given the high number of long direct repeats in this region, but even the 
use of E. coli cells developed specifically for use with plasmids containing direct repeats or other 
unstable DNA did not allow the generation of the desired transformants.   
 Multiple tri-parental matings with the smaller pBG-ORF4 produced antibiotic resistant, 
ORF4-positive V. vulnificus colonies that retained the translucent phenotype.  It was possible that 
the PCR-generated 1.8 Kb insert contained a mutation that rendered ORF4 inactive; it was also 
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possible that some essential upstream sequence was missing from this insert.  After adding an 
oriT sequence to pBG5.2 to yield pBG5.2d, a direct mating between the E. coli host and V. 
vulnificus GMB4(T) also yielded antibiotic resistant, ORF4-positive V. vulnificus colonies that 
retained the translucent phenotype.  Plasmids of the appropriate size were obtained from these 
cells.  Again, it was a formal possibility that the PCR-generated 5.2 Kb insert contained a 
mutation that rendered ORF4 inactive.  Alternately, we considered that it was more likely, given 
the numerous failed attempts at complementation with multiple cloned inserts, that ORF4 does 
not play a role in CPS expression in V. vulnificus and that GMB4(T) was a spontaneous 
translucent phase variant that had coincidentally acquired the transposon during the original 
transposon generation experiments.  It appears that a role for the V. vulnificus SI in CPS 
expression and pathogenesis in general remains to be determined.     
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CHAPTER 3: 
 
HIGH FREQUENCY PHASE VARIATION OF VIBRIO VULNIFICUS 1003:  
ISOLATION AND CHARACTERIZATION OF A RUGOSE PHENOTYPIC VARIANT* 
 
 
 
 
 
 
 
 
 
 
 
 
* Portions reprinted by permission of Journal of Bacteriology 
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INTRODUCTION 
Vibrio vulnificus is a marine bacterium that is capable of causing human disease and has 
been reported as the cause of over 95% of the deaths related to seafood consumption in the 
United States (3.5, 3.25, 3.40, 3.47, 3.65).  Infection usually occurs through the ingestion of raw 
oysters or by contact of a pre-existing wound with contaminated seawater.  Susceptible 
individuals include those with liver disease, immune dysfunction, or elevated serum iron levels.  
When a susceptible individual consumes raw oysters contaminated with V. vulnificus, the result 
can be a rapidly fulminating septicemia, with mortalities occurring in over 50% of cases (3.5, 
3.25, 3.40, 3.47, 3.65).   
Some V. vulnificus isolates produce a polysaccharide capsule (3.3, 3.23) which gives the 
colonies a smooth, mucoid, opaque phenotype.  It has been reported that the capsule is a major 
virulence factor, presumably protecting the bacteria from the host immune system (3.20, 3.35, 
3.61, 3.80).  In culture, many opaque (O) strains will spontaneously produce translucent (T) 
variants (3.76, 3.83).  Opaque strains have been shown to be virulent in an iron-supplemented 
mouse model while translucent strains have been shown to be avirulent in this model (3.20, 3.61, 
3.80, 3.83).  Several studies have shown capsular polysaccharide (CPS) expression varies 
between opaque and translucent strains as well as among different translucent strains (i.e., 
suggesting there are different degrees of translucence) (3.76, 3.77, 3.80).  Transposon 
mutagenesis insertions have been shown to produce completely acapsular translucent strains 
(3.52, 3.76, 3.77, 3.83).   
Opaque strains of V. vulnificus have been reported to switch spontaneously to the 
translucent phenotype at frequencies of 10-5 to 10-4 when the cells were grown in rich media 
(3.31, 3.77, 3.80).  If grown in a peptone-based yet more defined media, the switch occurs at a 
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higher frequency, with over 60% of the colonies exhibiting the translucent phenotype (3.61).  
The reverse switch, from translucent to opaque, has been reported to occur at frequencies of 9.2 
× 10-3 (3.77), less than 10-4 (3.80), or not at all (3.31, 3.61).  It was previously observed in this 
laboratory that opaque strains will spontaneously yield translucent variants much more often than 
the reverse.  However, the translucent to opaque switch did occur on rare occasions when strains 
were routinely subcultured in heart infusion broth at 37oC and then left to stand at room 
temperature for several days before plating and incubation of plates at 37oC (unpublished 
results).   
Vibrio cholerae, the etiological agent of cholera, is a close relative of V. vulnificus.  
Although the O1 strains of V. cholerae produce no CPS, they have been responsible for the first 
six pandemics of cholera.  The current, seventh pandemic has been caused not only by O1 strains 
but also by O139 strains, which do produce CPS (3.10, 3.26, 3.27, 3.47, 3.72).  In addition to the 
encapsulated and nonencapsulated smooth phenotypes, V. cholerae exhibits a third colony 
phenotype, rugose.  First identified in the late 1930’s (3.73), rugose (R) variants arise in both O1 
and non-O1 V. cholerae strains and are wrinkled and dry compared to the smooth, mucoid 
phenotypes of the non-rugose strains.   Typically, rugose variants are obtained following growth 
of cells in minimal medium or under prolonged starvation conditions.  Rugose variants have 
been shown to form well-developed biofilms as a result of production of copious amounts of 
extracellular polysaccharide (EPS).  Bacteria show multiple forms of EPS, some of which appear 
to be secreted from the cell, with no residual attachment to the cell wall.  Another form of EPS is 
CPS, which has been shown to be covalently linked to the cell surface (3.54).  The rugose 
variants  have been shown to be more resistant than the smooth forms to chlorine, hydrogen 
peroxide, UV light, complement activity, and osmotic stress (3.1, 3.30, 3.45, 3.48, 3.53, 3.68, 
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3.79).  It was suggested that the rugose phenotype may allow V. cholerae to survive under 
adverse environmental conditions (3.1, 3.68, 3.79).  A recent study reported that the rugose EPS 
may be required for the efficient colonization of the intestine by V. cholerae and that rugose 
variants may function as ‘helpers’ to increase virulence of smooth strains (3.51).   
Previously, it was observed during routine subculturing of opaque and translucent strains 
of V. vulnificus in this laboratory, that each could yield the other phenotype, although 
frequencies of these switching events were not determined.  Here, a more comprehensive 
analysis to determine the frequency of conversion between opaque and translucent phase variants 
was undertaken.  Under carefully controlled conditions, high frequencies of conversion from 
opaque to the translucent phenotype and also of translucent isolates switching to opacity were 
observed.  More significantly, this analysis revealed a new phenotypic form of V. vulnificus, the 
rugose variant.  Further characterization of this variant revealed it to be relatively non-motile on 
semi-solid media, more resistant to serum killing than its parental opaque or translucent versions, 
and capable of producing copious amounts of biofilm. 
MATERIALS AND METHODS 
Bacterial Strains and Growth Conditions.   V. vulnificus strains are described in Table 
3.1. and the relationship between the V. vulnificus 1003 phase variants is shown in Figure 3.1.  
All V. vulnificus strains were grown in heart infusion (Difco) broth or agar plates supplemented 
to 2% NaCl (HI).  HI plates contained 1.8% agar.  Motility plates were HI with 0.3% agar (3.33, 
3.34).  Cultures were incubated at 34o to 35oC with shaking at 200 rpm unless otherwise 
specified.  Plates were incubated at 30oC unless otherwise specified.  Kanamycin (50 μg/ml) was 
added as necessary. 
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TABLE 3.1. Bacterial strains used in this study. 
   
   
Strain Isolation and characterizationa Reference(s) or 
source 
   
   
Vibrio vulnificus 1003   
1003(O) Wound isolate, opaque, encapsulated, virulent; 
designated as wild type, smooth; CPS serotype 9, 
LPS serotype unk.;  Colr
(3.39, 3.60) 
BG(R) Spontaneous rugose derivative of 1003(O), dry, 
wrinkled 
This study 
BG(T1) Spontaneous translucent derivative of 1003(O), 
smooth 
This study 
BG(T2) Spontaneous highly translucent derivative of  
BG(T1), smooth 
This study 
AZ(T) Spontaneous highly translucent derivative of 
1003(O), avirulent, smooth, previously 1003(T) 
(3.83) 
ABZ1(T) Translucent, avirulent; defective in capsule 
expression due to mini-Tn10 insertion in the 
wcvA gene of 1003(O), smooth; Kanr
(3.62, 3.83)   
ABZ1(R) Spontaneous rugose derivative of ABZ1(T), dry, 
wrinkled; Kanr
This study 
GMB4(T) Translucent, avirulent; mini-Tn10 insertion in 
ORF4 of 1003(O) super-integron region, smooth; 
previously ABZ44(T); Kanr
(3.62, 3.82) 
GMB4(R) Spontaneous rugose derivative of GMB4(T), dry, 
wrinkled; Kanr
This study 
GMB4(O) Spontaneous opaque derivative of GMB4(T), 
smooth; Kanr
This study 
V. vulnificus   
1005(O) Blood isolate, opaque, smooth; CPS serotype 1, 
LPS serotype 3 
(3.39, 3.60) 
1005(R) Spontaneous rugose derivative of 1005(O), dry, 
wrinkled 
This study 
1007(O) Blood isolate, opaque, smooth; CPS serotype 4, 
LPS serotype O1 
(3.39, 3.60) 
1007(R) Spontaneous rugose derivative of 1007(O), dry, 
wrinkled 
This study 
1014(O) Blood isolate, opaque, smooth; CPS serotype 3, 
LPS serotype 2 
(3.39, 3.60) 
1014(R) Spontaneous rugose derivative of 1014(O), dry, 
wrinkled 
This study 
96-7-155(O) Eel isolate, opaque, smooth; CPS serotype 9, LPS 
serotype unk. 
Laboratory 
collection 
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TABLE  3.1. continued 
   
   
96-7-155(R) Spontaneous rugose derivative of 96-7-155(O), dry, 
wrinkled 
This study 
   
 
a Colr, colistin resistance; Kanr, kanamycin resistance; unk., unknown. 
 
 
1003(O) 
AZ(T) ABZ1(T) GMB4(T) BG(T1) BG(R) 
BG(T2) ABZ1(R) GMB4(R) 
 
 
 
 
 
FIGURE 3.1.  Relationship of phase variants used in this study.  All first level variants 
were derived directly from the Louisiana clinical isolate, V. vulnificus 1003(O).  O, opaque; T, 
translucent; R, rugose. 
 
Switching Assay.  The opaque parental strain 1003(O), three spontaneous translucent 
derivatives [AZ(T), BG(T1), and BG(T2)], as well as two previously described (3.62, 3.83)  
transposon-induced translucent strains [ABZ1(T) and GMB4(T)] (Table 3.1 and Figure 3.1) were 
subjected to culture conditions that allowed switching to the alternate phenotype.  In an 
adaptation of a previously described procedure (3.38), V. vulnificus strains were tested for 
phenotypic switching using heart infusion broth and heart infusion agar plates, both of which 
were supplemented to 2% NaCl (HI).  Briefly, 10-ml HI broth cultures were started from isolated 
colonies of the desired phenotypes, and following overnight incubation at 34o to 35oC with 
shaking at 200 rpm, the first passage was started by diluting the original culture 1:100 into fresh 
broth followed by overnight incubation as before.  Daily passages were continued for 5 to 6 days 
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total, the last of these passages was serially diluted and plated on HI agar, and the plates were 
incubated at 30oC overnight, whereupon colonies and their phenotypes were counted and scored.  
On the same day as the plating, the next passage was made in case there was no phenotypic 
switching.  In the latter case, daily passages were continued for another 5 to 6 days, followed by 
dilutions and platings as before.  Results were recorded as percentages (100 × [the number of 
colonies showing a particular phenotype divided by the total number of colonies]). 
To demonstrate that the rugose phenotype is not unique to V. vulnificus 1003 and its 
derivatives, 26 other strains of V. vulnificus, from both environmental and clinical sources, were 
tested qualitatively for the ability to form rugose colonies.  HI broth cultures were started from 
frozen stocks, incubated at 34o to 35o C and 200 rpm overnight, and then streaked to HI plates.  
After overnight incubation at 30oC, the plates were inspected for the presence of rugose colonies.    
To examine the persistence of rugose isolates at different temperatures, strains BG(R) 
and ABZ1(R) were subjected to switching assays where all inoculations, passages, and platings 
were done as described with all incubations at either 30 or 37oC throughout the assays.   
PCR Amplification, Sequencing, and Analysis of 16S rDNA.  Genomic DNA from V. 
vulnificus 1003(O) and other strains was extracted as described in Chapter 2.  Reaction mixtures 
for the amplification of 16S rDNA contained 5μl 10X Pfu Turbo buffer, 0.4 μl of each 25mM 
dNTP (Stratagene), 1 μl of 20 μM primer 27f (5’GAGTTTGATCCTGGCTCAG3’), 1 μl of 20 
μM primer 1525r (5’AGAAAGGAGGTGATCCAGCC3’) (3.50), 2.5 U of Pfu Turbo 
polymerase (Stratagene), and 100 ng template DNA.  The mixture was adjusted to 50 μl with 
sterile, nuclease-free H2O (Sigma).  The PCR conditions consisted of an initial temperature of 
95oC for 2 min followed by 30 cycles of 95oC for 30 sec, 60oC for 30 sec, and 72oC for 2 min.  A 
final extension step at 72oC for 10 min was included, after which samples were held at 4oC.  
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Desired PCR products were verified by analytical agarose gel electrophoresis, purified using the 
QIAquick PCR Purification Kit (QIAGEN) following the manufacturer’s instructions, and 
subjected to automated sequencing.     
DNA sequences were analyzed with the programs Clone Manager 5 and Align Plus, 
version 2.0 (Scientific and Educational Software) and BioEdit, version 5.0.9 (NCSU).  Each 
sequence was submitted to a BLASTN (3.2) search of relevant databases.  
Whole Colony Microscopy.  Cultures were grown as described earlier.  Dilutions were 
made and spread to HI agar plates.  After incubation at 30oC for 18 to 48 h, individual colonies 
were observed with a Wild M7S dissecting microscope with both transmitted and reflected light.  
Images were recorded with a Spot Insight digital camera. 
Serum and Chlorine Resistance/Sensitivity Assays.  Rugose V. vulnificus isolates 
BG(R) and ABZ1(R) along with their respective opaque and translucent parents were analyzed 
for their resistance to complement-mediated serum killing by exposing cells grown in broth 
culture to normal human serum (NHS; Sigma) at 37oC as described previously (3.6).  Each 
culture was started from a representative colony of a given phenotype and the experiments were 
conducted at least twice with the average percent survival reported.   
The same four strains were analyzed for their resistance to chlorine, a common 
disinfectant, as described previously for V. cholerae (3.79).  Only newly purchased NaOCl (6%) 
was used and the sealed containers were not opened until immediately prior to dilution to 3 ppm 
(free chlorine) in phosphate buffered saline (PBS, pH 7.2).   
Motility Test.  HI plates containing 0.3% agar were inoculated from isolated colonies of 
phase variants.  The plates were incubated at 30oC for 6 h when the motility zone was measured 
and the plates were photographed with a Sony Mavica MVC-FD91 digital camera.  
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Biofilm Tube Assay.  Isolated colonies of the appropriate phenotypes were used to 
inoculate 10 ml tubes of HI broth and the cultures were incubated overnight at 30oC and 200 
rpm.  The assay was conducted as described previously (3.1, 3.81), with modifications as 
follows. On the day preceding the assay, 1 ml of HI was added to sterile 12 x 75 mm borosilicate 
glass tubes and the tubes were incubated statically overnight at 30oC to verify sterility.  For the 
assay, the 1 ml tubes were inoculated 1:100 (in triplicate) from the overnight cultures.  Three 
tubes were uninoculated and served as media controls.  All tubes were then incubated statically 
at 30oC for 48 h.  After incubation, the cultures were decanted gently so as not to disturb any ring 
of biofilm that had formed.  Each tube was rinsed gently three times with 2% NaCl to remove 
any unattached cells and 1.1 ml of 0.1% crystal violet was added to each tube to cover the 
biofilm rings.  Staining continued for 30 minutes at room temperature after which the crystal 
violet was decanted gently and the tubes were rinsed gently three times with 2% NaCl to remove 
excess stain.  The biofilms were resuspended in 1.1 ml dimethyl sulfoxide (DMSO) and the 
absorbance of the extracted stain was measured at 570 nm.  Dilutions were made as necessary 
and the final absorbance value was multiplied by the dilution factor.  Biofilm data were analyzed 
using StatView 5 (SAS Institute, Inc.). 
Collodion Coverslide Biofilm Assay.  For each biofilm to be collected, a 400 mesh 
copper transmission electron microscopy (TEM) grid was placed on a sterile circular 1 cm 
diameter coverslip and both were overlain with a collodion polymer membrane prepared from a 
solution of 2% collodion in amyl acetate (Electron Microscopy Sciences) as described previously 
(3.24).  Prepared coverslips were dried overnight.  
Cultures were grown as for the biofilm tube assay.  HI broth (5 ml) was placed in each 
well of a 6-well culture plate (Costar) and incubated overnight at 30oC.  The next morning, the 
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HI in each well was inoculated 1:100 from the appropriate overnight culture and then incubated 
statically at 30oC for up to 6 h.  Biofilms that formed at the air-broth interface were harvested by 
their attachment upon contact to the collodion-coated surface of the previously prepared glass 
coverslips.  A coverslip was picked up from the back with suction forceps, its collodion-coated 
surface with embedded copper TEM grid was touched to the culture surface, and then dipped 
briefly in 2% NaCl to remove unattached cells.   The TEM grid with attached cells was removed 
and negative stained with 2% uranyl acetate, dried and later imaged with a JEOL 100CX 
transmission electron microscope.  Living organisms on the coverslip were mounted with their 
residual saline on a microscope slide, examined with 20X and 40X Differential Interference 
Contrast (DIC) objectives on a Nikon Microphot-FXA light microscope, and images were 
recorded with a Spot RT digital camera. 
  Biofilm Slide Assay.  To observe biofilm development on a glass slide, three strains 
were selected: the parental opaque strain 1003(O) and its spontaneous derivatives BG(R) and 
AZ(T).  The latter was selected from among the spontaneous translucent strains because it 
showed the highest stability in the switching assay.  Cultures were grown as for the biofilm tube 
assay.  HI broth (17.5 ml) was placed in each of 16 sterile 50 ml conical tubes (Corning) and 
incubated statically overnight at 30oC.  The next morning, the HI broth was inoculated 1:100 in 
quadruplicate from the overnight cultures.  Uninoculated broth served as a control.  One ethanol-
washed, sterile, glass microscope slide was placed on end into each of the 50 ml tubes.  The 
tubes were then incubated statically at 30oC.  Slides were removed from the broth after 30 min, 1 
h, 2 h, and 4 h of incubation at which time they were gently rinsed with 2% NaCl.  Slides were 
coverslipped, examined with a Nikon Microphot-FXA light microscope using 20X and 40X DIC 
objectives, and images were recorded with a Spot RT digital camera. 
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SEM and TEM.  Cultures were grown as described above.  Dilutions were made and 
spread to HI agar plates.  After incubation at 30oC for 18 to 48 h, colonies selected for scanning 
electron microscopy (SEM) were removed from the plate with the underlying agar, placed on 
filter paper in a Petri dish and vapor fixed overnight with 4% osmium tetroxide.  The agar plug 
was then placed on an adhesive-coated SEM stub, air dried, and treated with a graphite 
suspension to enhance conductivity.  Samples were then sputter coated with AuPd (60:40) on an 
Edwards S-150 sputter coater, fractured, and imaged with a Cambridge 260 Stereoscan SEM.     
Isolated colonies were selected for polycationic ferritin staining and treated as described 
previously (3.68) with modifications as follows.  Cells were fixed in 5% glutaraldehyde in 0.1 M 
cacodylate buffer (pH 7) for 2 h, then filtered onto a 0.2 μm polycarbonate filter, and gently 
rinsed 3 times with buffer.  Cells were then treated with polycationic ferritin (Sigma) (final 
concentration 1.0 mg/ml) for 30 min and rinsed in buffer.  Stained cells were then treated with 
2% osmium tetroxide for 1 h, rinsed with water, and stained with 0.5% uranyl acetate for 1 h.  
Samples were dehydrated with ethanol and allowed to infiltrate with a 1:1 mixture of ethanol and 
LR White resin overnight, after which the samples were infiltrated with 100% LR White for 2 h.  
They were then embedded at 60oC, sectioned, stained with Reynolds lead citrate, and imaged 
with a JEOL 100CX transmission electron microscope.   
Nucleotide Sequence Accession Numbers.  The GenBank nucleotide accession numbers 
for the V. vulnificus 16S rRNA genes sequenced in this study are as follows:  AY676129 
[1003(O)], AY676130 [1003 BG(R)], AY676131 [1003 AZ(T)], AY676132 [GMB4(R) 5’], and 
AY676133 [GMB4(R) 3’].   
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RESULTS 
Appearance of a Rugose Phenotype for V. vulnificus.  The opaque parental strain 
1003(O), three spontaneous translucent derivatives, as well as two previously described 
transposon-induced translucent strains (3.62, 3.83) were subjected to culture conditions that 
allowed switching to the alternate phenotype.  Table 3.2 shows the results of three independent  
 
TABLE 3.2.  Phenotypic switching of V. vulnificus 1003 phase variants. 
 
  
 Resulting phenotypes (avg percent of total colonies)b
  
  
Parent straina Opaque (SE) Translucent (SE) Rugose (SE) 
    
    
1003(O) 55.2  (23.0) 30.6  (16.2) 13.0    (3.0) 
BG(T1) 17.3  (12.4) 74.7  (15.9) 5.8    (2.9) 
BG(T2) 1.7    (0.9) 94.3    (2.1) 3.8    (2.2) 
AZ(T) 0.5    (0.4) 98.1    (1.7) 0       (0.0) 
ABZ1(T) 0       (0.0) 78.2  (16.0) 18.2  (12.8) 
GMB4(T) 7.9    (7.7) 79.8  (10.5) 8.3    (5.5) 
BG(R) – 30oC   15.8    (3.2) 0.1  (0.04) 53.8    (2.8) 
BG(R) – 37oC 26.3  (15.5) 0       (0.0) 53.1  (21.8) 
ABZ1(R) – 30oC  0       (0.0) 42.9  (21.0) 42.0  (13.0) 
ABZ1(R) – 37oC 0       (0.0) 3.7    (3.7) 94.2    (5.0) 
    
 
a O, opaque; T, translucent; R, rugose.  Switching assays were conducted for one to 
three cycles of culture passaging and plating as described in the text, with O and T broth 
cultures incubated at 34o to 35oC and plates incubated at 30oC; R broth cultures and 
plates were incubated at either 30oC or 37oC as indicated.    
b The total percent of colonies for a given strain does not equal 100 because some 
colonies were sectored, while others were of an intermediate phenotype.  SE, standard 
error. 
 
switching assays reported as percentages (100 × [the number of colonies showing a particular 
phenotype divided by the total number of colonies]).   
 72
Not only did the opaque strain often switch to the translucent phenotype but, as with most 
of the other strains, it also produced a small, wrinkled, and dry colony type (Figure 3.2) that 
resembled the rugose phenotype reported for V. cholerae (3.1, 3.45, 3.48, 3.68, 3.79) and other  
 
 
 
 
 
 
 
 
 
 
 
1 
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A B 
FIGURE 3.2.  V. vulnificus 1003 phase variants.  All colonies were grown on HI agar 
plates for 24 to 48 h at 30oC and  viewed with a dissecting microscope.  A. (1) Opaque, (2) 
translucent, and (3) rugose colonies.   B.  A rugose colony at higher magnification.  
 
bacterial species (3.4, 3.13).  Interestingly, the parental opaque strain showed the highest overall 
switching frequency, with over 30 percent of its resulting colonies being translucent and 13 
percent being rugose.  The translucent strains meanwhile, varied considerably in their conversion 
to the alternate phenotypes.  Of the spontaneously isolated strains, BG(T1) produced opaque 
colonies at a frequency 10-fold greater than that of its more highly translucent derivative, 
BG(T2). Strain AZ(T), the most translucent of the spontaneous translucent strains used here, 
produced 35-fold fewer opaque colonies than BG(T1) and never produced a rugose colony 
during any of the three switching assays.  It was thus the most stable translucent strain overall 
used in the study.   
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Two previously described translucent variants of parental strain 1003(O) that were 
isolated following transposon mutagenesis (3.62, 3.83) were also examined for their switching 
frequencies.  The first of these, ABZ1(T), contains an insertion in a gene (wcvA) that is essential 
for capsule production, and, as expected, it showed no conversion to opacity (Table 3.2).  It did, 
however, yield rugose colonies, which demonstrates that the rugose phenotype in V. vulnificus 
can occur independently from capsule production.  In contrast, strain GMB4(T), which contains 
an insertion in ORF4 of the super-integron region of the V. vulnificus genome (3.8, 3.62), 
produced not only a rugose form but, surprisingly, also converted to the opaque phenotype.  This 
result, along with other evidence (see Chapter 2), suggests that GMB4(T) arose spontaneously 
from 1003(O) and coincidentally acquired the transposon during the original transposon 
mutagenesis experiments (3.82).  
To demonstrate that the rugose phenotype is not unique to V. vulnificus strain 1003 and 
its derivatives, 26 other V. vulnificus strains, from both environmental and clinical sources, were 
tested qualitatively for the ability to form rugose colonies.  The rugose phenotype was shown 
readily by three Louisiana clinical isolates (1005, 1007, and 1014) and one eel isolate (96-7-155) 
from Denmark.  The parent phenotype of those four strains is opaque.   The other 22 strains 
produced only opaque or translucent colonies in this shortened assay.   
Switching of Rugose Forms Back to Opaque and Translucent Colony Forms.  V. 
vulnificus strains have been grown routinely at 37oC in this laboratory, and no rugose phenotype 
was observed previously.  This included switching assays involving opaque and translucent 
isogenic pairs, which were performed similarly to the one reported here, except that alkaline 
peptone water minimal medium and a consistent temperature of 37oC were used for all culture 
and plate incubations (3.38).  In the present study, the rugose variants appeared when HI broth 
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cultures were incubated at temperatures below 37oC and plates were incubated at 30oC.  To 
examine the persistence of rugose isolates at different temperatures, strains BG(R) and ABZ1(R) 
were subjected to switching assays in which all incubations were performed at either 30 or 37oC.  
The results (Table 3.2) show that significant numbers of the opaque-derived rugose isolate 
BG(R) could persist at both 30oC and 37oC.  Switching of BG(R) back to the opaque form also 
was observed, while, interestingly, conversion to a translucent form was barely detectable (at 
30oC) or was not seen at all (at 37oC).  Persistence of ABZ1(R), the rugose derivative of the 
acapsular transposon mutant ABZ1(T), also was detected at 30oC and even more so at 37oC.  As 
expected, no switching back to the opaque phenotype was observed for ABZ1(R), while 
conversion to translucence was observed at both temperatures.  As reported below for all 
variants, opaque and translucent derivatives of rugose strains obtained during these assays 
showed increased motility and lost the ability to form pellicles during static growth in broth (data 
not shown).  These characteristics were consistent with their new phenotypes.        
Characterization of the V. vulnificus Rugose Variants.   The 16S rRNA genes from 
1003(O), BG(R), GMB4(R), and AZ(T) were amplified by PCR, and the sequences of the 
resulting products were used in BLASTN (3.2) searches of relevant databases.  The genomes of 
two strains of V. vulnificus have been sequenced recently (3.8, 3.32) and shown to possess nine 
different rRNA operons each.  The sequences obtained here showed greatest identity (97 to 99%) 
to 16S rRNA genes from known V. vulnificus strains (data not shown).   
Rugose V. vulnificus isolates BG(R) and ABZ1(R) along with their parent opaque 
[1003(O)] and translucent [ABZ1(T)] variants were analyzed for their resistance to complement-
mediated serum killing by exposing cells grown in broth culture to normal human serum (NHS, 
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Sigma) as described previously (3.6).  As expected, the parental opaque strain 1003(O) showed 
much greater resistance to serum than the translucent parent ABZ1(T) (Table 3.3).  Specifically,  
 
TABLE 3.3.  Survival of V. vulnificus 1003 phase variants after exposure to normal 
human serum (NHS). 
 
   
 Colony forming units (cfu) after 1 h Percent survivala
   
      
Strain PBSb NHS NHS* Per trial Avg (SE) 
      
      
1003(O) 1.2 × 107 9.2 × 107 2.0 × 108 45.3  
 4.4 × 107 9.9 × 107 1.5 × 108 68.3 56.8(11.5) 
BG(R) 3.6 × 107 1.8 × 108 3.5 × 108  51.4  
 3.3 × 107 1.0 × 108 8.2 × 107      122.0 86.7(35.3) 
ABZ1(T) 3.5 × 106 5.2 × 103 1.5 × 107       0.035  
 4.9 × 106 5.5 × 104 1.7 × 107       0.315  
 1.2 × 107 1.2 × 105 6.8 × 107       0.175 0.18(0.08) 
ABZ1(R) 2.3 × 107 1.0 × 106 6.4 × 107   1.6  
 3.4 × 106 4.5 × 104 1.0 × 107     0.43 1.0(0.6) 
      
      
a Percent survival = 100 × (cfu in NHS/cfu in NHS*). 
b PBS, phosphate buffered saline, pH 7.2; NHS, normal human serum; NHS*, heat 
inactivated NHS; SE, standard error. 
 
 
1003(O) demonstrated serum resistance of approximately 57%, while ABZ1(T) was over three 
hundred-fold less resistant at 0.18% survival.  While serum resistance relative to that of the 
specific parents appeared slightly elevated for rugose isolates BG(R) (87%) and ABZ1(R) 
(1.0%), the latter translucent-derived rugose isolate was still more sensitive by over 50-fold 
compared to the opaque strain 1003(O) and by over 80-fold compared to the opaque-derived 
rugose derivative BG(R). 
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The same four strains were tested also to determine their resistance to chlorine 
disinfectant (Table 3.4).  Surprisingly, and in contrast to the findings for V. cholerae rugose  
 
TABLE 3.4.  Effect of chlorine on survival of V. vulnificus 1003 phase variants. 
 
     
 Colony forming units (cfu) after exposurea (% survivalb) 
  
   
 5 min 30 min 
   
   
Strain PBS NaOCl PBS NaOCl 
 
     
1003(O) 4.4 × 107 0 (0) 4.5 × 107 0 (0) 
BG(R) 7.2 × 107 0 (0) 6.5 × 107 0 (0) 
ABZ1(T) 2.4 × 107 8.5 × 104 (0.35) 1.0 × 107 1.5 × 103 (0.02) 
ABZ1(R) 2.3 × 107 1.4 × 104 (0.06) 4.6 × 107 2.9 × 103 (0.01) 
     
  
a NaOCl was used at a concentration of 3 ppm in PBS, pH 7.2.   
b Percent survival is reported as 100 × (Number of cfu from NaOCl treated cultures/ 
number of cfu from PBS treated cultures).  Survival in PBS is designated as 100%.   
 
forms (3.1, 3.48, 3.53, 3.79), V. vulnificus BG(R) and its opaque, smooth parent 1003(O) were 
both totally eradicated by exposure to 3 ppm (free chlorine) fresh NaOCl for both 5 min and 30 
min.  Strain ABZ1(R) and its translucent, smooth parent ABZ1(T) exhibited a 3-log decrease in 
viable cell counts after 5 min exposure and survived even 30 min of treatment with a 4-log 
decrease in viable cell counts relative to the PBS controls.   
Because rugose isolates of V. cholerae show decreased motility relative to their smooth 
counterparts (3.1), rugose strains of V. vulnificus were tested for their motility characteristics 
relative to their opaque or translucent parents.  Following inoculation onto motility plates and 
incubation for 6 h at 30oC, both BG(R) and ABZ1(R) showed much lower motility than their 
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respective parental opaque and translucent strains, which produced wide motility zones of 
similar sizes (Figure 3.3).  Interestingly, ABZ1(R) consistently demonstrated a greater than two-
fold motility increase over the opaque-derived BG(R), and similar results were observed for  
 
 
1003(O) 
BG(R) 
ABZ1(T) 
ABZ1(R) 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.3.  Swimming motility of V. vulnificus 1003 strains.  Motility agar plates 
were inoculated from isolated colonies of each phase variant and incubated at 30oC for 6 h.  
Thirty-five colonies of each variant were tested.  
 
the rugose isolates derived from other translucent parents (data not shown).  Despite their 
decreased motility in 0.3% agar, both BG(R) and ABZ1(R) cells were observed under TEM to 
possess a polar flagellum and under phase contrast microscopy to actively swim in phosphate-
buffered saline (data not shown).  The presence of a polar flagellum for rugose isolates is similar 
to the findings for rugose V. cholerae as described by Ali et al. (3.1).    
Rugose V. vulnificus Produce Copious Biofilms.  When inoculated into broth and 
incubated at 30oC with shaking, all V. vulnificus 1003 phase variants grew suspended in the 
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broth, although rugose isolates formed an aggregate ring at the air-broth-glass interface.  When 
broth was incubated statically at 30oC (Figure 3.4), opaque and translucent strains grew 
suspended in the broth while rugose variants formed a pellicle at the air-broth interface as well as 
the aggregate ring and did not grow in suspension; rather, aggregates formed at the pellicle, sank 
to the bottom of the tube, and accumulated there while the broth remained clear.  The aggregate 
ring and pellicle did not form when rugose isolates were incubated at 37oC (data not shown).   
 
 
 
1 2 3  
 
 
 
 
 
 
 
 
FIGURE 3.4.  Distribution of V. vulnificus 1003 phase variants in broth culture.  The 
rugose variant BG(R) (2) forms a pellicle and aggregate ring after static growth in HI broth for 
24 h at 30oC.  As cells accumulate in the pellicle, aggregates break off and sink to the bottom of 
the tube.  Both the 1003(O) (1) and AZ(T) (3) strains grow dispersed in the broth and do not 
form a pellicle or aggregates. 
 
The aggregate ring produced at the air-broth-glass interface in culture tubes by rugose 
strains of V. vulnificus resembled biofilms produced by V. cholerae rugose variants (3.21, 3.22, 
3.30, 3.67, 3.71, 3.79, 3.81).  The production of a biofilm by V. vulnificus has been reported 
(3.37, 3.42, 3.49), but an opacity/translucence phenotype associated with biofilm production was 
only recently described (3.29).   Biofilms produced by V. vulnificus phase variants grown at 30oC 
statically for 48 h in glass culture tubes were quantified by first staining with crystal violet, 
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resuspending the stained biofilms in DMSO, and then measuring the absorbance of the extracted 
stain at 570 nm.  Rugose variants produced significantly more biofilm than did opaque or 
translucent strains (Table 3.5).  Strains BG(R), ABZ1(R), and GMB4(R) produced 16 (P<0.005), 
20 (P<0.05), and 17 (P<0.0005) times, respectively, the amount of biofilm produced by the 
opaque strain 1003(O).  Meanwhile, 1003(O) produced relatively minimal biofilms, which 
appeared to be consistently greater than those produced by its translucent derivatives; in most 
cases, the difference in biofilm formation between opaque and translucent was not statistically 
significant (Table 3.5).   
 
TABLE 3.5.  Biofilm production by V. vulnificus 1003 phase variants. 
   
   
Strain Absorbance at 570 nm (SE)a Relative biofilm productionb
   
   
1003(O) 0.279  (0.041) 1.00 
AZ(T) 0.140  (0.019) 0.51 
ABZ1(T) 0.163  (0.045) 0.58 
GMB4(T) 0.191  (0.033) 0.68 
BG(R) 4.429  (0.528) 15.87 
ABZ1(R) 5.602  (1.322) 20.19 
GMB4(R) 4.857  (0.421) 17.41 
   
 
a Absorbance is the average of triplicate measurements obtained in biofilm tube assays as 
described in the text.  Absorbance values of incubated HI broth also were measured and 
subtracted from the experimental sample values to correct for background.  SE, standard error. 
b Relative biofilm production is calculated relative to that produced by 1003(O). 
 
To confirm and extend the results from the tube assay, biofilms produced by phase 
variants of V. vulnificus were examined directly by DIC microscopy after collection using 
collodion-coated glass coverslips.  Figure 3.5 shows that while the rugose strains BG(R) and  
ABZ1(R) (Figure 3.5 B and D, respectively) produced a thick pellicle and adhered to the 
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FIGURE 3.5.  Differential interference contrast micrographs of V. vulnificus 1003 
biofilms collected with a collodion-coated coverslip.  Fresh media was inoculated 1:100 into 6-
well plates from the appropriate overnight cultures and the resulting cultures were incubated 
statically up to 6 h at 30oC.  Biofilms that formed at the air-broth interface were harvested upon 
contact with collodion-coated coverslips.  Each strain was grown in triplicate cultures and the 
assay was conducted at least twice for each strain.  A. 1003(O); B. BG(R); C. ABZ1(T); and D. 
ABZ1(R).  Bars, 10 μm.  
 
collodion-coated coverslip as a biofilm, their respective parental strains 1003(O) and ABZ1(T) 
(Figure 3.5 A and C, respectively) did not produce pellicles and adhered as individual cells.  
Compared to the quantitative results for the tube assay, the difference in biofilm formation 
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between the opaque and translucent strains here appears to be greater; however, it is noteworthy 
that while the earlier assay involved staining biofilms that had adhered to glass tubes at the air-
broth interface, the latter method involved capturing previously formed biofilms upon contact 
with collodion-coated coverslips.  
Biofilm Development on Glass Slides.  Three strains were selected for the glass slide 
biofilm assay: the opaque parent strain 1003(O) and its spontaneous derivatives BG(R) and 
AZ(T).  AZ(T) was selected over other spontaneous translucent strains because of its stability in 
the switching assay.  Figure 3.6 shows the progression of biofilm development in strain BG(R).  
At 30 min post-inoculation, there were a few isolated microcolonies (small aggregates of cells) 
that had adhered to the slide, while after 1 h of incubation, microcolonies were larger and had 
assumed a definite 3-dimensional (3-D) appearance and free-swimming cells appeared to swim 
toward the aggregates.  By 2 h post-inoculation, there were several more 3-D microcolonies 
adhered to the slide and again, free-swimming cells were seen apparently swimming toward the 
microcolonies.  By 4 h post-inoculation, there was a visible line on the slide at the broth surface 
and an almost completely contiguous biofilm had formed.  In contrast to BG(R), 1003(O) and 
AZ(T) cultures did not form a biofilm on the glass slide.  Rather, those cells were seen to be free-  
swimming with only a few isolated individuals adhered to the glass throughout the 4 h assay 
(data not shown).    
Rugose Colonies are 3-D Surface-Air Interface Biofilms.  Fixed colonies of 1003(O), 
BG(R), AZ(T), ABZ1(T), and ABZ1(R), both whole and fractured, were observed under SEM to 
ascertain any differences in colony architecture.  As shown in Figure 3.7A and B, opaque and 
translucent strains have a smooth colony surface and a flat architecture, reminiscent of a biofilm 
monolayer.  Rugose strains, however, exhibit a wrinkled colony surface and a distinct 3-D 
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 FIGURE 3.6.  Differential interference contrast micrographs of biofilm development on 
a glass slide by V. vulnificus BG(R).  Sterile glass slides were added to fresh HI inoculated and 
incubated as described in the text.  Biofilms were allowed to develop until the slides were 
removed at different time points for examination.  Micrographs were taken at the following 
times.  A. 30 min; B. 1 h; C. 2 h; and D. 4 h.  Bars, 10 µm.     
 
 
colony architecture reminiscent of classic biofilm structure (Figure 3.7C, D, E, F).  Pillars, 
channels, and arches are present in these colonies as described for 3-D biofilms formed in liquid 
(3.14, 3.64).          
Both Opaque and Rugose Strains of V. vulnificus Produce More CPS/EPS than 
Translucent Strains.  EPS produced by rugose variants of V. cholerae has been shown to bind  
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FIGURE 3.7.  Rugose V. vulnificus colonies are solid-air interface 3-dimensional 
biofilms.  Whole colonies grown on HI were fixed, fractured, and viewed with SEM.  Opaque 
(A) and translucent (B) colony surfaces show no complex structure while rugose (C, D, E, F) 
colony surfaces show the pillars, channels, and arches reminiscent of biofilms formed in liquid.  
A. 1003(O); B. ABZ1(T); C, E, F. BG(R); D. ABZ1(R).  Bars, A, B, C, E, 100 µm; D, 50 µm; 
F, 20 µm. 
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polycationic ferritin (3.26, 3.68), producing a dark halo around the cells when viewed with TEM.  
To investigate potential CPS/EPS production by V. vulnificus phase variants, whole colonies of 
1003(O), BG(R), AZ(T), GMB4(R), ABZ1(T), and ABZ1(R) were stained with polycationic 
ferritin, prepared and sectioned, and then viewed with TEM (Figure 3.8).  Cells of both the 
opaque 1003(O) and its rugose derivative BG(R) showed a thick layer of ferritin-stained material 
around each cell as well as between cells; there did not appear to be any difference in the 
thickness of this layer between the two strains (Figure 3.8A and B, respectively).  In contrast, the 
acapsular transposon mutant ABZ1(T) and its rugose derivative ABZ1(R) showed little or no 
ferritin-stained material surrounding the cells (Figure 3.8C and D, respectively).  Interestingly, 
ABZ1(R) and other translucent-derived rugose colonies tended to float and lose their coherence 
during the preparation process.  All preparations showed ribbons of ferritin-stained material of 
varying length and thickness not associated with cells in some areas of the TEM grid (data not 
shown).  The spontaneous translucent strain AZ(T) showed minimal ferritin-stained material on 
the cell surfaces, while some stained material appeared in the spaces between cells (Figure 3.8E).   
DISCUSSION 
The marine bacterium V. vulnificus, an opportunistic pathogen capable of causing 
significant human disease, has historically been known to exhibit two phenotypic variations 
related to the production of CPS, opaque (O) and translucent (T).  The existence of the two  
phenotypes has been thought to serve an adaptive function, allowing the organism to survive 
under different conditions.  Encapsulated opaque strains, for example, survive in higher numbers 
than translucent ones in human serum as the capsule confers a survival advantage through 
protection from complement-mediated lysis and phagocytosis by macrophages (3.35, 3.77, 3.80); 
consistent with these occurrences, opaque strains of V. vulnificus are virulent while translucent 
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FIGURE 3.8.  Electron micrographs of polycationic ferritin stained whole colonies of V. 
vulnificus phase variants.  Whole colonies were stained and sectioned as described in the text.  
The following strains were examined.  A. 1003(O); B. BG(R); C. ABZ1(T); D. ABZ1(R); E. 
AZ(T).  Bars, 1 µm.  
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strains are avirulent.  Switching between phases occurs at frequencies greater than that expected 
for spontaneous mutation.  It was shown that, under the conditions of this study, the opaque form 
of V. vulnificus 1003 can switch to the translucent form at a higher frequency than previously 
reported.  Of greater interest is that the translucent strains varied considerably in their switching 
frequencies, with the degree of parental translucence apparently inversely related to conversion 
to the opaque phenotype.  V. cholerae has been reported to show as many as ten levels of 
opacity/translucence (3.19) and multiple levels have been observed in V. vulnificus, illustrated by 
translucent strains BG(T1) and BG(T2), as well as varying levels of opacity in different strains 
(unpublished observations).  A group 1-like CPS operon has been described for V. vulnificus 
(3.75); it has recently been reported that there are at least three different genotypes associated 
with the translucent phenotype and that two of the three appear to be the result of accumulated 
deletions in this operon in the different translucent strains while the ability to switch from the 
translucent phenotype to the opaque phenotype is similarly related to these deletions (3.7, 3.28).   
As strain BG(T2) is more highly translucent than its parent BG(T1) and also produced 10-fold 
fewer opaque colonies in the switching assay than its parent, it is possible that the progression 
from BG(T1) to BG(T2) resulted from additional rearrangements or deletions in its genome 
relative to the genes for CPS expression.   
The spontaneous translucent strain AZ(T) was the only 1003 derivative tested that did not 
produce a rugose variant.  This strain has been shown to have a chromosomal rearrangement 
involving an insertion sequence (3.62) when compared to 1003(O), but the exact relationship 
between this rearrangement and CPS expression has not been determined.  While it is possible 
that this rearrangement may have rendered the strain unable to yield a rugose phenotype, it is 
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also possible that, as this strain produces opaque variants only rarely, it may also produce rugose 
variants, but at a low level undetected in the switching assay.   
The inability of ABZ1(T), the acapsular wcvA transposon mutant, to convert to the parent 
opaque phenotype was consistent with the notion that wcvA plays an essential role in CPS 
expression (3.62, 3.83).   The fact that ABZ1(T) readily produced rugose variants suggests that 
production of the rugose phenotype is independent of CPS production in V. vulnificus, as it 
appears to be in V. cholerae (3.1, 3.45, 3.68, 3.79), and provides support for the assertion made 
here that the EPS of rugose cells and the CPS of opaque cells are probably inherently different.  
Like ABZ1(T), the acapsular strain GMB4(T) was isolated following transposon 
mutagenesis (3.62, 3.83) and was shown to harbor a copy of the kanamycin-resistant transposon 
within ORF4 in a region of the V. vulnificus genome designated as a super-integron (3.8).  Super-
integrons were first described in V. cholerae and have been shown to function as gene capture 
systems (3.9, 3.41, 3.55, 3.56).  The implication from the original mutagenesis study was that 
ORF4 and potentially other genes within this super-integron region are essential for capsule 
production in V. vulnificus (3.62).  When subjected to the switching assay, not only did 
GMB4(T) produce rugose forms, but it also switched to the opaque phenotype.  One of these, 
GMB4(O), was shown to retain both the kanamycin resistance and the mutant ORF4 PCR 
product that are characteristic of GMB4(T) (Appendix Figure A.9).  Also, introduction of an 
uninterrupted version of ORF4 on a plasmid into GMB4(T) did not restore the opaque phenotype 
of the original parental strain (see Chapter 2).  Based on these data, it appears that GMB4(T) 
arose spontaneously from 1003(O) and coincidentally acquired the transposon during the original 
transposon mutagenesis experiments (3.82).  A role for the super-integron of V. vulnificus in 
capsule production and pathogenesis thus remains undetermined.  
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Although V. cholerae rugose variants have been isolated and maintained at various 
temperatures, including 37oC, the production of rugose or rugose-like forms of other bacteria has 
been demonstrated to be affected by temperature.  The rugose form of Salmonella enterica 
serovar Typhimurium, for example, has been shown to be temperature dependent, observed only 
when incubated at 19 to 28oC (3.4), and converting to a smooth form at 37oC.  Also, the wrinkled 
phenotypic variant of Pseudomonas aeruginosa PAO1 produced a pellicle in static broth at 23oC, 
but grew dispersed in the broth at 42oC (3.13), suggesting temperature dependence of the 
wrinkled phenotype.  As shown here, the rugose phenotype of V. vulnificus was isolated only 
after incubations below 37oC; however, phenotypic switching from both rugose to opaque and 
rugose to translucent states was observed at both 30oC and 37oC.  Strain BG(R) produced 
approximately 10% more opaque colonies at 37oC than at 30oC, while ABZ1(R) produced 
approximately 11-fold more translucent colonies at 30oC than at 37oC.  While ABZ1(R) and its 
translucent parent, ABZ1(T), did not produce any opaque colonies, as expected of the transposon 
mutants, it is possible that rugose cells derived from spontaneous translucent cells could switch 
to opaque at either temperature.  Thus, it is also possible that similar switching events (e.g., 
rugose to opaque) could occur in the mammalian host and therefore contribute to the disease 
process.   
V. cholerae phase variants exhibit differential resistance to normal human serum (NHS) 
with non-O1 and O139 opaque strains that expressed a capsule more resistant than translucent 
variants that did not express a capsule (3.26, 3.69).  Rugose strains of V. cholerae survived in 
decreased numbers in NHS while smooth strains were eradicated (3.48).  There have been 
numerous reports of serum resistance in V. vulnificus phase variants and it also has been well 
established that opaque strains are more resistant to the killing effects of NHS than are 
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translucent strains (3.3, 3.63, 3.77, 3.80).  The results given here were similar to those earlier 
reports in that the opaque strain had a higher percent survival than did the translucent strain and 
the rugose strains both had a higher percent survival than did their respective parents.  Rugosity 
did appear to confer a survival advantage over smoothness in V. vulnificus when the cells were 
exposed to NHS; hence, it is possible that the rugose strains, such as BG(R), would be able to 
survive in a mammalian host.  Their pathogenic potential, unlike that of V. cholerae rugose 
forms that are known to be virulent, remains to be determined.    
In addition to protection from the bactericidal effects of NHS, the V. cholerae rugose 
phenotype and its EPS have been shown to confer protection against chlorine disinfectant.  
Rugose cells survived exposure to 0.5 ppm through 3 ppm free chlorine, in some instances for at 
least 30 min, while smooth cells were killed quickly (3.1, 3.48, 3.53, 3.79) and purified rugose 
EPS was shown actually to inactivate free chlorine (3.79).  Surprisingly, and in contrast to the 
findings for V. cholerae rugose EPS, the results reported here suggest that V. vulnificus rugose 
EPS does not confer any chlorine survival advantage to the cells, nor does CPS.  Compared to 
the resistance shown by ABZ1(R), ABZ1(T) had a percent survival almost 6-fold greater after 5 
min and 2-fold greater after 30 min, while the opaque 1003(O) and its rugose derivative BG(R) 
were totally eradicated.  These data suggest that in V. vulnificus, it is the absence of CPS 
especially, rather than the presence of rugose EPS, that promotes survival when exposed to 
chlorine disinfectant.  It has been suggested that bacterial EPS (including CPS) functions as an 
ion-exchange substance and also as a nutrient-trapping substance (3.11, 3.66).  Perhaps the CPS 
traps the dissociated ions from the NaOCl close to the cell and allows the OCl- ion to make 
contact with the cell membrane where it can denature membrane proteins (3.57), resulting in 
disruption of the membrane and cell death.  Unlike V. cholerae, V. vulnificus cannot survive in 
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fresh water and thus, is not transmitted through drinking water, which is treated with chlorine in 
attempts to kill pathogenic bacteria.  V. cholerae strains are often tested for resistance to 
chlorine, but V. vulnificus strains are not.  In the study that tested one V. vulnificus strain for 
chlorine resistance, exposure to 500 ppm NaOCl for 30 min killed not only V. vulnificus, but also 
V. cholerae and Vibrio parahaemolyticus (3.58).   
It has been reported that a modified Dakin’s solution (0.025% NaOCl; 250 ppm) is useful 
in the treatment of V. vulnificus wound infections in a clinical setting (3.43, 3.74).  No mention 
was made of colony morphology in these studies, but as all V. vulnificus strains tested were of 
clinical origin, it is likely they were all opaque and smooth.  It is tempting to suggest using a 
NaOCl solution diluted in sea water to treat oysters to remove V. vulnificus; however, oysters are 
known to close their valves and stop pumping at chlorine concentrations of 1 ppm or greater.  
Even smaller amounts of chlorine adversely affect oysters: at 0.005 ppm, pumping rates are 
reduced; at 0.12 through 0.16 ppm, growth and reproduction are diminished; levels greater than 
0.16 ppm are toxic to the oyster (3.36).  Consequently, even though chlorine appears to be a 
highly effective disinfectant against V. vulnificus, the levels necessary to eradicate the bacteria 
would be deleterious to the oysters.   
Biofilms are an accumulation of cells encased in an exopolymeric matrix produced by the 
cells and are usually attached to a surface (3.16, 3.59).  In bacterial strains that form biofilms, 
flagella play a role in the initial attachment to and movement over a surface, while pili are 
required for monolayer formation in some strains (3.46, 3.49, 3.70).  Once the monolayer is 
formed, microcolonies form, flagellar expression is down regulated, and the exopolymeric 
substance is produced, encasing the growing biofilm (3.14).  V. vulnificus strains are motile due 
to a polar flagellum.  As shown here, upon switching to the rugose phenotype, previously motile 
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strains greatly reduced their motility in 0.3% agar medium, yet individual cells were seen to 
swim in liquid, while the CPS-expressing opaque and acapsular translucent strains maintained 
motility in 0.3% agar medium as well as liquid.   Taken together, the motility data along with the 
serum and chlorine resistance data demonstrate that although rugose isolates derived from 
opaque and translucent parents appear identical in colony morphology, they show significant 
differences with respect to other characteristics.   
Production of biofilms has been reported previously for V. vulnificus (3.29, 3.37, 3.42, 
3.49).  In particular, a recent study reported that various translucent strains of V. vulnificus 
produced over three times more biofilm than their parent opaque strain, suggesting that CPS 
inhibits the formation of a biofilm in opaque strains of V. vulnificus (3.29).  In the current study, 
however, the V. vulnificus 1003(O) parental strain consistently appeared to produce more biofilm 
than did its translucent derivatives.  Although the basis for the apparent discrepancy between that 
study and this one remains undetermined, it is possible that strain differences and/or differences 
in the media and experimental protocols used for biofilm formation may be contributing factors.   
Previously, a significant difference in biofilm production was observed for different smooth 
strains of V. cholerae O1 El Tor (3.78).   
The collodion-coated coverslip biofilm-capture technique further showed that the rugose 
strains produce biofilms in the form of a pellicle at the air-broth interface while the opaque and 
translucent strains do not.  On a glass slide, the development of biofilms in a rugose strain 
followed the steps described for V. cholerae and other Gram-negative bacteria (3.14, 3.70).  
After attachment and formation of microcolonies, individual cells of the rugose phenotype were 
observed apparently swimming toward established microcolonies in the early stages of biofilm 
development.  Opaque and translucent V. vulnificus strains did not produce biofilms in this assay; 
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in fact, they were seen to adhere to the slide only as single cells.  These data suggest that it is the 
production of rugose EPS that allows the rugose strains to complete development into a 3-D 
biofilm as is the case in V. cholerae rugose strains (3.79).   
It has been suggested that bacterial colonies on a plate are actually biofilms at a surface-
air interface (3.17).  V. vulnificus (and other bacterial) colonies consist of cells adhered to each 
other in a matrix, so they do fit the definition.  However, opaque and translucent colonies show 
only a limited development as they are flat and smooth, similar to a monolayer in biofilms 
formed in liquid.  Rugose colonies do show a highly structured, 3-D development that is 
reminiscent of the complex pillars, arches, and channels exhibited by biofilms formed in liquid.  
Whatever triggers the switch from opaque or translucent to rugose is unknown in this species; it 
not only encourages the production of the rugose EPS, but it must also stimulate a complex 
developmental pathway.   
To show that opaque, translucent, and rugose strains possess differing amounts of 
CPS/EPS, whole colonies were stained with polycationic ferritin, known to bind negatively 
charged polysaccharides.  Opaque strain 1003(O) and its rugose derivative BG(R) appeared 
identical with a dense layer of stained material on the cell surfaces and between the cells while 
ABZ1(T) and ABZ1(R) appeared identical with little to no stained material on the cell surfaces 
and between the cells.  It must be noted that the translucent-derived rugose colonies prepared for 
TEM tended to float and dissociated in the aqueous fixative solution while opaque-derived 
rugose colonies did not.  However, all preparations showed ribbons of ferritin-stained material 
not associated with cells.  As biofilm production in general is known to be promoted by EPS 
(3.14) and as it has been shown that CPS is attached to the cell while EPS is not (3.54), it is 
interesting to note that both rugose strains resemble their respective parents in regard to ferritin 
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staining.  It is therefore proposed that the excess polysaccharide produced by both the opaque-
derived and translucent-derived rugose strains is stripped away in the fixation process.   
It is also proposed that BG(R) produces both CPS and EPS while transposon mutant-
derived ABZ1(R) produces only EPS and that for both rugose strains, the loosely associated EPS 
was removed during the fixation process, leaving the cells with only the attached CPS [BG(R)] 
or no CPS [ABZ1(R)] so that they closely resembled their respective parents.  The spontaneous 
translucent strain AZ(T) however, showed minimal ferritin-stained material surrounding its cells.  
Some translucent strains make CPS but are defective in transport (3.76).  Along with the 
appearance of the thin ferritin-stained layer on the surface of AZ(T), it has been observed in this 
laboratory that some translucent colonies begin to resemble opaque colonies when left on plates 
at room temperature for several days.  There are two possibilities to explain these observations.  
First, if transport is not completely eliminated but simply slow, CPS would be made inside the 
cell in the same amounts as in an opaque cell, but it would not be transported out of the cell at 
the same rate; alternately, CPS production in the cell may be repressed so that minimal amounts 
are made but exported normally.  In either event, the colony would eventually resemble an 
opaque colony on a plate.  These staining and biofilm results taken together thus argue that the 
biofilm-promoting EPS produced by rugose V. vulnificus cells is distinct from CPS.  However, it 
cannot be definitively said that the two polysaccharides are different without extracting and 
purifying them and subjecting the substances to monosaccharide composition analysis.   
Could the ferritin-stained material on the surface of AZ(T), ABZ1(T), ABZ1(R), and 
some of it on 1003(O) and BG(R) instead be lipopolysaccharide (LPS) with the ferritin staining 
the sugar moiety (‘O’ antigen) of the LPS?  In V. cholerae, rough colony variants have a deletion 
in their LPS and are unable to switch back to the smooth phenotype (3.15); they also do not 
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differ in appearance from the smooth phenotype and can be differentiated only serologically 
(3.44).  As shown here, V. vulnificus rugose variants can switch back to the smooth phenotype 
and they are distinctly different in appearance from the smooth variants, both opaque and 
translucent.  In addition, 1003(O), AZ(T), BG(R), ABZ1(T), and ABZ1(R) all reacted strongly 
with a monoclonal antibody (mAb) specific to 1003(O) LPS (R. Schulz and K. O’Reilly, 
personal communication).  These data further indicate that these 5 strains are not LPS deficient.  
It has been shown that there is no difference in LPS between opaque and translucent V. 
parahaemolyticus (3.18) nor between smooth and rugose V. cholerae (3.45).  Both their 
phenotypic switching ability and their reaction to an anti-LPS mAb strongly suggest that the V. 
vulnificus rugose strains characterized here are truly rugose and not rough variants.     
Described here is a new phenotypic version of V. vulnificus, the rugose variant, which is 
produced at high frequencies from both opaque and translucent parental strains when they are 
cultured repeatedly at temperatures below 37oC, and which, once formed, persists even at 37oC.  
Rugose cells are capable of forming prodigious biofilms, and rugose isolates derived from the 
opaque parent were highly resistant to the complement-mediated killing of human serum.  Based 
on these characteristics, the rugose form of V. vulnificus may play an important role not only in 
pathogenesis within the human host but also in survival within the cooler temperatures of its 
natural marine environment.  Biofilm formation in the latter case may allow the organism to 
persist under conditions that are often nutritionally deficient or are otherwise unfavorable (3.12, 
3.14).    
Previous studies of phase variation in V. vulnificus involved inoculating rich medium 
with a single colony, incubating it overnight, and plating dilutions the next day.  None of these 
studies reported the existence of a rugose phenotype (3.31, 3.61, 3.77, 3.80).  Most of the studies 
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that resulted in isolation of the V. cholerae rugose variant involved incubating starvation media 
cultures for extended times (3.45, 3.68, 3.79); however, a high-frequency rugose-producing 
strain of V. cholerae was isolated after only 24 to 48 h of incubation (3.1).  In the present study, 
the aggregate ring appeared in the culture tubes as early as the third day of the incubation cycle. 
The method described here of inoculating rich medium and subculturing each day for a total of 5 
to 6 days before plating seems to allow not only for high-frequency opaque and translucent phase 
variation, but also for high-frequency rugose production by both opaque and translucent strains.  
Though rich medium was used and cells were not under the continuous nutritional stress of 
growing in starvation medium, cultures did undergo many hours in stationary phase each day 
prior to their next passage.  Such nutritional deprivation, though temporary, may have 
contributed to the observed high frequency of switching events. 
Clearly more study is needed to elucidate the mechanisms that underlie the ability of V. 
vulnificus to convert between encapsulated opaque and nonencapsulated translucent forms, as 
well as to switch from these variants to the newly documented rugose form.  Alteration of its 
morphology among these distinct phenotypes has obvious and important consequences for the 
ability of V. vulnificus to survive and cause disease. 
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INTRODUCTION 
 Vibrio vulnificus is a Gram-negative marine bacterium capable of causing severe disease 
in susceptible individuals.  This bacterium is normally found in fish and shellfish, including 
oysters.  Several medical conditions will predispose a person to being susceptible to infection 
from this organism, including diabetes, liver disease, or a compromised immune system.  When 
people with such a condition consume raw oysters containing V. vulnificus, they are at risk of 
developing a rapidly progressing primary septicemia that can be fatal within 48 hours.  If a break 
in the skin is exposed to seawater containing this organism, a severe wound infection may 
develop that could necessitate amputation if treatment is not begun soon after the onset of 
symptoms.  V. vulnificus does not infect as many people as do other members of its genus, but it 
is the leading cause of death from the consumption of seafood in the United States (4.8, 4.24, 
4.31, 4.33, 4.49).   
 V. vulnificus produces several virulence factors: multiple enzymes, siderophores, and a 
polysaccharide capsule [reviewed by Gulig et al. (4.19)].  While the other factors may assist in 
virulence, the capsular polysaccharide (CPS) is considered the primary virulence factor, reported 
to protect the bacteria from phagocytosis and complement-mediated killing by the host immune 
system (4.18, 4.27, 4.46, 4.60).  When grown on solid media, colonies of cells producing CPS 
appear opaque (O), smooth, and mucoid (4.5, 4.22).  Opaque strains are capable of undergoing 
spontaneous phase variation and producing translucent (T) strains that are smooth, sticky, and 
express little or no CPS (4.55, 4.62).  Several studies have documented that opaque strains are 
virulent while translucent strains are avirulent in an iron-supplemented mouse model (4.18, 4.46, 
4.47, 4.56, 4.60).   
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Genes associated with CPS production in V. vulnificus have been identified, including a 
recently characterized epimerase gene (4.35), a group 1-like CPS operon (4.54), and numerous 
genes identified in three separate clones, but all on the same 200 Kb fragment produced by 
pulsed-field gel electrophoresis (PFGE) of NotI digested chromosomal DNA (4.47).  The same 
group 1-like CPS operon was recently identified in the genome sequence of V. vulnificus YJ016, 
along with two similar operons in different locations of  the genome (4.14).  There has been one 
report of using V. vulnificus CPS-specific monoclonal antibodies labeled with fluorescein 
isothiocyanate (FITC) and flow cytometry to measure differential expression of CPS by phase 
variants (4.55).  Differential expression of two genes from the group 1-like operon, wzaVv and 
wzbVv, was recently reported to occur in isolates of clinical, oyster, and water origins as the cells 
entered and remained in the viable but nonculturable (VBNC) state (4.48).  To date, there has 
been no comprehensive study of the expression of CPS genes in phase variants of V. vulnificus. 
As reported in Chapter 3, V. vulnificus is capable of producing a third colony 
morphotype, the rugose variant, that produces copious amounts of extracellular polysaccharide 
(EPS) and forms robust biofilms, which the opaque and translucent variants do not form.  The 
rugose phenotype in Vibrio cholerae was described in the 1930’s (4.51) and in just the past ten 
years, many of the genes responsible for the production of the rugose EPS and mechanisms of 
their regulation have been described (4.1-4.3, 4.12, 4.17, 4.21, 4.25, 4.34, 4.37, 4.38, 4.57-4.59).  
The rugose EPS has been shown to differ in chemical composition from the CPS of encapsulated 
V. cholerae (4.59) and the smooth and rugose forms exhibit differential expression of genes 
involved in the production of  rugose polysaccharide (4.58).  It was proposed in Chapter 3 that 
the CPS and rugose EPS of V. vulnificus phase variants are different, which suggests differential 
expression of CPS and EPS genes in these variants.  As the V. vulnificus rugose variant has been 
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described only recently, there has been no comprehensive study of genes associated with rugose 
EPS expression in phase variants of this species.   
In this study, the objective was to acquire the nucleotide sequences of genes shown to be 
necessary for or associated with CPS production in V. vulnificus and rugose EPS production in V. 
cholerae.  Candidate genes that showed high identity to V. vulnificus genes in the databases were 
selected for study and an initial survey of their expression in different phase variants at different 
points in the life cycle was conducted using reverse transcriptase PCR (RTase-PCR) followed by 
second strand and amplification PCR.  Reported here, with but a couple of exceptions, all 
previously identified CPS genes from V. vulnificus that were tested showed some level of 
expression in the opaque, translucent, and rugose variants during mid-exponential growth.  
Provided here is the first report of a rugose gene cluster whose genes are more highly expressed 
or only expressed in the rugose variants during both mid-exponential and late-exponential 
growth.  Expression of all genes in this study during late-exponential growth was more variable 
than in mid-exponential and expression of all genes during stationary phase was greatly 
diminished.  Also reported is the presence and expression of a second ORF located within the 
sequence of the IS492 homolog of V. vulnificus described in Chapter 2. 
 
METHODS AND MATERIALS 
 
Bacterial Strains and Growth Conditions.  Bacterial strains are listed in Table 4.1.  All 
V. vulnificus were grown in Heart Infusion broth (Difco) supplemented to 2 percent NaCl (HI).   
For growth on agar plates, 18 g of agar (Difco) were added per liter of HI.  Broth cultures were 
incubated at 30oC and 200 rpm; plates were incubated at 30oC for 24 to 48 hours.   
Gene Identification and Primer Design.   Genes previously described as essential to or 
associated with CPS production in V. vulnificus and rugose EPS production in V. cholerae  
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TABLE 4.1.  Bacterial strains used in this study. 
   
   
Strain Isolation and characterizationa Reference(s) or 
source 
   
   
Vibrio vulnificus 1003   
1003(O) Wound isolate, opaque, encapsulated, virulent; 
designated as wild type, smooth; CPS serotype 9, 
LPS serotype unk.;  Colr
(4.30, 4.45) 
BG(R) Spontaneous rugose derivative of 1003(O), dry, 
wrinkled 
This study 
AZ(T) Spontaneous highly translucent derivative of 
1003(O), avirulent, smooth, previously 1003(T) 
(4.47, 4.62) 
ABZ1(T) Translucent, avirulent; defective in capsule 
expression due to mini-Tn10 insertion in the 
wcvA gene of 1003(O), smooth; Kanr
(4.47, 4.62) 
ABZ1(R) Spontaneous rugose derivative of ABZ1(T), dry, 
wrinkled; Kanr
This study 
   
 
 a CPS, capsular polysaccharide; LPS, lipopolysaccharide; Colr, colistin resistance; Kanr, 
kanamycin resistance; unk., unknown. 
 
 
(4.1, 4.2, 4.12, 4.21, 4.25, 4.32, 4.37, 4.54, 4.57, 4.59, 4.62)  were selected and their nucleotide 
sequences were obtained from GenBank and submitted to a BLAST (4.4) search to identify 
potential orthologs in the two sequenced genomes of V. vulnificus strains YJ016 (4.14) and 
CMCP6 (4.26).  Some previously identified sequences were specific to V. vulnificus 1003.  
Candidate genes, their predicted products, and GenBank accession numbers are listed in Table 
4.2.  V. vulnificus gene sequences homologous to genes associated with rugose EPS in V. 
cholerae are given with their designation in the sequenced strain V. vulnificus YJ016 (4.14).  
Homologous sequences in multiple strains were aligned using the program Align Plus, v. 2.0 
(Scientific and Educational Software) and conserved regions were identified and used for primer 
design.  Controls included primers for 16S rRNA genes (4.50) and the following that were  
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TABLE 4.2.  Genes under study, their predicted products, and GenBank accession 
numbers. 
 
 
GENE GENE PRODUCT ACCESSION 
NUMBER 
 
 
ΔwcvA  Nucleotide sugar epimerase  AF499932 
wecA Undecaprenylphosphate N-acetylglucosamine 1-
phosphate transferase 
AF499932 
wcvB Nucleotide sugar dehydrogenase AF499932 
wcvA  Nucleotide sugar epimerase AF499932 
wcvH  
VVA0390 
Unknown protein AF499931 
wcvI 
VVA0389 
Glycosyltransferase AF499931 
rmlA  Glucose-1-phosphate thymidylyltransferase AY097060 
rmlD  dTDP-4-keto-L-rhamnose reductase  AY097060 
rmlC dTDP-6-deoxy-D-xylo-4-hexulose-3,5-epimerase AY097060 
wcvE  Glycosyltransferase or putative LPS biosynthesis protein AY097060 
wcvFa Rhamnosyl transferase AY097060 
wzx  Flippase AY097060 
wcvG  Glycosyl transferase AY097060 
wzy  Polymerase AY097060 
wzaVv  
VV0337 
CPS transport protein AY055488 
ORF3  Var1 homologue This study 
ORF2  Unknown This study 
ORF1 Unknown This study 
ORF4  Unknown This study 
AY676134 
VV0341 UDP-N-acetylglucosamine 2-epimerase BAC93105 
VV0342 UDP-N-acetyl-D-mannosaminuronate hydrogenase BAC93106 
VV0670 Sigma-54 dependent transcriptional regulator similar to 
VpsR 
BAC93434 
VV0897 Hypothetical protein NP_933690 
VV0898 Serine hydroxymethyltransferase BAC93662 
VV1264  Protein-tyrosine phosphatase  BAC04028 
VV1623 Uncharacterized membrane protein BAC94387 
VV1625 Glycosyl transferase BAC94389 
smcR 
VV2770 
SmcR; transcriptional activator similar to LuxR AAF72582 
VV2957 Hypothetical protein, YJ016; Lipid A core – O-antigen 
ligase, CMCP6 
BAC95721 
VV3013 Transcriptional regulator, similar to CytR BAC95777 
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TABLE 4.2.  continued 
   
   
VVA0382 DNA-binding HTH domain-containing protein; similar 
to VpsT 
BAC96408 
VVA0391 Putative lipopolysaccharide biosynthesis protein NP_936447 
VVA0392 
wczEc
Putative exopolysaccharide biosynthesis protein NP_936448 
VVA0393 
wzaEc
Putative polysaccharide export-related protein NP_936449 
VVA0394 Hypothetical protein NP_936450 
VVA0395 
wcaJEc
Putative capsular polysaccharide biosynthesis 
glycosyltransferase 
NP_936451 
   
   
a Genes and their products listed in bold print are unique to V. vulnificus 1003. 
 
 
specific to V. vulnificus: a 23S rRNA gene, gyrB, and the hemolysin gene, vvhA (4.10, 4.16).  
Primers were designed using the program Primer Design, v.2 (Scientific and Educational 
Software), submitted to a BLAST (4.4) search to determine uniqueness and proper location, 
synthesized by Sigma-Genosys, and are listed in Table 4.3.   
Nucleic Acid Isolation and Purification.  Genomic DNA was isolated and quantified as 
described in Chapter 2.  For total RNA isolation, freezer stocks were used to inoculate a 3 ml 
culture of HI for each phase variant.  Cultures were incubated overnight, then streaked for 
isolation to HI plates and incubated as described above.  Well-isolated colonies of the desired 
phenotype were selected and used to inoculate a 3 ml culture of HI for each phase variant.  These 
cultures were incubated overnight and then cultures were prepared for RNA isolation.  For mid-
exponential and late-exponential RNA isolation, each culture was diluted 1:100 into 10 ml fresh 
HI broth (30oC) and incubated until the culture reached an OD600 of approximately 0.400 or 
1.000, respectively.  To better synchronize growth, cultures were diluted again 1:100 in 10 ml of 
30oC HI and incubated until they reached the desired OD600, when multiple 1 ml aliquots were 
TABLE 4.3.  Primers used in this studya. 
 
 
 
 
Primer 
 
 
Description 
 
 
Sequence 
Product size 
(bp)/annealing 
temperature (oC), 
± DMSO 
    
 
Genes used as controls 
 
RRN1A Forward primer for 16S rDNAb 5’-TAACACATGCAAGTCGAACG-3’  
RRN2B Reverse primer for 16S rDNAb 5’-CCCATTGTGCAATATTCCCC-3’ 330/60+ 
O212-F Forward primer for 23S rDNA 5’-CGATAAGCGTAGATGAGGCA-3’  
O212-R Reverse primer for 23S rDNA 5’-GTACGCAGTCACACCACGAA-3’ 483/55- 
GYRB-F Forward primer for gyrB 5’-GGTTACTCAGTTGAACGCCA-3’  
GYRB-R Reverse primer for gyrB 5’-CGAGATTCCTTAATCAGCCA-3’ 294/50+ 
vvhA-F Forward primer for vvhAc 5’-GCTATTTCACCGCCGCTCAC-3’  
vvhA-R Reverse primer for vvhAc 5’-CATCAACATAGCGGCTAATG-3’ 604/55+ 
vvhACW-F Forward primer for vvhAd 5’-TGTTTATGGTGAGAACGGTGACA-3’  
vvhACW-R Reverse primer for vvhAd 5’-TTCTTTATCTAGGCCCCAAACTTG-3’ 99/55+ 
    
Genes associated with CPS expression in V. vulnificus 
 
CAP1 Forward primer for ΔwcvA 5’-TTGAAGGAGTGGTGCGTATC-3’  
CAP2 Reverse primer for ΔwcvA 5’-GCTTGACGGTTACTTGAGGT-3’ 285/60+ 
CAP3 Forward primer for wecA 5’-CACTTATGGATATGGCCGCA-3’  
CAP4 Reverse primer for wecA 5’-GCGGATAAGCTGGTAATACG-3’ 283/50+ 
CAP5 Forward primer for wcvB 5’-GAAGCGGTGAAGTTGTTCTC-3’  
CAP6 Reverse primer for wcvB 5’-CCGGTTAGCATCGACAATAG-3’ 264/50+ 
CAP7 Forward primer for wcvA 5’-AGTCTAACGAACTTATGGCT-3’  
CAP8 Reverse primer for wcvA 5’-TCGCTTCAATACCAAGTTCA-3’ 384/50+ 
CAP9 Forward primer for rmlA 5’-ATCGAACTATGCCGTCACAG-3’  
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TABLE 4.3. continued 
    
    
CAP10 Reverse primer for rmlA 5’-ATCTCTTCTAAGCAGGCCAC-3’ 267/60+ 
CAP11 Forward primer for rmlD 5’-CCGTAGCTGAAGCTTGTCCT-3’  
CAP12 Reverse primer for rmlD 5’-CCAGAGAAGTGATACACACC-3’ 241/60+ 
CAP13 Forward primer for rmlC 5’-TGAAGAGCTAGTAACAGGCA-3’  
CAP14 Reverse primer for rmlC 5’-CCGCTTCTTCACTGGTTACA-3’ 281/55+ 
CAP15 Forward primer for wcvE 5’-GGCCATGCTGATAGGAATTG-3’  
CAP16 Reverse primer for wcvE 5’-TTGCCAGCTCGGAACTATCT-3’ 274/55+ 
CAP17 Forward primer for wcvF 5’-TAAGCCTCAAGCGTTGACTG-3’  
CAP18 Reverse primer for wcvF 5’-TTATGGCTCCTCTTAAGTGC-3’ 443/60+ 
CAP19 Forward primer for wzx 5’-ACAAGAACAGAACCGCGTTA-3’  
CAP20 Reverse primer for wzx 5’-AAGTTGACAATGACAGGAAG-3’ 271/55+ 
CAP21 Forward primer for wcvG 5’-TAAGTGACGAATTGCACGAG-3’  
CAP22 Reverse primer for wcvG 5’-TTGCAGCAACGCCAACATGA-3’ 276/60+ 
CAP23 Forward primer for wzy 5’-TTGCCATCGAAGAGTAGAGC-3’  
CAP24 Reverse primer for wzy 5’-TGCATTCTCCACGACGTAAC-3’ 181/55- 
CAP25 Forward primer for wcvH 5’-CATCGAGACATGGAGAGAAC-3’  
CAP26 Reverse primer for wcvH 5’-GTAGAGTGGCAGATCGTACA-3’ 369/55+ 
CAP27 Forward primer for wcvI 5’-TACCAATCTAACGCCGGCAA-3’  
CAP28 Reverse primer for wcvI 5’-TGTCACGCAACTGCTGTTCT-3’ 199/60+ 
CAP29 Forward primer for SI ORF3 5’-CTGAAGCGACGCCTGTCTAC-3’  
CAP30 Reverse primer for SI ORF3 5’-TGCACCAAGAGCCTCAAAGC-3’ 179/55+ 
CAP31 Forward primer for SI ORF2 5’-CCGTATCAACGCCGACATTA-3’  
CAP32 Reverse primer for SI ORF2 5’-GTTCGATTGAACGCTGGCTC-3’ 178/55+ 
CAP33 Forward primer for SI ORF4 5’-TCGTACCATCGAAGAGCCAA-3’  
CAP34 Reverse primer for SI ORF4 5’-GCCACCAATTCGTAAGTACA-3’ 311/55+ 
CAP33.1 Forward primer for SI ORF4 5’-GATGAGGTGAGTGATGGTGC-3’  
CAP34.1 Reverse primer for SI ORF4 5’-GACACCTGTTCCATTCGTGA-3’ 171/60+ 
CAP35 Forward primer for SI ORF1 5’-TCCATCGTGGTGAGTCAATC-3’  
CAP36 Reverse primer for SI ORF1 5’-TATACTCTGAGCCTGAGCTG-3’ 276/60+ 
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TABLE 4.3. continued 
    
    
CAP37 Forward primer for wza 5’-GCGATATCATCCACGTGCCA-3’  
CAP38 Reverse primer for wza 5’-ATATCCGCCATGCGTTCAGA-3’ 211/55+ 
 
Genes associated with EPS expression in rugose V. cholerae with homologues in V. vulnificus 
 
RUG1 Forward primer for VV1264 (VC0916) 5’-GCATCCGTTCGCGTCAAGT-3’  
RUG2 Reverse primer for VV1264 (VC0916) 5’-CCTCACCGCCGTAATAAGG-3’ 189/55+ 
RUG3 Forward primer for VV0341 (VC0917) 5’-CGCACAGGCAACATCTATTC-3’  
RUG4 Reverse primer for VV0341 (VC0917) 5’-TACCGTATTGCCAGTGACGA-3’ 159/NDe
RUG5 Forward primer for VV0342 (VC0918) 5’-ATGATGGTGCATGCTGCAGT-3’  
RUG6 Reverse primer for VV0342 (VC0918) 5’-ACGTTGATGTCTAGCTTGTC-3’ 569/ND 
RUG7 Forward primer for VV1623 (VC0921) 5’-AATCGCTATCGGATCGCTTC-3’  
RUG8 Reverse primer for VV1623 (VC0921) 5’-GCGCACAGACCAGATTCAGT-3’ 505/55+ 
RUG9 Forward primer for VV1625 (VC0925) 5’-ACCTTCATCACGATTGGCTC-3’  
RUG10 Reverse primer for VV1625 (VC0925) 5’-ACAGCAGCTCCTTACGACGA-3’ 607/55+ 
RUG11 Forward primer for VV2957 (VC0931) 5’-CAGCAAGAGCCTATACCTTC-3’  
RUG12 Reverse primer for VV2957 (VC0931) 5’-CCAGTTGACTGTGTAGTACG-3’ 327/55+ 
RUG13 Forward primer for VVA0395 (VC0934) 5’-CGAGAGAGATGAGAGCAATG-3’  
RUG14 Reverse primer for VVA0395 (VC0934) 5’-GCTGTGGTGTCTGAGAACTG-3’ 162/55+ 
RUG15 Forward primer for VVA0394 (VC0935) 5’-CAAGAGCATACGACCTGGAC-3’  
RUG16 Reverse primer for VVA0394 (VC0935) 5’-TTCCTCTCGCAATACGCCAC-3’ 198/55+ 
RUG17 Forward primer for VVA0393 (VC0936) 5’-TGGCGAGGATGACTTATCAA-3’  
RUG18 Reverse primer for VVA0393 (VC0936) 5’-CGGAACTTATTAATCGAGAC-3’ 186/55+ 
RUG19 Forward primer for VVA0392 (VC0937) 5’-ACGCAGACCTCCACTAGAGA-3’  
RUG20 Reverse primer for VVA0392 (VC0937) 5’-CCTGTAGCGTGTTCAGTAGA-3’ 209/55+ 
RUG21 Forward primer for VV0897 (VC0940) 5’-TTGACCGGCACCTTCCTCGT-3’  
RUG22 Reverse primer for VV0897 (VC0940) 5’-AAGCGCCGAGAATCGACAGT-3’ 496/55+ 
RUG23 Forward primer for VV0898 (VC0941) 5’-GTCTTATCCTGTCTAACGCT-3’  
RUG24 Reverse primer for VV0898 (VC0941) 5’-GTCAACAAGGAACAGGTGGT-3’ 254/55+ 
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TABLE 4.3. continued 
    
    
RUG25 Forward primer for VV0670 (VC0665) 5’-ACTAGAGCAGGCTGATGGTG-3’  
RUG26 Reverse primer for VV0670 (VC0665) 5’-CTCTTGCAGGTAGTAACGAG-3’ 298/55+ 
RUG27 Forward primer for SmcR (HapR) 5’-GCTTAACCATGTCGTTCGTC-3’  
RUG28 Reverse primer for SmcR (HapR) 5’-TCACACACTTCACCACGCTC-3’ 264/55+ 
RUG29 Forward primer for VV3013 (VC2677) 5’-TTCCTCCGATGGTCATGGCT-3’  
RUG30 Reverse primer for VV3013 (VC2677) 5’-CATGGTGTCACAATGGCAGA-3’ 332/55+ 
RUG31 Forward primer for VVA0382 (VCA0952) 5’-ACGAACGACGAGTTATTCTT-3’  
RUG32 Reverse primer for VVA0382 (VCA0952) 5’-CAATTAATCAGAACCTCTTG-3’ 132/50+ 
RUG33 Forward primer for VVA0391 (VC0920) 5’-GAAGGTGCAGGAAGAGTTGA-3’  
RUG34 Reverse primer for VVA0391 (VC0920) 5’-TAGATAACCAGCGTTGCCGA-3’ 475/55+ 
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a Primer sequences were designed for this study except where indicated otherwise. 
b Forward and reverse primer sequences from Vliegenthart et al. (4.50). 
 c Forward and reverse primer sequences from Fischer-Le Saux et al. (4.16). 
 d Forward and reverse primer sequences from Campbell and Wright (4.10). 
 e ND, not determined.   
 
 
 
 
 
 
 
 
harvested into 1.5 ml tubes and pelleted by centrifuging at 14,000 rpm for 2 min in a mini-
centrifuge.  Each pellet was resuspended in 500 μl cold TRI REAGENT (Molecular Research  
Center, Inc.) and the resuspended pellets for two aliquots were combined to give 1 ml of 
resuspended cells.  For stationary phase RNA isolation, 0.5 ml aliquots of the overnight cultures 
were harvested, pelleted, and resuspended in 1 ml cold TRI REAGENT.  Before proceeding 
further, each culture used for RNA isolation was streaked to HI agar plates and incubated 
overnight.  Resulting colonies as well as the primary and secondary streaks were scrutinized to 
verify that the correct phenotype was expressed uniformly.  If not, the RNA samples were 
discarded, new cultures were started, and the procedure was begun anew.   
After cells were suspended in TRI REAGENT, all samples were treated the same and the 
extraction process was modified slightly from that suggested by the manufacturer.  Briefly, 
approximately 100 μl of sterile 0.1 mm Zirconia/Silica beads (Biospec Products, Inc.) were 
added to the resuspended cells and vortexed to disrupt the cells.  After incubation at room 
temperature (RT) for 5 min, samples were centrifuged at 14,000 rpm for 10 min at 4oC to remove 
EPS, cell debris, and the glass beads.  The supernatant (approximately 1 ml) was transferred to 
fresh, nuclease-free 1.5 ml tubes and 100 μl of 1-bromo-3-chloropropane (BCP) was added to 
each tube.  The tubes were shaken vigorously for 15 sec, incubated for 10 min at RT, and 
centrifuged at 14,000 rpm for 15 min at 4oC to produce three distinct layers.  The aqueous, top 
layer containing RNA (500 µl) was transferred to fresh, nuclease-free 1.5 ml tubes; 250 μl of 
isopropanol (RT) and 250 μl of high salt precipitation solution (RT) (Molecular Research Center, 
Inc.) were added to precipitate RNA and reduce polysaccharide contamination.  Samples were 
incubated 10 min at RT, centrifuged at 14,000 rpm for 8 min at 4oC to pellet the RNA, and the 
supernatant was removed using a micropipette.  If necessary, the tubes were briefly pulse 
 115
centrifuged to bring the remaining supernatant to the bottom of the tube. After removal of all 
supernatant, 1 ml of 75% ethanol (RT) was added to each tube to wash the RNA and tubes were 
centrifuged at 14,000 rpm for 5 min at 4oC.  All ethanol was removed by pipetting, tubes were 
laid on their sides, and pellets were allowed to air dry for up to 30 min at RT.  Dried pellets of 
RNA were then rehydrated in 58 μl nuclease-free H2O (Ambion) and incubated for 15 min at 55o 
to 60oC followed by incubation for 2 min on ice.  RNA was either stored at –80oC or 
immediately subjected to DNase treatment to eliminate possible DNA contamination.   
 For DNase treatment, 10 μl of 10X DNase buffer, 1 μl dithiothrietol (DTT; 100 mM), 1μl 
RNasin (40 U/μl; Promega), and 30 μl DNase I (1 U/μl; Promega) were added to the 58 μl of 
RNA and the reaction mixture was incubated for 30 min at 37oC.  After incubation, 1 μl of 
DNase STOP solution (Promega) was added and the reactions were allowed to cool to RT.  The 
DNase reactions were purified using the RNeasy kit (QIAgen) using a slightly modified 
suggested protocol.  Briefly, 10 μl 2-mercaptoethanol (2-ME) were added to each 1 ml Buffer 
RLT and 350 μl of this freshly prepared mixture were added to each of the 100 μl DNase 
reactions and the solution was gently mixed.  Next, 250 μl of 100% ethanol (RT) were added and 
the samples again gently mixed.  The entire solution was transferred to an RNeasy mini-column 
in a 2 ml collection tube.  The tubes were centrifuged at ≥ 10,000 rpm for 15 sec.  Each column 
was then transferred to a new collection tube, 500 μl of Buffer RPE was added to the column, 
and tubes were centrifuged again at ≥ 10,000 rpm for 15 sec.  The flow-through was discarded, a 
second 500 μl of Buffer RPE was added to the column, and the tubes were centrifuged at ≥ 
10,000 rpm for 2 min to dry the membrane.  The columns were then transferred to a fresh 2 ml 
collection tube and the tubes were centrifuged at 14,000 rpm for 1 min to prevent carryover of 
ethanol from Buffer RPE.  The columns were then transferred to a fresh, nuclease-free 1.5 ml 
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tube, 50 μl of nuclease-free H2O were added to the membrane, and the columns were incubated 
for 5 min at RT.  Finally, the tubes were centrifuged at 14,000 rpm for 1 min to elute the RNA.   
To estimate the concentration of the RNA, each sample was diluted 1:50 in nuclease-free 
water, incubated at 55o to 60oC for 15 min, and placed on ice for 2 min.  Each sample was pulse 
centrifuged briefly and the concentration was estimated by determination of the 260/280 ratio 
(4.43).  The integrity of the RNA was ascertained by loading 500 ng of each sample in a 1% 
agarose gel containing ethidium bromide (10 µg/ml) which was then electrophoresed at 120 V 
for 30 min (4.44) and visualized using an Eagle Eye II system (Stratagene).   
PCR was conducted on purified RNA samples to determine if they contained any residual 
DNA contamination.  Genomic DNA samples (positive controls) as well as nuclease-free H2O 
(negative control) were run in parallel reactions.  Each 25 μl reaction contained 2.5 μl 10X 
buffer, 1.5 μl 25 mM MgCl2, 1 μl dNTPs (2.5 mM each dNTP; Applied Biosystems), 0.5 μl each 
primer (20 μM) specific for a V. vulnificus 1003 23S rRNA gene (O212-F and O212-R; Table 
4.3), 0.2 μl AmpliTaq polymerase (5 U/μl; Applied Biosystems), 100 ng of template (RNA, 
DNA, or nuclease-free H2O) and nuclease-free H2O to 25 µl.  The PCRs were run in a Perkin 
Elmer Gene Amp 2400 with an initial temperature of 94oC for 1 min followed by 35 cycles 
consisting of 94oC for 1 min, 55oC for 1 min, and 72oC for 2 min, with a final extension of 72oC 
for 5 min and a holding temperature of 4oC.  PCR reactions were electrophoresed at 80 V for 75 
min on a 2% agarose gel containing ethidium bromide and then visualized using an Eagle Eye II.  
If DNA contamination was indicated by the presence of a PCR product, DNase treatment and 
PCR were repeated. 
Gene Detection PCR.  All primer sets were optimized for PCR using genomic DNA 
from each of the phase variants under study.  The detection PCRs used the cycling conditions 
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listed above for detecting DNA contamination in RNA.  The annealing temperature was adjusted 
to 50oC or 60oC for some primer sets and most primer sets required the addition of dimethyl 
sulfoxide (DMSO) at 10% of the total reaction volume (Table 4.3).  In those cases, the amount of 
nuclease-free H2O was decreased by that same amount so that the total PCR volumes were 
consistently 25 μl.  For CPS and EPS gene detection PCR, the modified reaction components 
were as follows: 2.5 μl 10X buffer, 1.5 μl 25 mM MgCl2, 2 μl dNTPs (2.5 mM each dNTP), 1.25 
μl each primer (20 μM), 0.2 μl AmpliTaq polymerase, 2.5 μl DMSO (if needed), 1 μl template 
(100 ng/μl DNA or nuclease-free H2O), and nuclease-free H2O to bring the total volume to 25 μl.  
PCR products were analyzed by agarose gel electrophoresis as described above.  In the case of 
two primer sets that gave either no product or one not of the expected size, touchdown PCR was 
utilized.  Reaction components were the same as above, but the cycling conditions were 94oC for 
2 min, followed by 35 cycles of 94oC for 30 sec, annealing temperatures starting at 58oC and 
ending at 43oC declining by 0.5oC per cycle, 72oC for 1 min.  These cycles were then followed 
by 15 cycles of 94oC for 30 sec, 43oC for 30 sec, and 72oC for 1 min with a final extension of 
72oC for 5 min and a holding temperature of 4oC. 
Two-step cDNA Generation and Amplification PCR.  Once conditions were optimized 
for the different primer sets and the genes of interest had been detected in the genomic DNA of 
the phase variants, reverse-transcriptase PCR (RTase-PCR) was used to generate cDNA as 
follows.  First strand cDNA was synthesized from purified total RNA using SuperScript II 
reverse transcriptase (Invitrogen) and a modification of the suggested protocol.  Briefly, 2 μl 
total RNA (100 ng/μl), 2.8 μl random hexamer primer (100 ng), 1 μl dNTP mix (10 mM each; 
Stratagene) and 6.2 μl nuclease-free H2O were combined in a nuclease-free 1.5 ml tube, 
incubated at 60oC for 5 min and then on ice for 2 min, and pulse-centrifuged.  The following 
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were added to each tube: 4 μl of 5X First Strand Buffer, 2 μl 0.1 M DTT, and 1 μl RNasin (40 
U/μl).  Reactions were mixed gently and incubated at RT for 10 min followed by incubation at 
42oC for 15 minutes to equilibrate the mixture.  Then, either 1 μl (200 U) SuperScript II reverse 
transcriptase or 1 μl nuclease-free H2O (negative control to rule out DNA contamination in 
subsequent second strand and amplification PCR; see below) was added, the tube contents were 
mixed gently, and the tubes were incubated at 42oC for 50 min.  Reverse transcriptase was added 
to an additional negative control reaction with nuclease-free H2O as the template to identify 
possible contamination from the recombinant reverse transcriptase.  This control was performed 
in tandem with the other reactions.  Thus, each set of cDNA consisted of two reactions for each 
strain, both containing RNA from that strain, but one having reverse transcriptase and the other 
without reverse transcriptase, as well an overall negative control.  The reactions were inactivated 
by incubation at 70oC for 15 min followed by incubation on ice for 2 min and pulse 
centrifugation.  cDNA was stored at –20oC.   
Second strand and amplification PCR was conducted on the cDNA samples from the 
different time points.  Control reactions with genomic DNA or nuclease-free H2O as the template 
were run in parallel.  These reaction mixtures consisted of 2.5 μl 10X buffer, 1.5 μl  25 mM 
MgCl2, 0.5 μl dNTPs (2.5 mM each dNTP), 0.5 μl each primer (20 μM), 0.2 μl AmpliTaq 
polymerase, 2.5 μl DMSO (if needed), 1 μl template (cDNA, 100 ng/μl genomic DNA, or 
nuclease-free H2O), and nuclease-free H2O to bring the total volume to 25 μl.  The cycling 
parameters were the same as given above except that the PCR ran for only 30 cycles at the 
empirically determined annealing temperature.  Reactions were run in either a Perkin Elmer 
Gene Amp 2400 (24 wells) or a Bio-Rad MyCycler (96 wells).  PCR products were analyzed by 
agarose gel electorphoresis as described above.  Reactions were scored qualitatively: +, if a PCR 
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product was easily visible; 2+ or 3+, if a PCR product was estimated to show one or two levels 
of intensity greater than others in the same set; tr, if a faint (trace) PCR product was visible; 0, if 
no PCR product was observed; and nd, if PCR products were not determined for that set of 
primers.  Each set of reactions was scored independently from other sets, thus the qualitatively 
estimated levels of expression cannot be carried over from one gene to another.    
PCR Gene Linkage Analysis of the Rugose Gene Cluster of V. vulnificus.  To 
determine if the genes in the cluster VVA0389 through VVA0395 in strain YJ016 are linked in 
strain 1003, PCR was conducted on genomic DNA of 1003(O) using various combinations of the 
primers listed in Table 4.3.  Pfu Turbo polymerase (Stratagene) was used and the reaction 
mixtures and run conditions were as directed by the manufacturer. 
RESULTS 
 Identification of CPS and EPS Genes in Phase Variants of V. vulnificus.  Table 4.2 
shows the genes studied, their predicted gene products, and their GenBank accession numbers.  
In the designation of genes in V. vulnificus YJ016, genes on the larger chromosome I are given 
the prefix “VV” while those on the smaller chromosome II are given the prefix “VVA”.  Of the 
genes previously identified as associated with CPS genetic loci in V. vulnificus 1003 (4.47), four 
showed no significant identity to any CPS gene in the sequenced strains YJ016 or CMCP6 as 
determined by a BLAST search.  Those genes, specific to strain 1003, were wcvF, wzx, wcvG, 
and wzy.  The gene immediately preceding these four genes, wcvE, showed identity to 
VVA0391, one in a cluster of genes identified as a paralog of the group 1-like CPS operon 
containing wzaVv in strain YJ016 (4.14).  Interestingly, two other genes from strain 1003, wcvH 
and wcvI were identified as homologs of other genes in the same cluster, VVA0390 and 
VVA0389, respectively.  Not all genes reported to be associated with rugose EPS expression had 
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homologs in either sequenced V. vulnificus strains.  Those genes that did have homologs were 
the ones selected for investigation.   
Primers used in this study generally gave the predicted-size PCR product with genomic 
DNA or cDNA as the template.  However, the primers for VV0341 (RUG3 and RUG4) gave no 
product under any conditions using V. vulnificus genomic DNA as a template while the primers 
for VV0342 (RUG5 and RUG6) gave a PCR product of approximately 300 bp, instead of the 
expected 569 bp.  As the primers were designed from the sequences of VV0341 and VV0342 in 
strain YJ016 and subjected to a BLAST search to determine their uniqueness and correct 
location, the appearance of no product in the case of VV0341 and a different product in the case 
of VV0342 indicated that these genes might not be present in V. vulnificus 1003 and its 
derivatives.  Each set of primers was used in touchdown PCR with genomic DNA from V. 
vulnificus, V. cholerae, or Vibrio parahaemolyticus as the template; the reaction containing the 
primers for VV0341 gave a product of the 159 bp predicted size only in V. cholerae (Figure 4.1), 
indicating that the primers would function in a reaction with matching template.   
The PCR product from the primers for VV0342 was sequenced and the sequence was 
submitted to a BLAST search (data not shown) that revealed the sequence to be of VV1432, a 
gene encoding an ABC-type antimicrobial peptide transport system.  Consequently, it was not 
possible to determine the presence and expression in strain 1003 and its derivatives of VV0341 
and VV0342, genes found in V. vulnificus YJ016 downstream of the wzaVv operon.  Also, wcvA 
has been shown to be necessary for CPS expression in strain 1003(O).  This intact gene was 
detected by PCR in 1003(O), AZ(T), and BG(R), but not, as expected,  in the translucent 
transposon mutant, ABZ1(T), or its rugose derivative, ABZ1(R), both of which contain a 
transposon inserted into the wcvA gene (4.47).   
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phase variants at some point in the life cycle, with expression generally higher in mid-
exponential and late-exponential growth and declining in stationary phase.  ORF4, the gene 
interrupted by a transposon in a previous study (4.47), but shown to be non-essential for CPS 
expression (Chapters 2 and 3) was expressed by all strains at some point in this study.  ORF3,  
Expression of CPS Genes in Phase Variants of V. vulnificus during Different 
Growth Phases: Super-Integron ORFs.  Table 4.4 shows the qualitatively scored expression of 
CPS and EPS related genes by the five phase variants during mid-exponential, late-exponential, 
and stationary phases of the life cycle.  Open reading frames (ORFs) from a region of the V. 
vulnificus super-integron (SI) described in Chapter 2 (see Figure 2.1) were expressed by all  
 FIGURE 4.1.  Genes VV0341 and VV0342 are not present in the genome of V. 
vulnificus 1003(O).  Touchdown PCR was conducted on genomic DNA from three Vibrio spp. 
with primers designed from the genome sequence of V. vulnificus YJ016 specific for the genes of 
interest.  No band was produced in V. vulnificus for VV0341 and the band shown for VV0342 
was not of the expected size.  Annealing temperatures began at 58oC and gradually decreased to 
43oC over 35 cycles.  Reactions contained genomic DNA from the following organisms.  1, V. 
vulnificus 1003(O); 2, V. cholerae ATCC 14035, 3, V. parahaemolyticus 17802; 4, negative 
control.  M, 100 bp marker (New England Biolabs).   
 
    
 M    1       2      3       4       1     2      3      4     M    
VV0341 VV0342 
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TABLE 4.4.  Capsular polysaccharide and rugose exopolysaccharide gene expression in V. vulnificus 1003 phase variants during 
different stages of growth. 
 
 
 Mid-Exponential  Late-Exponential  Stationary Phase 
      
 
 Straina  Strain  Strain 
      
 
Gene O T OR ET ETR  O T OR ET ETR  O T OR ET ETR 
 
 
ΔwcvA tr + tr + tr  + 0 tr + 0  0 0 0 0 tr 
wecA + + + + tr  + tr + + 0  0 0 0 0 0 
wcvB + 2+ + + +  2+ 2+ + 2+ 2+  tr + + + + 
wcvA + + + 0 0  tr tr 0 0 0  0 0 0 0 0 
rmlA 2+ 2+ + + 2+  2+ + + + 2+  0 0 0 0 tr 
rmlD + + + + +  + + + tr tr  0 0 tr + + 
rmlC 2+ 2+ 2+ 2+ 2+  2+ 2+ 2+ 2+ 2+  tr 0 0 tr tr 
wcvE 2+ 2+ 2+ 2+ 2+  2+ 2+ 2+ 2+ 2+  0 0 0 0 tr 
wcvF tr + + + +  + 0 + + tr  0 0 tr 0 tr 
wzx 2+ 2+ 2+ 2+ 2+  2+ 2+ tr 2+ 2+  tr tr tr tr Tr 
wcvG + + + + +  + + tr + +  0 tr tr tr Tr 
wzy + + + + +  + + + tr 0  tr tr tr 0 0 
wcvH tr tr 2+ + 2+  + 0 3+ 0 3+  0 0 0 0 + 
wcvI tr tr + 0 +  0 0 + 0 +  0 0 tr 0 + 
ORF3 2+ + 2+ 2+ 2+  + + + + +  tr tr tr 0 Tr 
ORF2 tr + tr tr 0  tr tr tr tr tr  0 0 tr tr Tr 
ORF4b + + + + +  tr tr 0 tr +  0 tr tr 0 Tr 
ORF4c + + + + +  tr + + tr 2+  0 0 0 0 Tr 
ORF1 + + 2+ + +  2+ + 2+ + 2+  0 tr tr 0 0 
wza 3+ 3+ 3+ 2+ 2+  + + 2+ + 3+  + + + + + 
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TABLE 4.4.  continued 
                 
                 
VV1264 + 2+ 2+ + tr  + + 2+ + 2+  tr tr 0 tr Tr 
VV0341 nd nd nd nd nd  nd nd nd nd nd  nd nd nd nd Nd 
VV0342 nd nd nd nd nd  nd nd nd nd nd  nd nd nd nd Nd 
VV1623 tr tr tr tr tr  0 0 0 0 0  0 0 0 0 0 
VV1625 0 tr 0 0 0  0 0 0 0 0  0 0 0 0 0 
VV2957 + 2+ 3+ + tr  tr 0 0 0 0  0 0 tr tr Tr 
VVA0395 0 0 2+ 0 +  0 0 + 0 2+  0 0 0 0 0 
VVA0394 0 0 3+ tr 3+  0 0 2+ 0 2+  0 0 0 0 0 
VVA0393 tr tr 3+ tr 3+  0 0 + 0 +  0 0 0 0 0 
VVA0392 tr tr 3+ tr 3+  + tr 2+ 0 2+  0 0 + 0 2+ 
VV0897 2+ tr 2+ tr tr  + + + + +  0 0 0 0 0 
VV0898 2+ + 2+ 2+ 2+  tr tr tr 0 0  0 0 0 0 0 
VV0670 2+ 2+ 3+ 2+ 3+  3+ + 3+ + 3+  tr + + tr + 
smcR + 2+ + + tr  2+ 3+ 3+ 3+ 3+  + + + + + 
VV3013 + + + + +  3+ 3+ 2+ 3+ 3+  0 0 tr tr Tr 
VVA0382 0 tr 2+ 0 +  0 0 tr tr 2+  0 0 0 0 Tr 
VVA0391 tr tr 3+ tr 3+  0 0 + 0 2+  0 0 0 0 Tr 
                  
                  
a O, 1003(O); T, AZ(T); OR, BG(R), ET, ABZ1(T); ETR, ABZ1(R); +, PCR product observed; 2+ and 3+, increasingly brighter 
PCR products observed; tr, trace (faint) PCR product observed; 0, no PCR product observed; nd, not determined. 
b ORF4 using primers CAP33 and CAP34. 
c ORF4 using primers CAP33.1 and CAP34.1. 
 
 
 
 
 
 
encoding the Var1 homolog, was expressed at higher levels by all strains other than AZ(T) 
during mid-exponential growth and levels appeared more uniform during late-exponential.  
ORF1 was expressed at an apparently higher level in BG(R) than in the other strains during mid-
exponential growth, but in late-exponential growth, both rugose strains and the opaque strain 
expressed this gene at higher levels than either translucent strain.   ORF2 was expressed at 
apparently higher levels in AZ(T) compared to the other strains during mid-exponential growth.  
Interestingly, the undefined ORF2 and its primers (CAP31 and CAP32; Table 4.3) are within the 
sequence of the IS492 homolog but in the opposite orientation to the transposase.  The sequence 
of primer CAP31 is actually located in the transposase coding region (at bp 464 in the sequence 
described in Chapter 2) near its 5’ end.  The sequence of reverse primer CAP32 is located at bp 
C622 outside the transposase coding region, but still within the IS492 homolog nucleotide 
sequence.  Given that ORF2 overlaps the promoter region for the transposase and is divergently 
transcribed, a revised portion of the left hand end of Figure 2.1 is shown in Figure 4.2.   
     
    
      IS Nucleotide Sequence 
Tpase ORF2 VVR9 
FIGURE 4.2.  The V. vulnificus 1003 IS492 homolog encodes two ORFs.  The 
previously identified transposase gene is in the opposite orientation to the newly identified ORF2 
whose transcription may serve to regulate expression of the transposase and limit transposition.    
 
When the sequence of the SI region shown in chapter 2 was annotated (Appendix Table 
A.1), ORF2 (bp 357 through bp 669) was assumed to be an artifact of transposition, because 
when submitted to a BLAST search, the only homologous protein was the IS transposase.  
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However, expression of ORF2 suggests that it is not an artifact of transposition.  No other ORFs 
have been reported associated with the transposase from IS492 (4.6, 4.7, 4.36).  To discover if a 
similar second ORF is also present in IS492, the 1276 bp sequence of IS492 from 
Pseudoalteromonas atlantica was obtained from GenBank (accession number M24471) and 
aligned with the first 713 bp of the sequence from the SI region and with different portions of 
that 713 bp (the first VVR begins at position 714).  The alignments revealed not only a high level 
of identity between the transposase sequences of strain 1003 and IS492, but also between ORF2 
and sequence within IS492 (Table 4.5; Appendix Figures A.10, A.11, A.12, and A.13). 
 
TABLE 4.5.  Results of nucleotide alignment between IS492 from P. atlantica and V. vulnificus 
1003 SI transposase and ORF2. 
    
    
 Positions showing nucleotide identity  
   
   
 
Position in V. vulnificus IS 
sequence aligned with IS492 
 
P. atlantica 
 
V. vulnificus 
Percent 
nucleotide 
identity 
     
    
    1 – 713 (713 bp)   531 – 1233 (703 bp)     1 – 702 (702 bp) 77 
357 – 713 (ORF2; 357 bp)a   908 – 1233 (326 bp) 379 – 703 (325 bp)   83 
    1 – 509 (Tpase; 509 bp)   531 – 1039 (509 bp)     1 – 509 (509 bp)  73 
510 – 713 (204 bp) 1040 – 1233 (194 bp) 510 – 709 (193 bp) 86 
    
    
a ORF2 is at positions 357 through 669.  Positions 510 through 713 include the 3’ portion of 
ORF2 and nucleotide sequence showing identity to IS492.  Positions 710 through 713 are 
between the IS sequence and VVR9, whose sequence begins at position 714. 
 
 
Using the default setting of an ORF encoding a minimum of 100 amino acids, an ORF 
search of the IS492 sequence revealed only one ORF, the transposase at positions 238 through 
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1192.  When the setting was changed to 50 amino acids, two additional ORFs in the opposite 
orientation to the transposase were revealed; one completely within the transposase at positions 
C326 through C488 (ORF3Pa) and another at positions C195 through C387 (ORF2Pa) that 
overlaps the start position of the transposase and is similar to the position of ORF2 in V. 
vulnificus depicted in Figure 4.2.  This is the first report of ORF2Pa and ORF3Pa; earlier studies 
focused on characterization of IS492 in P. atlantica and mechanisms of its transposition in 
Escherichia coli (4.6, 4.7, 4.36).  
Expression of CPS Genes in Phase Variants of V. vulnificus during Different 
Growth Phases: Nucleotide Sugar Biosynthesis Genes.  As shown in Table 4.4, qualitatively 
scored expression of CPS genes by the five phase variants during mid-exponential growth was 
more universal than for either late-exponential or stationary phase.  The majority of the genes 
identified by Smith and Siebeling (4.47) associated with CPS expression were expressed by the 
five phase variants, including the spontaneous translucent strain, AZ(T).  One expected 
exception was that of wcvA, encoding a nucleotide sugar epimerase (Table 4.2); it was not 
expressed in any growth phase by the translucent wcvA::Tn10 mutant, ABZ1(T), or its rugose 
derivative, ABZ1(R).  Interestingly, a partial homolog of wcvA found in strain 1003, ΔwcvA, 
whose sequence was truncated presumably by an insertion sequence, was expressed in all strains 
during mid-exponential growth with variable expression noted in the later growth stages.  wcvB, 
encoding a nucleotide sugar dehydrogenase, was one of only five genes of the 36 studied to be 
expressed by all phase variants in all growth stages.   
The genes involved in the synthesis of L-rhamnose, rmlA, rmlD, and rmlC, were 
expressed in all variants during mid-exponential and late-exponential growth with expression in 
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stationary phase lower and more variable.  Interestingly, the spontaneous translucent strain 
AZ(T) was the only strain to show no expression of all three genes in stationary phase.    
Expression of CPS Genes in Phase Variants of V. vulnificus during Different 
Growth Phases: Assembly and Transport Genes.  Genes likely to be involved in assembly and 
transport of CPS include the four genes unique to strain 1003 (wcvF, wzx, wcvG, and wzy) as 
well as wecA, wcvE, and wcvI.  The latter two genes have been identified as also associated with 
rugose EPS production and their results will be reported in a later section.  Expression of wcvF, 
encoding a rhamnosyl transferase, was noted in all strains during mid-exponential growth and by 
all except AZ(T) during late exponential growth.  Interestingly, only the two rugose strains 
expressed this gene during stationary phase.  Another transferase gene, wcvG, was expressed by 
all strains throughout exponential growth and surprisingly, in all but the opaque strain during 
stationary phase.  The flippase gene, wzx, was the second of five genes to be expressed in all 
strains during each stage of growth.  The product of this gene is responsible for translocating 
repeat polysaccharide units across the cell membrane (4.47).  The wzy gene encodes a 
polymerase necessary for the elongation of the polysaccharide and it was expressed by all strains 
during mid-exponential growth, but its expression was variable during the other growth stages.  
An initiating glycosyltransferase is encoded by wecA.  As noted for wzy, it was expressed 
universally during mid-exponential phase while expression varied between strains during late-
exponential growth.  Unlike wzy, wecA expression by any variant during stationary phase was 
not dectected.        
The previously identified wzaVv, encoding a CPS transport protein and reported to be 
missing in some translucent strains (4.13, 4.54), was the third gene expressed by all phase 
variants at all time points tested (Figure 4.3).  Expression appeared slightly higher in 1003(O),  
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 FIGURE 4.3.  Gene expression in V. vulnificus phase variants.  A. The CPS exporter gene wza is expressed in all phase 
variants throughout the life cycle.  B.  The rugose EPS regulator gene, vpsR, is also expressed in all phase variants throughout the life 
cycle.  Both genes appear to be expressed at different levels by some of the phase variants at different times during growth.  Shown 
are the results of reverse transcriptase (RTase)-PCR, second strand, and amplification PCR on RNA from five phase variants at three 
different points in the life cycle.  Second strand and amplification PCRs were conducted on cDNA (lanes 1 – 11) made from the 
following RNA-RTase combinations:  1, 1003(O), + RTase; 2, 1003(O), no RTase; 3, AZ(T), + RTase; 4, AZ(T), no RTase; 5, BG(R), 
+ RTase; 6, BG(R), no RTase; 7, ABZ1(T), + RTase; 8, ABZ1(T), no RTase; 9, ABZ1(R), + RTase; 10, ABZ1(R), no RTase; 11, 
H2O, + RTase.  The following lanes represent PCR controls: 12, genomic DNA; N, negative (H2O) control.  M, 100 bp marker; shown 
are the 100 to 500 bp fragments (New England Biolabs); ME, mid-exponential; LE, late-exponential; ST, stationary phase.  
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AZ(T), and BG(R) than in ABZ1(T) and ABZ1(R) during mid-exponential growth, while all 
strains apparently expressed this gene at similar levels during stationary phase.  Interestingly, 
expression of wzaVv by the rugose strains appeared to be higher than that observed in the opaque 
and translucent strains during late-exponential growth.  
Expression of CPS and Rugose EPS Genes in Phase Variants of V. vulnificus during 
Different Growth Phases: Possible Dual Purpose Genes.  Three genes identified as associated 
with CPS production in strain 1003 [wcvI, wcvH, and wcvE (4.47)], were found to have 
homologs in a V. cholerae rugose EPS cluster [the vpsII operon (4.2)] as well as in a paralog of 
the wzaVv operon identified in V. vulnificus YJ016 (4.14).  The expression of wcvE, encoding a 
glycosyltransferase, was uniform in all strains until stationary phase when it was expressed in 
trace amounts by ABZ1(R) only.  Interestingly, ABZ1(T) was the only variant tested that showed 
no expression, at any time point, of the wcvI gene (also encoding a glycosyltransferase), while 
ABZ1(R) did express this gene, previously shown to be required for CPS production in strain 
1003 (4.47).  During late-exponential growth and stationary phase, wcvI appeared to be 
expressed by only the two rugose strains.  While wcvH, encoding an unknown protein, was 
expressed by all phase variants during mid-exponential growth, it was expressed by only the 
opaque and rugose strains during late-exponential growth.  The rugose strains appeared to 
express this gene at higher levels than did the opaque strain. As mentioned, these two genes, part 
of a CPS genetic locus in strain 1003, are also part of a gene cluster associated with rugose V. 
cholerae, so it is not completely surprising that they would be more highly expressed in the 
rugose V. vulnificus strains. 
Expression of Rugose EPS Genes in Phase Variants of V. vulnificus during Different 
Growth Phases: Rugose-Associated Genes.  Expression of genes associated with rugose EPS 
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in V. cholerae showed much more variability between strains here.  VV1264, encoding a protein-
tyrosine phosphatase, was expressed by all strains in both mid-exponential and late-exponential 
growth.  VV1623, encoding an uncharacterized membrane protein, was expressed at very low 
levels and only in mid-exponential growth.  A nearby gene, VV1625, encoding a glycosyltrans-
ferase, showed only trace expression in only AZ(T) at the earliest time point.  This gene was not 
expressed by any other strains or at any other time points.  VV2957, encoding a hypothetical 
protein, was expressed by all strains during mid-exponential growth, but at trace amounts or not 
at all during later growth stages.   
VV0897, encoding a hypothetical protein, was more highly expressed in 1003(O) and 
BG(R) than in either translucent strain or ABZ1(R) during mid-exponential growth, while 
expression appeared to be relatively equal in the five strains during late exponential growth and 
disappeared completely in stationary phase.  VV0898, encoding a serine hydroxymethyltrans-
ferase, appeared to be evenly expressed by all strains in mid-exponential growth, with trace 
amounts only in the opaque strain and the spontaneous translucent and rugose strains during late 
exponential growth; both ABZ1(T) and ABZ1(R) showed no expression of this gene at this time 
point.  No expression was noted in any strain in stationary phase.   
On the second chromosome of strain YJ016, a cluster of genes identified as a low-
identity paralog of the group 1-like operon containing wzaVv (4.14) includes VVA0387 through 
VVA0395.  The arrangement of these genes in strain YJ016 is shown in Figure 4.4.  VVA0387 
and VVA0388 were not identified as homologs of V. cholerae rugose genes in the initial BLAST 
search; thus, they were not included in this study but are shown in Figure 4.4.  Interestingly, 
VVA0389, VVA0390, and VVA0391 from the sequenced strain YJ016 were identified as 
homologs of wcvI, wcvH, and wcvE, respectively, from strain 1003(O).    
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FIGURE 4.4.  Order of the rugose gene cluster in the genome of V. vulnificus YJ016.  Block arrows represent the direction of 
tion of the genes.  Smaller arrows above the genes represent the approximate position of primers used in gene linkage PCR: 
C, CAP primer; R, RUG primer.  Boxes (not to scale) beneath the primer names represent the PCR products obtained with these 
primers and indicate that the associated genes are linked in V. vulnificus 1003.  Block arrow filling represents predicted gene function 
or product: black, transferase genes; horizontal stripes, polysaccharide export; diagonal stripes, biosynthesis genes; white, hypothetical 
or unknown protein; gray, not included in this study. 
 
 VVA0387 VVA0388  VVA0389   VVA0390 VVA0391 VVA0392 VVA0393   VVA0394   VVA0395 
C28 C25 R34  R19 R18 
R16  R13 
R15 
  wcvI         wcvH 
 
 
 
 
 
 
 133
Table 4.6 shows the distribution of these genes (VVA0389 through VVA0395) in Vibrio 
species other than V. cholerae, while Table 4.7 shows their distribution in different strains of V. 
cholerae.  These genes appear to be widespread in species of this genus and, with minor 
exceptions, they also appear to be conserved in both gene order and sequence identity.  It is 
interesting that this cluster of genes has been shown to be required for CPS expression in V. 
parahaemolyticus (4.20).  Expression of genes VVA0389 and VVA0390 in the five V. vulnificus 
phase variants was reported above and will not be mentioned again here.  While wcvE was 
identified as a homolog of VVA0391, the two genes showed different expression patterns in 
strain 1003 and its derivatives.  While wcvE was expressed by all strains, VVA0391 was 
expressed at much higher levels in the two rugose strains than in the opaque or translucent strains 
during mid-exponential growth and by both or only one of the rugose strains in late-exponential 
or stationary phase, respectively.  The same pattern was shown by other genes in this cluster, 
with expression of VVA0392, VVA0393, VVA0394, and VVA0395 (Figure 4.5) much higher in 
the rugose strains during mid-exponential and late-exponential growth than in the other strains.  
In fact, VVA0395, encoding a putative CPS biosynthesis glycosyltransferase, appears to be 
expressed by only rugose strains throughout exponential growth.  Others in this cluster were 
expressed in trace amounts by other strains, but in late-exponential or stationary phase only one 
gene, VVA0392, encoding a putative EPS biosynthesis protein, was expressed in any strain other 
than rugose.  Also, VVA0392 was the only one of these genes to be expressed by both rugose 
strains at all time points.  As this cluster of genes appears to be associated primarily with the 
rugose phenotype, it will be referred to as a rugose gene cluster.   
Expression of CPS and Rugose EPS Genes in Phase Variants of V. vulnificus during 
Different Growth Phases: Regulatory Genes.   Four regulatory genes known to influence the  
TABLE 4.6.  Distribution of rugose-related genes among Vibrio species other than V. cholerae. 
        
        
 Species and strain designation 
        
        
 
 
Gene 
Vibrio 
vulnificus 
YJ016a
Vibrio 
vulnificus 
CMCP6b
Vibrio 
parahaemolyticus
BB22c
Vibrio 
parahaemolyticus 
RIMD 
2210633d
Vibrio 
fischeri 
ES114e
Vibrio 
splendidus 
12B01f
Vibrio sp. 
Ex25f
        
        
wcvI VVA0389 VV21576 cpsI VPA1410 VF0344 23230 01001287 
wcvH VVA0390 VV21577 cpsH VPA1411 none none 01001288 
wcvE VVA0391 VV21578 cpsF VPA1408 VFA1028 23230 01001290 
wzcEc VVA0392 VV21579 cpsD VPA1406 VF0349 23165 01001292 
wzaEc VVA0393 VV21580 cpsC VPA1405 VF0350 23155 01001293 
Hypothetical VVA0394 VV21581 cpsB VPA1404 VF0351 none 01001294 
wcaJEc VVA0395 VV21582 cpsA VPA1403 VF0352 23265 01001295 
        
        
a Genome sequenced by Chen et al. (4.14). 
b Genome sequenced by Kim et al. (4.26). 
c Identified by Guvener and McCarter (4.20). 
d Genome sequenced by Makino et al. (4.29). 
e Genome sequenced by Ruby et al. (4.42). 
f Genome sequencing in progress (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). 
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TABLE 4.7.  Distribution of rugose-related genes among V. cholerae strains. 
        
        
 V. cholerae strains 
        
        
Gene N16961a O395b MO10b V52b V51b RC385b 1552c
        
        
wcvI VC0920 01000388 01001331 01000909 01000830 01000649 vps76 
wcvH none None none none none none none 
wcvE VC0925 01000394 01001326 01000904 01000825 01000654 vps32 
wzcEc VC0937 01000404 01001316 01000894 01000815 01000664 vps65 
wzaEc VC0936 01000403 01001317 01000895 01000816 01000663 vps69 
Hypothetical VC0935 01000402 01001318 01000896 01000817 01000662 none 
wcaJEc VC0934 01000401 01001319 01000897 01000818 01000661 vps54 
        
        
a Genome sequenced by Heidelberg et al. (4.23); gene numbers indicate members of vpsI and vpsII operons (4.2). 
b Genome sequencing in progress (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). 
c Strain in which rugose genes were first identified by Yildiz and Schoolnik (4.59). 
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A. 
 FIGURE 4.5.  Rugose cluster genes VVA0394 and VVA0395 are differentially expressed by V. vulnificus phase variants.   
Gene VVA0394, encoding a hypothetical protein, is expressed by rugose variants throughout exponential growth while ABZ1(T) 
appears to express it in trace amounts during mid-exponential growth.  B. Gene VVA0395, encoding a putative CPS biosynthesis 
glycosyltransferase, is expressed only by rugose variants during exponential growth.  Both genes show no expression by any variant 
during stationary phase. Shown are the results of reverse transcriptase (RTase)-PCR, second strand, and amplification PCR on RNA 
from five phase variants at three different points in the life cycle.  Second strand and amplification PCRs were conducted on cDNA 
(lanes 1 – 11) made from the following RNA-RTase combinations:  1, 1003(O), + RTase; 2, 1003(O), no RTase; 3, AZ(T), + RTase; 
4, AZ(T), no RTase; 5, BG(R), + RTase; 6, BG(R), no RTase; 7, ABZ1(T), + RTase; 8, ABZ1(T), no RTase; 9, ABZ1(R), + RTase; 
10, ABZ1(R), no RTase; 11, H2O, + RTase.  The following lanes represent PCR controls: 12, genomic DNA; N, negative (H2O) 
control.  M, 100 bp marker; shown are the 100 to 500 bp fragments (New England Biolabs); ME, mid-exponential; LE, late-
exponential; ST, stationary phase.  
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expression of the rugose phenotype in V. cholerae were selected for study.  VpsR has been 
shown to upregulate the production of rugose EPS (4.38, 4.57).  Its homolog in V. vulnificus is 
VV0670, which was highly expressed by all strains during mid-exponential growth but still 
highly expressed by only the opaque and rugose strains in late-exponential (Figure 4.3).  All 
strains continued to express this gene at lower levels during stationary phase.  Thus, VV0670 
was the fourth gene to be expressed at some level by all strains at all time points surveyed. 
HapR is a LuxR homolog and when it is knocked out, V. cholerae produces constitutively 
rugose colonies indicating that HapR represses the rugose phenotype (4.25).  SmcR, also a LuxR 
homolog, represses biofilm formation in V. vulnificus and SmcR mutants produce five times the 
amount of biofilm as does the wild type strain (4.32).  As biofilm production is a hallmark of the 
rugose phenotype of V. vulnificus (see Chapter 3), it is interesting that the gene smcR was 
expressed in the rugose strains here at similar levels to those shown in the other strains.  This 
gene has also been shown to be necessary for survival in stationary phase, which may account 
for its apparently uniform expression at that time point.  It was the fifth gene expressed by all 
strains during all time points, with somewhat different levels than those observed for VV0670 
(vpsR). 
Another regulator gene, VV3013, is a homolog for cytR.  CytR also represses the 
expression of the rugose phenotype in V. cholerae and mutants produce constitutively rugose 
colonies (4.21).  As shown for smcR, cytR was expressed in all variants throughout exponential 
growth, also at apparently different levels than those seen for VV0670 (vpsR).  In contrast to 
both vpsR and smcR, the opaque and spontaneous translucent strains were not shown to express 
cytR during stationary phase.   
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VVA0382, encoding a DNA-binding helix-turn-helix domain-containing protein similar 
to VpsT in V. cholerae, was one of several genes located on the second chromosome of V. 
vulnificus YJ016 to be more highly expressed here in the rugose strains, both the opaque-derived 
BG(R) and the translucent-derived ABZ1(R).  VpsT is another regulator of the rugose phenotype 
in V. cholerae, but it has been shown to induce expression of the vps genes.  It was also shown to 
work in concert with VpsR to allow maximum expression of the vps genes and the rugose 
phenotype (4.12).  VVA0382 (vpsT) did not appear to be expressed at as high a level as VV0670 
(vpsR) in the current study. 
Of the 36 genes investigated, only five showed expression by all five phase variants at all 
three time points: wcvB encodes a nucleotide sugar dehydrogenase; wzx encodes a flippase; 
wzaVv encodes a CPS transport protein; VV0670 encodes a σ54-dependent transcriptional 
regulator similar to VpsR of V. cholerae; and smcR encodes a LuxR homolog similar to HapR in 
V. cholerae.  It is interesting to note that three of the five are associated with production of 
CPS/EPS while the latter two are opposite regulators of the rugose phenotype.  The role of these 
five genes in CPS and EPS production throughout the life cycle remains to be determined in V. 
vulnificus.  
PCR Gene Linkage Analysis of the Rugose Gene Cluster of V. vulnificus.  Positions 
of some primers used to determine possible gene linkage in strain 1003 relative to the gene 
cluster of strain YJ016 are shown in Figure 4.4, while the various combinations of all primers 
associated with this region along with their expected and obtained products are shown in Table 
4.8.  Products obtained in the initial gene identification PCRs are indicated by “*”, while those 
obtained in the gene linkage PCRs are indicated by “**”. The results of the first linkage PCR 
experiment, to produce products up to 4 Kb, are shown in Figure 4.6.  Primer combinations 
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TABLE 4.8.  PCR gene linkage primers, their locations in the V. vulnificus YJ016 rugose gene cluster, and estimated product sizes. 
        
        
Primer  
Gene 
Location 
CAP28 
VVA0389/wcvI 
3578 
CAP26 
VVA0390/wcvH 
4349 
RUG34 
VVA0391 
5431 
RUG20 
VVA0392 
6563 
RUG18 
VVA0393 
8747 
RUG16 
VVA0394 
9221 
RUG14 
VVA0395 
11026 
        
        
CAP27 
VVA0389/wcvI 
         C3757 
 
199*a
      
CAP25 
        VVA0390/wcvH 
        C4698 
 
1140** 
 
369* 
     
RUG33 
       VVA0391 
       C5886 
 
2328NP
 
1557NP
 
475* 
    
RUG19 
       VVA0392 
       C6752 
 
3194NP
 
2423NP
 
1341** 
 
209* 
   
RUG17 
       VVA0393 
       C8913 
 
5335ND
 
4584ND
 
3502NP
 
2370NP
 
186* 
  
RUG15 
       VVA0394 
       C9399 
 
5841ND
 
5070ND
 
3988NP
 
2856NP
 
672** 
 
198* 
 
RUG13 
       VVA0395 
       C11168 
 
7610ND
 
6839ND
 
5757ND
 
4625ND
 
2441NP
 
1967** 
 
162* 
        
 
a *,  products obtained in gene detection PCR; **, products obtained in gene linkage PCR; NP, no product obtained in gene linkage 
PCR; ND, not done. 
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 FIGURE 4.6.  Evidence for linkage of rugose-associated genes in V. vulnificus 1003.  
The results of gene-linkage PCR indicate that three sets of genes shown in Figure 4.4 are linked.  
Positive PCRs are indicated with an asterisk.  Primers used in each reaction are as indicated (R, 
RUG; C, CAP): 1, R15+R18; 2, C25+C28; 3, R33+C26; 4, R19+R34; 5, R13+R16; 6, R33+C28; 
7, R19+C26; 8, R17+R20; 9, R15+R20; 10, R13+R18; 11, R19+C28; 12, R17+R34; 13, 
R15+R34.  M, 1 Kb ladder (New England Biolabs) with sizes of pertinent bands shown to the 
left of the gel.    
 
RUG15+RUG18 (lane 1), CAP25+CAP28 (lane 2), RUG19+RUG34 (lane 4), and 
RUG13+RUG16 (lane 5) gave the expected size products (< 2 Kb) shown in Table 4.8, 
indicating that the genes harboring these primer sequences are linked.  In the same order as the 
primers given above, those genes are VVA0393+VVA0394, VVA0389 (wcvI)+VVA039(wcvH), 
VVA0391+VVA0392, and VVA0394+VVA0395.  All reactions designed to produce products 
below 2 Kb in size also produced artifacts of differing sizes.  In the case of RUG13+RUG16, the 
expected size product was a faint band (lane 5) as were the artifacts.  Primer combination 
RUG33+CAP26 produced no product of the expected size (lane 3).  As shown in Figure 4.6, 
none of the reactions designed to produce a product 2 to 4 Kb gave the expected result (lanes 6 
through 13).  It appears from the PCR linkage analysis that VVA0393, VVA0394, and 
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VVA0395 are linked in V. vulnificus 1003, while each of the other two pairs of linked genes 
have not been shown to be linked to each other or the three-gene group.   
DISCUSSION 
The genes associated with CPS and EPS production have been well documented in other 
Gram-negative bacteria, including E. coli, Haemophilus influenzae, Neisseria meningitidis, 
Salmonella typhi, and Klebsiella pneumoniae, among others [reviewed by Roberts (4.40), 
Whitfield and Roberts (4.53), and Whitfield and Paiment (4.52)].  The genes encoding CPS and 
EPS are usually located at a single chromosomal locus that allows for coordinate control of 
CPS/EPS expression.  The identification and study of these genes has begun only recently for V. 
vulnificus. Three of the four gene clusters previously identified in strain 1003 (4.47) were 
reported to be on the same 200 Kb fragment produced by PFGE of NotI digested chromosomal 
DNA, suggesting that those three clusters form a CPS gene locus on the same chromosome in 
this strain.  The fourth gene cluster was located on a segment of the V. vulnificus SI (located on 
chromosome I; Chapter 2), and also found on a 330 Kb fragment in strain 1003(O), but on only a 
260 Kb fragment in strain AZ(T).  These data suggested the genetic rearrangement involving this 
region in AZ(T) may be related to the switch from opaque to translucent colony morphology.  
Another gene investigated here was wzaVv, part of a group 1-like CPS operon (4.54) and located 
on the large chromosome in strain YJ016 (4.14).  Genes involved in rugose EPS production in V. 
cholerae have been shown to be in a cluster containing two linked operons, vpsI and vpsII, found 
in a 27 Kb region of the large chromosome (4.2, 4.59).  Rugose EPS genes as well as CPS/EPS 
regulatory genes that were found to have homologs in the sequenced V. vulnificus strains were 
also selected for investigation here.   
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It was shown that almost all of the genes selected for this study are present and expressed 
in V. vulnificus 1003(O) and its derivatives.  One expected exception was wcvA, disrupted in the 
translucent transposon mutant, ABZ1(T), and its rugose derivative, ABZ1(R).  The presence of 
CPS-associated genes specific to strain 1003 was not unexpected; wcvF, wzx, wcvG, and wzy 
showed only limited homology to CPS/EPS genes in any Vibrio spp. in the databases.  The 
sequenced strain YJ016 possesses no homologs to any of the genes identified in strain 1003 
except wcvH and wcvI (4.14).  With the large number of capsule types possible in V. vulnificus, 
(4.9, 4.22, 4.39)  it is not surprising that different strains possess different genes encoding CPS 
components.   
Nevertheless, it was interesting that strain 1003 and its derivatives do not possess genes 
VV0341 and VV0342.  In strain YJ016, these two genes are downstream of wza (VV0337), wzb 
(VV0339), and wzc (VV0340), genes that comprise the wzaVv operon.  These two genes also 
show homology to two genes in the vpsI operon of V. cholerae.  Scrutiny of the sequence in this 
area of the genome of strain YJ016 revealed that there are three 9 bp tandem repeats upstream of 
VV0337, five 7 bp tandem repeats after VV0341, and two 12 bp tandem repeats after VV0344.  
It has been reported that the wzaVv operon also contains repeat regions associated with loss of 
CPS production (4.13, 4.54).  It is possible that these genes were lost from strain 1003, but as 
their absence does not appear to affect CPS expression in this strain, they may have instead never 
been present in the genome of strain 1003.  Southern hybridization with probes specific for these 
genes would verify their absence or reveal the presence of homologs not identifiable by the more 
stringent PCR.    
It is interesting that all three SI ORFs reported in Chapter 2 were expressed.  None of the 
three had any discernible separate promoter sequence and there was little, if any, space between 
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the start of the ORFs and the end of the preceding VVRs.  However, the associated 5’ VVRs all 
contain sequences that may function as promoters (Appendix Figures A.1, A.2, A.3, and A.4) 
and this function of VVRs has been suggested for similar XXRs in other SIs (4.41).  The 
function of the products of these genes is unknown.  ORF4 was expressed by all variants at some 
time and was shown in Chapter 2 to have no direct relationship to CPS expression.  However, its 
actual role in the cell remains undetermined.  Interestingly, ORF1 is also unique to strain 1003 
(Tables 2.3 and 4.2) and showed higher expression in the opaque and rugose strains than in either 
translucent strain during late-exponential growth.  This uncharacterized ORF may indeed play a 
role in CPS and EPS expression, but that role has yet to be determined.  Var1/ORF3 is the only 
ORF whose predicted product showed homology to a known protein.  Var1 functions as a 
stationary phase regulator in Xenorhabdus nematophilus.  However, with its lower levels of 
expression during stationary phase in V. vulnificus, it is unlikely that its function, if the same, is 
carried out specifically in that stage of the life cycle.  More likely, whatever function it fulfills 
would be during mid-exponential through late-exponential growth, perhaps preparing the cells 
for survival during stationary phase.    
What was surprising, however, was that ORF2 was expressed.  Previously, this ORF had 
been considered to be an artifact of transposition, existing only after the IS transposed into a 
region of the SI that presumably had contained a different ORF native to the SI.  The expression 
of ORF2 is intriguing as its sequence completely overlaps and extends beyond the promoter 
region of the transposase.  Previous studies have dealt with identifying the mechanism of 
transposition of IS492 in E. coli as well as characterizing its distribution in P. atlantica (4.6, 4.7, 
4.36).  Perkins-Balding et al. (4.36) reported that when this element excised itself from a 
plasmid, it formed a circle with a junction formed from the 5 bp target sequence and this junction 
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sequence then acted as a strong promoter that increased transcription of the transposase, but at 
the same time blocked the target sequence so the transposase could not bind, thus lowering the 
rate of transposition.  Conversely, when transposase levels were high, circle formation levels 
were low, indicating a lowered level of excision.  These authors suggested that circle formation 
upon excision may be a way of autoregulation of transposase expression.   
Transposition of mobile elements is usually tightly regulated, as high levels of 
transposition are generally unfavorable to the host and consequently, to the element itself 
[reviewed by Craig (4.15)].  This control can be accomplished best by keeping transcription 
and/or translation of the transposase at a low level, thus ensuring that transposition will be a rare 
event.  The transcription of ORF2 is one way that the levels of transposase may be kept low in 
this IS.  Possibly, the ORF2 transcript may be translated into a protein that binds the promoter 
region of the transposase and blocks transcription or binds to and blocks the recognition 
sequences for the transposase.  The latter case is how transposition of IS1 is controlled (4.61).  
Alternately, both ORF2 and the transposase may be transcribed with the ORF2 transcript (anti-
sense) binding to the complementary sense sequence of the transposase transcript, producing 
double-stranded RNA (dsRNA) and blocking translation of the transposase as occurs in IS10 
(4.11).  It is proposed here that ORF2 does play a role in preventing transposition of the IS492 
homolog in V. vulnificus, by a mechanism yet to be determined.  It is of interest that a similar 
sequence, ORF2Pa, is also found in IS492.  As the mechanism of excision cited above was 
studied using plasmids containing the IS in E. coli, and not the IS in its chromosomal location in 
P. atlantica, this previously undetected ORF may serve an as yet unknown regulatory role in 
preventing transposition of IS492 in its natural host.  IS492 is in the IS110 family of atypical ISs 
(4.28) and the IS in the SI region of V. vulnificus is considered an IS492 homolog, most likely 
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placing it in the same family.  It would be interesting to review other members of this family to 
determine if any similar, oppositely encoded ORFs exist in those elements and what their 
function may be.    
The differences in expression of nucleotide sugar biosynthesis, assembly, and transport 
genes were unremarkable, as these genes and their products are required not only for CPS 
expression, but also LPS and possibly EPS expression.  What is of interest is that these genes are 
expressed universally by all strains during mid-exponential growth and to varying degrees by 
most strains during late-exponential growth [with the exception of wcvA in ABZ1(T) and 
ABZ1(R)].   Expression of almost all of these genes decreased during stationary phase.  These 
results are in agreement with those of Wright et al. (4.55) who reported that CPS expression 
increased during exponential growth and declined during stationary phase.  They used a FITC-
labeled, CPS-specific monoclonal antibody (mAb) to tag cells producing CPS and counted the 
cells at different time points using flow cytometry.  Their translucent transposon mutants did not 
bind the mAb, indicating no CPS expression, whereas a spontaneous translucent strain did bind 
the mAb, showing reduced levels of CPS compared to the opaque strain.     
It would be difficult to pinpoint any one gene from this study expressed only in opaque or 
only in translucent strains.  On occasion, a gene may have been more highly expressed in one or 
the other during a particular stage of growth, only to show the opposite level of expression in a 
different growth stage.  However, there were two genes associated with CPS to show no 
expression at any time point in a translucent strain: wcvA and wcvI in ABZ1(T).   As mentioned 
above, this strain harbors a transposon insertion in wcvA, so that result was expected.  However, 
the lack of expression of wcvI in this strain was unexpected, especially since ABZ1(R) did 
express this gene at all time points.  It is remotely possible that the lack of expression of wcvI in 
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ABZ1(T) is related in some manner to the transposon insertion in wcvA.  These two genes have 
been shown to be located in a 200 Kb portion of the genome of strain 1003, but do not appear to 
be closely linked (4.47).  What is more likely, is that wcvI is required for rugose EPS expression 
as it is expressed by ABZ1(R) and BG(R) at all time points, and by 1003(O) and AZ(T) in trace 
amounts only during mid-exponential growth.  This conclusion is supported by the fact that wcvI 
(and wcvH) shows homology to genes in the vpsII operon of V. cholerae.  Those genes in V. 
vulnificus YJ016 (VVA0387 through VVA0395) constitute a region designated here as the 
rugose gene cluster.  Expression of all genes in this cluster is elevated in, if not exclusive to, the 
rugose strains compared to the opaque and translucent strains.  Interestingly, this cluster has been 
shown to be required for CPS expression as well as expression of a mild rugose colony 
morphology in V. parahaemolyticus (4.20).  As shown here, these genes are expressed in rugose 
strains derived from both opaque and translucent parents, so it appears that their function in CPS 
expression in V. parahaemolyticus is different than their function in rugose EPS expression in V. 
vulnificus. 
The rugose gene cluster is on chromosome II in V. vulnificus YJ016, while the genes 
related to CPS expression are located on chromosome I in both sequenced strains, YJ016 and 
CMCP6 (4.14, 4.26).  The chromosomal location of all of these genes is unknown in strain 1003.  
Since wcvH and wcvI were reported to be linked to the CPS genes in strain 1003, that would 
place the entire 200 Kb region documented by Smith and Siebeling (4.47) most likely on 
chromosome I.  Attempts here to show linkage of the genes in the rugose cluster were successful 
in verifying that wcvH and wcvI are linked, as well as showing linkage of two genes, VVA0391 
and VVA0392, and a separate linkage of three genes, VVA0393, VVA0394, and VVA0395.  
Linkage between the three groups remains to be determined.  In V. parahaemolyticus 
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RIMD2210633, homologs of wcvH and wcvI are in the corresponding gene cluster, but in the 
opposite order from that in V. vulnificus YJ016 (Table 4.6).  It is possible that these two genes in 
strain 1003 are also in a reverse order, yet still in the rugose cluster.  However, the PCR linkage 
results could be interpreted to mean that these gene groups are not linked in strain 1003; but as 
all are involved in expression of rugose EPS, it is more likely that at least two of the three sets 
are linked, while their actual location in the genome relative to the CPS genes remains to be 
determined. 
As longer PCR products have been generated using Pfu Turbo previously in this study 
(Chapter 2), it is unclear why these reactions did not produce the desired products.  Primers used 
in this study were designed from individual gene sequences, not lengthy sequences containing 
many genes.  Consequently, even though the primers matched only one location in the genome 
of YJ016, as determined by a BLAST search, there could be other locations of homology with 
the 3’ end of the primers in the genome of strain 1003, resulting in false priming and the 
generation of artifacts.  Alternately, the genes could be separated by distances in the genome too 
large to be spanned by the PCR conditions, resulting in no products.  It may be necessary to 
design new primers from the entire sequence of the V. vulnificus YJ016 rugose gene cluster 
before continuing with attempts to show linkage using PCR.  Another possible method to show 
linkage would be to use Southern hybridization with probes for the different genes.  This could 
be performed in parallel with PFGE of undigested chromosomal DNA to demonstrate on which 
chromosome the rugose gene cluster resides in strain 1003 and its derivatives.   
It must be stressed that this study was intended to be a preliminary survey of gene 
expression to identify genes of interest for further, in-depth study.  As such, the results were 
reported qualitatively.  Any differences in expression in one strain when others showed no 
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differences or lack of expression when it might have been expected might be attributed to the 
fact that the cDNA was generated using random hexamer primers.  Each batch of cDNA was 
thus randomly generated, which may have excluded some transcripts in some batches, even 
though the same RNA was used.  Generation of cDNA using gene specific primers would 
provide a definitive answer for the expression of any genes in question.  To produce more 
quantitative results on differential expression of these genes, the PCRs from several sets could be 
run on the same gel with a control set and the intensity of the products measured by 
densitometry.  Alternately, real-time PCR (RT-PCR) could be utilized; this approach would most 
likely require that new primers be designed and reactions optimized.  Northern blotting with  
gene-specific probes could also be used to determine if genes in the rugose cluster are co-
expressed, while the products of individual gene expression slot-blots could be quantified by 
densitometry. 
As AZ(T) expressed all genes at some time point, it is evident that the reason for its loss 
of CPS expression has yet to be determined.  As suggested by Smith and Siebeling (4.47), it may 
be related to the genomic rearrangement involving the IS492 homolog.  As the IS appears to 
insert at or near VVRs (Chapter 2), it is possible that a currently unidentified gene required for 
CPS expression at an unknown locus was disrupted by transposition; thus, it is suggested that 
further investigation of this region is warranted.  Specifically, PFGE of NotI digested genomic 
DNA should be conducted to first, replicate the results of Smith and Siebeling, and second, to 
identify the 330 Kb and 260 Kb fragments of 1003(O) and AZ(T) DNA, respectively, for 
excision from the gel.  These fragments could then be digested (and possibly cloned) and 
subjected to Southern hybridization with a probe specific to the IS492 homolog.  Any differences 
revealed could then be investigated further.   
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The expression of CPS and EPS related genes at different times in the life cycle in 
different phase variants of V. vulnificus 1003 has been reported in this study.  A previously 
unknown ORF in IS492 was identified divergent to the transposase and it was shown that the 
similarly divergent ORF2 is transcribed in the IS492 homolog of V. vulnificus.  Also reported is 
the presence of a rugose gene cluster in this species, genes that are expressed by rugose 
derivatives of both opaque and translucent strains.  It is evident from the many questions raised 
by this limited survey of gene expression that there is much work yet to be done to identify 
which genes actually are necessary for CPS and EPS expression in this species.    
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 This work has dealt with the phenomenon of phase variation as displayed by the marine 
bacterium, Vibrio vulnificus, found in association with oysters and other seafood.  It has been 
known for many years that this organism shows two colony morphologies, the encapsulated 
opaque and nonencapsulated translucent phenotypes (5.1), with numerous studies conducted in 
attempts to identify the differences between the two phase variants (5.5, 5.24, 5.30, 5.35-5.37, 
5.40).  The differences are more than just appearance on an agar plate.  The opaque strains are 
virulent and quite deadly for people with certain predisposing conditions; whereas the translucent 
strains are avirulent (5.11, 5.13, 5.23).  The direction and rate of switching between the two 
phenotypes has also been studied, with the opaque to translucent switch reported as occurring 
much more often than the reverse switch (5.16, 5.29, 5.37, 5.38).  The initial goal of this work 
was to study the different phase variants to identify molecular differences between the two 
phenotypes that might allow for the eventual development of a method either to differentiate 
quickly between virulent and avirulent strains in oysters or to develop a treatment for oysters to 
eliminate V. vulnificus before the bivalve mollusks could be eaten by consumers.     
 The initial focus was on a putative transposon mutant that exhibited a translucent colony 
morphology (Chapter 2); the region surrounding the transposon insertion was sequenced, and a 
segment of a super-integron (SI) in V. vulnificus was identified.  Attempts to verify that the 
disrupted gene was necessary for capsule production were futile and, indeed, in Chapter 3 it was 
shown that this particular translucent strain was not a true transposon mutant, but a spontaneous 
translucent strain that had incidentally acquired the transposon.  However, this study as well as 
another (5.30) did result in the identification of an insertion sequence (IS), an IS492 homolog 
that appears to insert at or near the VVRs (V. vulnificus repeats), highly repetitive sequences that 
characterize the SI.  This IS belongs to the IS110 family of atypical ISs and some of them have 
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been shown to insert in or near REP (repetitive extragenic palindromic) sequences found in 
enteric bacteria and others (5.6, 5.26).   
Subsequently, in Chapter 4 it was reported that a second ORF within the IS492 homolog, 
originally thought to be an artifact of transposition into an SI cassette gene, is transcribed 
divergently to the ORF encoding the transposase.  This result suggests a method of controlling 
transposition of this element.  As a similar divergent ORF was identified in IS492 that had not 
been reported previously in the literature, it would be interesting to determine if these additional 
ORFs are found in other ISs of the same family.  It would be interesting to determine if ORF2 
actually does control transposition in the V. vulnificus IS, as is the case with IS10 (5.4).  This 
could be accomplished by first isolating the complete IS, then disrupting ORF2 on a plasmid 
bearing a transposase – lacZ fusion in E. coli and monitoring β-galactosidase levels compared 
with levels from an intact ORF2 plasmid.  For in situ measurement, and in case the IS does home 
in on the VVR sequences, plasmids with or without a disrupted ORF2 could be conjugated into 
V. vulnificus 1003 or another strain shown here to contain this IS and copy number could be 
monitored by Southern hybridization.  To determine if this IS could colonize a naïve strain, both 
constructs could be conjugated (separately) into one of the strains in which it was shown to be 
absent. As Smith and Siebeling (5.30) showed that there was a difference between opaque and 
translucent strains with respect to this IS, it must be considered that this IS may also target 
capsular polysaccharide (CPS) or extracellular polysaccharide (EPS) genes as does IS492, so 
colony morphology should also be monitored in these experiments conducted on V. vulnificus.   
 The switching assay was described in Chapter 3.  It was used to assess conversion 
between phenotypes, and the topic of phase variation in V. vulnificus was complicated further 
with the isolation and characterization of the rugose variant.  It was shown that the latter 
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produces copious biofilms while the opaque and translucent strains produce very little.  These 
biofilms were formed in attachment to glass, on the surface of broth as a pellicle, and on the 
surface of agar as a well differentiated colony with 3-dimensional (3-D) pillars, troughs, and 
channels reminiscent of 3-D biofilm formation in liquid (5.7, 5.31).  It was also reported that 
both opaque and translucent strains can switch to the rugose phenotype and that this phenotype 
appears to be unrelated to CPS expression, as a CPS- translucent transposon mutant produced 
rugose variants.  It was suggested that opaque-derived rugose express CPS and EPS and that 
translucent-derived rugose do not express CPS, only EPS.  In fact, it was also suggested that the 
presence or absence of CPS in all phase variants is what determines their susceptibility or 
resistance, respectively, to killing with NaOCl.     
 To further characterize the rugose variants, it is necessary to determine their virulence 
potential by using an iron-supplemented mouse model.  It was reported here that the rugose 
variants survive better in normal human serum than do their opaque or translucent parents, but 
virulence can only be determined in this mouse model (or a human volunteer).  To differentiate 
between CPS and rugose EPS, these substances should be extracted and subjected to analysis of 
their carbohydrate constituents; that would either support or refute the assertion that they are 
different.  The biofilm-forming ability of these strains should also be tested in such a way that 
the development can be monitored in 3-D.  Plasmids encoding a green fluorescent protein (a 
recent, generous gift from Linda McCarter) should be conjugated into the different strains of V. 
vulnificus and biofilm chambers inoculated and monitored with either confocal scanning laser 
microscopy or deconvolution microscopy.  These plasmids have been used successfully to 
visualize biofilm formation in Vibrio parahaemolyticus (5.3, 5.8, 5.9) and it is likely they will do 
as well in the closely related V. vulnificus. 
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 An initial screening was performed concerning expression in different phase variants for 
genes related to CPS production in V. vulnificus and rugose EPS production in Vibrio cholerae.  
No one gene was shown to be expressed exclusively by opaque or translucent strains, but a group 
of genes expressed at higher levels, or exclusively, by rugose strains was identified.  This rugose 
gene cluster contains three groups of linked genes and the possibility remains that two or all of 
these groups are also linked.  One of these genes, wcvI (VVA0389), previously reported to be 
required for CPS expression in strain 1003 (5.30), was not produced by a translucent strain but 
was produced by the translucent-derived rugose in all stages of growth examined.  It was 
suggested that this gene, along with others in the rugose gene cluster, is required for expression 
of rugose EPS.   Expression of most genes examined was at the highest level during mid-
exponential growth, followed by lower levels in late-exponential growth, and dramatically lower 
levels in stationary phase.  These results agree with an earlier report of CPS expression, as 
measured with monoclonal antibodies specific to CPS, being highest during exponential growth 
(5.36).  Only five of the genes studied were expressed by all variants in all three stages of 
growth, with one additional gene (VVA0392) expressed by the rugose variants at all stages.   
As these results are considered preliminary, there is much more work to be done.  The 
reverse-transcriptase (RTase) PCR should be repeated on a fresh batch of cDNA for any genes 
whose expression was recorded as “0”.  Also, the experiments should be repeated for the genes 
suggested to be rugose specific.  To obtain a better and more quantitative relationship between 
the expression of different genes in different strains, the archived PCRs of interest should be run 
on a single gel, followed with analysis by densitometry.  Real-time (RT) PCR using SYBR 
Green is another excellent option to quantify gene expression in the different variants.  As 
mentioned in Chapter 4, this would most likely require the design of new primers and 
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optimization of reactions, but it would provide not only quantification of expression, but also 
verification of the qualitatively scored RTase-PCR results.  Another option, in lieu of RT-PCR, 
for quantifying differences in gene expression would be northern slot blots which could be 
analyzed by densitometry.  Additionally, to further define expression differences, 2-dimensional 
(2-D) gel elecrophoresis should be conducted on protein extracts from each of the phase variants.  
Any proteins present in one variant and not others would be candidates for further study.   
It is also essential to determine if the genes identified as the rugose gene cluster are 
linked.  Southern hybridization would show linkage in the DNA and northern blotting would 
show not only the size of the transcript, but also could indicate if the message is polycistronic.  
The entire rugose gene cluster, including the two genes not included in this study (VVA0387 and 
VVA0388) should be isolated and sequenced in V. vulnificus 1003(O) and the presence and 
expression of these genes in phase variants of other strains (both clinical and environmental) 
should be investigated using PCR, Southern hybridization, and RTase-PCR.  To further 
characterize which genes are essential for rugose EPS production, targeted mutations should be 
generated of the genes in the rugose gene cluster, as well as in the regulators VpsR, VpsT, CytR, 
and SmcR, with the resulting colonies visually screened for colony morphology and pellicle 
formation in static broth culture.  It may be necessary to subject the transconjugants to the 
switching assay to verify that they do or do not produce rugose colonies.  Random mutagenesis 
would also be useful to identify any additional genes related to CPS and rugose EPS expression.  
We suggest that any putative transposon mutants be subjected to the switching assay.   
 This work began in an effort to better define differences between phase variants of V. 
vulnificus, but instead, those differences were expanded with the identification of the rugose 
variant.  With the gene expression studies, knowledge regarding this phenotype has been 
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increased, but until its pathogenicity has been established, it is just a beautiful curiosity (Figure 
3.2).  Due to its high capacity for biofilm formation, the rugose variant most likely allows a 
portion of the population to survive during adverse environmental conditions.  If it is determined 
to be virulent in the iron-supplemented mouse model, it then becomes a hazard to public health 
like its opaque alternate phenotype.   
 It has been observed that levels of V. vulnificus in seawater and oysters are low during 
cooler months (5.18, 5.25, 5.34) and evidence has been presented that the bacterial cells enter the 
“viable but non-culturable” (VBNC) state at lower temperatures with the ability to be 
resuscitated when temperatures rise (5.22, 5.27).  This may be true for some of the cells, but it is 
possible that some V. vulnificus pass the winter months in biofilms formed as temperatures begin 
to decline, where they are protected from lower temperatures and decreased nutrient availability, 
swapping DNA with each other and other bacterial species likely to be encased in the EPS matrix 
with them.  To date, no studies have been conducted on biofilm formation and maintenance at 
lower temperatures for any Vibrio species.  Horizontal gene transfer (HGT) in the biofilms 
would be possible through any number of methods, including conjugation between two live cells, 
possibly related to active exchange of SI cassettes, plasmids, or other DNA, and uptake of 
exogenous DNA released by dead cells.  HGT is especially likely if the biofilms are formed on 
chitinaceous structures (5.21).  To provide evidence for this assertion, biofilm formation and 
maintenance would need to be studied at different temperatures and on different surfaces, 
including oyster shells, as V. vulnificus has been reported to form biofilms on these surfaces 
(5.32).  Once this information has been established, HGT could be investigated as described for 
V. cholerae (5.21).    
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Based on studies of phase variation in other bacteria, a variety of mechanisms could 
potentially be responsible for the phenotypic switching seen for V. vulnificus.  These 
mechanisms include: genomic rearrangements [seen in AZ(T)] in the form of inversions, 
deletions, or recombination; changes due to insertion or excision of insertion sequences; changes 
in transcriptional or translational control by slipped-strand mispairing; and differential 
methylation (5.14, 5.28, 5.33).  Another possible factor is adaptive mutation, or stationary-phase 
mutation, a process that produces mutations in a bacterial population under stress, starvation, or 
other conditions in which the cells grow slowly or not at all.  The mutations that arise may 
relieve the stress and allow the mutated cells to persist better under the adverse conditions (5.2, 
5.10, 5.17, 5.20).  
 Regarding the possibility that repeated exposure to stationary phase conditions may be 
the stimulus for the phase variation events observed in the switching assay, it is interesting to 
note that, SmcR, a Vibrio harveyi LuxR homologue, was recently identified in V. vulnificus and 
shown to be important for survival under starvation conditions (5.19).  A SmcR mutant was 
reported to produce five times the amount of biofilm as did the parent strain, but no mention was 
made as to the phenotype of the mutant colonies.  The results reported here showed that the gene 
for this regulator was expressed by all phase variants at all time points.  As LuxR and its 
homologs are involved in the regulation of quorum sensing, the possibility exists that this 
phenomenon plays a role in regulation of the rugose phenotype in V. vulnificus, as has been 
reported for V. cholerae (5.12, 5.15, 5.39), and it should be investigated.   
In summary, V. vulnificus is an opportunistic human pathogen capable of causing fatal 
disease in susceptible people.  Although one specific and unique difference between opaque and 
translucent phase variants was not identified, a new rugose phase variant for this species was 
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described, and genes expressed only by this variant were identified.  It was shown that the rugose 
variant produces robust biofilms which may allow V. vulnificus to survive adverse environmental 
conditions and may also contribute to pathogenicity.  Perhaps these results will lead to 
information about all of the phase variants and conditions that serve to stimulate the expression 
of CPS and rugose EPS.  This knowledge could then be used to devise a treatment for oysters 
that would disrupt production of these known and putative virulence factors without adversely 
affecting the quality of the oysters for the consumer.     
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   VVR1              1 -  122   (  122 bps)   Homology 
 
       Sequence  2:   VVR2              1 -  121   (  121 bps)       71% 
       Sequence  3:   VVR3              1 -  123   (  123 bps)       74% 
       Sequence  4:   VVR4              1 -  120   (  120 bps)       76% 
       Sequence  5:   VVR5              1 -  122   (  122 bps)       74% 
       Sequence  6:   VVR6              1 -  122   (  122 bps)       86% 
       Sequence  7:   VVR7              1 -  122   (  122 bps)       72% 
       Sequence  8:   VVR8              1 -  122   (  122 bps)       72% 
       Sequence  9:   VVR9              1 -  122   (  122 bps)       67% 
       Sequence 10:   VVR10             1 -  121   (  121 bps)       75% 
 
Parameters set:  Mismatch =  2;   Open Gap =  4;   Extend Gap =  1 
 
 
 
VVR1           (   1)   TAACAAAGCGTTCAAGAGGGACTTGGCACGCGTGGCATTTTCAATTTGCG 
VVR2           (   1)   TAACAAgGCGTTCAAGAGGGAtTcatgcCGCGTGGCATTTTtggTaTGCG 
VVR3           (   1)   TAACAAgGCGTTCAAGtGGGAtTcatgcCGCGTGGCATTTTtggTaTGCG 
VVR4           (   1)   TAACAAAcaGTTtAAGAGGGAtTcaGCACGCGTGGCATTTTtAgTaTGCG 
VVR5           (   1)   TAACAAgGCGTTCAAGtGGGAtTcGtgcCGCGTGGCATTTTtggTaTGCG 
VVR6           (   1)   TAACAAAGCGTTtAAGtGGGAtTTGGCACGCGTGGCATTTTCggTaTGCG 
VVR7           (   1)   TAACAAgGCGTTCAAGAGGGAtTcatgcCGCGTGGCATTTTtggTaTGCG 
VVR8           (   1)   TAACAAgGCGTTCAAGAGGGAtTcatgcCGCGTGGCATTTTtggTaTGCG 
VVR9           (   1)   TAcaAggcCGTTtAAGtGGGAtTcatgcCGCGTGGCATTTTtggTaTGCG 
VVR10          (   1)   TAACAAActGTTtAAGAGtGAtTcGcaACGCGTGGCATTTTtAcTaTGCG 
 
VVR1           (  51)   -TTGAGT-TT-AG-TGGTTAA-GTTGTCATGCGGTTACTTTTGTATTGCG 
VVR2           (  51)   -gTGAGTaTT-gG-cGGTgAA-tgTGgtcTGCGG--AagTTgGTtTaGgc 
VVR3           (  51)   -gTGAGT-TTtAG-TGGTgAAaGTgGTtcTGCGG-aAggTTgGTtTaGgc 
VVR4           (  51)   -gTGgtT-TT-gG-TGtTgAA-G-TGcCATGCGGcagCTTggtcATTGCG 
VVR5           (  51)   -gTGAGT-TT-cGgTGGTgAA-agTGgCcTGCGGaaAC-TTgGTtTaGgc 
VVR6           (  51)   -TTGgGT-Tc-gG-TGaTTAA-GTcGctgTGCGGTagCTTTTGTATTGCG 
VVR7           (  51)   gTTGttT-TT-gG-TGGTgAA-agTGgtcTGCGGcaggTTggtTtaTGCG 
VVR8           (  51)   -gTGAGT-TT-tGgTGGTgAA-agTGgtcTtCGG-aAggTTgGTtTgGgc 
VVR9           (  51)   -gTGAtT-TT-tGgTGGTgAA-agTGgtcTGCGGaaAgcTggtTtaTGCG 
VVR10          (  51)   -TTGtGT-TT-AG-TGtTTAA-GgTGgtATGCGGaggCaTcgGTATaGCG 
 
VVR1           (  96)   TGCCTGCGCCCCTTAACGCGGCGTTAT 
VVR2           (  95)   gGCaTtCaCCCCTTAACGCaGCGTTAg 
VVR3           (  97)   gGCaTtCaCCCCTTAACGCaGCGTTAg 
VVR4           (  95)   TG-CTtCaCCCCTTAACtgGGCGTTAT 
VVR5           (  96)   gGCactCaCCCCTTAACGCaGCGTTAT 
VVR6           (  96)   TGCCTGCaCCCCTTAACGCGGCGTTAT 
VVR7           (  97)   -GCaTtCaCCCCTTAACGCaGCGTTAT 
VVR8           (  96)   gGCaTtCaCCCCTTAACGCaGCGTTAT 
VVR9           (  97)   -GCaTtCaCCCCTTAACGCaGCGTTAT 
VVR10          (  96)   TtaCT-CaCaCCTTAACagGGCGTTAT 
 
 
 FIGURE A.1.  Nucleotide alignment of 10 VVR sequences against VVR1, a VCR 
homolog.  All sequences show less than 90% identity when aligned against a VCR homolog. 
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   VVR1.TXT          1 -  122   (  122 bps)   Homology 
 
       Sequence  2:   VVR4.TXT          1 -  120   (  120 bps)       76% 
       Sequence  3:   VVR6.TXT          1 -  122   (  122 bps)       86% 
       Sequence  4:   VVR10.TXT         1 -  121   (  121 bps)       75% 
 
Parameters set:  Mismatch =  2;   Open Gap =  4;   Extend Gap =  1 
 
 
 
VVR1.TXT       (   1)   TAACAAAGCGTTCAAGAGGGACTTGGCACGCGTGGCATTTTCAATTTGCG 
VVR4.TXT       (   1)   TAACAAAcaGTTtAAGAGGGAtTcaGCACGCGTGGCATTTTtAgTaTGCG 
VVR6.TXT       (   1)   TAACAAAGCGTTtAAGtGGGAtTTGGCACGCGTGGCATTTTCggTaTGCG 
VVR10.TXT      (   1)   TAACAAActGTTtAAGAGtGAtTcGcaACGCGTGGCATTTTtAcTaTGCG 
 
VVR1.TXT       (  51)   TTGAGTTTAGTGGTTAAGTTGTCATGCGGTTACTTTTGTATTGCGTGCCT 
VVR4.TXT       (  51)   gTGgtTTTgGTGtTgAAG-TGcCATGCGGcagCTTggtcATTGCGTG-CT 
VVR6.TXT       (  51)   TTGgGTTcgGTGaTTAAGTcGctgTGCGGTagCTTTTGTATTGCGTGCCT 
VVR10.TXT      (  51)   TTGtGTTTAGTGtTTAAGgTGgtATGCGGaggCaTcgGTATaGCGTtaCT 
 
VVR1.TXT       ( 101)   GCGCCCCTTAACGCGGCGTTAT 
VVR4.TXT       (  99)   tCaCCCCTTAACtgGGCGTTAT 
VVR6.TXT       ( 101)   GCaCCCCTTAACGCGGCGTTAT 
VVR10.TXT      ( 101)   -CaCaCCTTAACagGGCGTTAT 
 
 
 FIGURE A.2.  Nucleotide alignment of four VVRs identified as VCR homologs.  All 
show 86% or less identity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 169
ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   VVR2.TXT          1 -  121   (  121 bps)   Homology 
 
       Sequence  2:   VVR1.TXT          1 -  122   (  122 bps)       72% 
       Sequence  3:   VVR3.TXT          1 -  123   (  123 bps)       96% 
       Sequence  4:   VVR4.TXT          1 -  120   (  120 bps)       77% 
       Sequence  5:   VVR5.TXT          1 -  122   (  122 bps)       92% 
       Sequence  6:   VVR6.TXT          1 -  122   (  122 bps)       74% 
       Sequence  7:   VVR7.TXT          1 -  122   (  122 bps)       93% 
       Sequence  8:   VVR8.TXT          1 -  122   (  122 bps)       95% 
       Sequence  9:   VVR9.TXT          1 -  122   (  122 bps)       89% 
       Sequence 10:   VVR10.TXT         1 -  121   (  121 bps)       74% 
 
Parameters set:  Mismatch =  2;   Open Gap =  4;   Extend Gap =  1 
 
 
 
VVR2.TXT       (   1)   TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR1.TXT       (   1)   TAACAAaGCGTTCAAGAGGGAcTtggcaCGCGTGGCATTTTcaaTtTGCG 
VVR3.TXT       (   1)   TAACAAGGCGTTCAAGtGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR4.TXT       (   1)   TAACAAacaGTTtAAGAGGGATTCAgcaCGCGTGGCATTTTTaGTATGCG 
VVR5.TXT       (   1)   TAACAAGGCGTTCAAGtGGGATTCgTGCCGCGTGGCATTTTTGGTATGCG 
VVR6.TXT       (   1)   TAACAAaGCGTTtAAGtGGGATTtggcaCGCGTGGCATTTTcGGTATGCG 
VVR7.TXT       (   1)   TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR8.TXT       (   1)   TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR9.TXT       (   1)   TAcaAgGcCGTTtAAGtGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR10.TXT      (   1)   TAACAAactGTTtAAGAGtGATTCgcaaCGCGTGGCATTTTTacTATGCG 
 
VVR2.TXT       (  51)   GTGAGTATTGGCGGTGAATGTGGT-CTGCGG--AA-G--TTGGTTTAGGC 
VVR1.TXT       (  51)   tTGAGT-TTaGtGGTtAAgtTGtc-aTGCGGttAc-t--TTtGTaTtGcg 
VVR3.TXT       (  51)   GTGAGTtTTaGtGGTGAAaGTGGTtCTGCGG--AA-Gg-TTGGTTTAGGC 
VVR4.TXT       (  51)   GTG-GTtTTGGtGtTGAA-GTGcc-aTGCGG--cA-Gc-TTGGTcattGC 
VVR5.TXT       (  51)   GTGAGTtTcGGtGGTGAAaGTGGc-CTGCGG--AA-ac-TTGGTTTAGGC 
VVR6.TXT       (  51)   tTGgGT-TcGGtGaTtAAgtcGcT-gTGCGG--tA-GctTTtGTaTtGcg 
VVR7.TXT       (  51)   GTtgtTtTTGGtGGTGAAaGTGGT-CTGCGG--cA-Gg-TTGGTTTAtGC 
VVR8.TXT       (  51)   GTGAGTtTTGGtGGTGAAaGTGGT-CTtCGG--AA-Gg-TTGGTTTgGGC 
VVR9.TXT       (  51)   GTGAtTtTTGGtGGTGAAaGTGGT-CTGCGG--AAaG--cTGGTTTAtGC 
VVR10.TXT      (  51)   tTGtGT-TTaGtGtTtAAgGTGGT-aTGCGG--Ag-GcaTcGGTaTA-GC 
 
VVR2.TXT       (  95)   GGCATTCACCCCTTAACGCAGCGTTAG 
VVR1.TXT       (  96)   tGCcTgCgCCCCTTAACGCgGCGTTAt 
VVR3.TXT       (  97)   GGCATTCACCCCTTAACGCAGCGTTAG 
VVR4.TXT       (  94)   GtgcTTCACCCCTTAACtggGCGTTAt 
VVR5.TXT       (  96)   GGCAcTCACCCCTTAACGCAGCGTTAt 
VVR6.TXT       (  96)   tGCcTgCACCCCTTAACGCgGCGTTAt 
VVR7.TXT       (  96)   GGCATTCACCCCTTAACGCAGCGTTAt 
VVR8.TXT       (  96)   GGCATTCACCCCTTAACGCAGCGTTAt 
VVR9.TXT       (  96)   GGCATTCACCCCTTAACGCAGCGTTAt 
VVR10.TXT      (  95)   GttAcTCACaCCTTAACaggGCGTTAt 
 
 
 FIGURE A.3.  Nucleotide alignment of 10 VVR sequences against VVR2, a true VVR.  
Sequences of VCR homologs show only 72 – 77% identity to true VVRs.   
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   VVR2.TXT          1 -  121   (  121 bps)   Homology 
 
       Sequence  2:   VVR3.TXT          1 -  123   (  123 bps)       96% 
       Sequence  3:   VVR5.TXT          1 -  122   (  122 bps)       92% 
       Sequence  4:   VVR7.TXT          1 -  122   (  122 bps)       93% 
       Sequence  5:   VVR8.TXT          1 -  122   (  122 bps)       95% 
       Sequence  6:   VVR9.TXT          1 -  122   (  122 bps)       89% 
 
Parameters set:  Mismatch =  2;   Open Gap =  4;   Extend Gap =  1 
 
 
 
VVR2.TXT       (   1)   TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR3.TXT       (   1)   TAACAAGGCGTTCAAGtGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR5.TXT       (   1)   TAACAAGGCGTTCAAGtGGGATTCgTGCCGCGTGGCATTTTTGGTATGCG 
VVR7.TXT       (   1)   TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR8.TXT       (   1)   TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
VVR9.TXT       (   1)   TAcaAgGcCGTTtAAGtGGGATTCATGCCGCGTGGCATTTTTGGTATGCG 
 
VVR2.TXT       (  51)   GTGAGTATTGGCGGTGAATGTGGT-CTGCGGAA-G-TTGGTTTAGGCGGC 
VVR3.TXT       (  51)   GTGAGTtTTaGtGGTGAAaGTGGTtCTGCGGAA-GgTTGGTTTAGGCGGC 
VVR5.TXT       (  51)   GTGAGTtTcGGtGGTGAAaGTGGc-CTGCGGAA-acTTGGTTTAGGCGGC 
VVR7.TXT       (  51)   GTtgtTtTTGGtGGTGAAaGTGGT-CTGCGGcA-GgTTGGTTTAtGCGGC 
VVR8.TXT       (  51)   GTGAGTtTTGGtGGTGAAaGTGGT-CTtCGGAA-GgTTGGTTTgGGCGGC 
VVR9.TXT       (  51)   GTGAtTtTTGGtGGTGAAaGTGGT-CTGCGGAAaG-cTGGTTTAtGCGGC 
 
VVR2.TXT       (  98)   ATTCACCCCTTAACGCAGCGTTAG 
VVR3.TXT       ( 100)   ATTCACCCCTTAACGCAGCGTTAG 
VVR5.TXT       (  99)   AcTCACCCCTTAACGCAGCGTTAt 
VVR7.TXT       (  99)   ATTCACCCCTTAACGCAGCGTTAt 
VVR8.TXT       (  99)   ATTCACCCCTTAACGCAGCGTTAt 
VVR9.TXT       (  99)   ATTCACCCCTTAACGCAGCGTTAt 
 
 
 FIGURE A.4.  Nucleotide alignment of five VVRs identified as true VVRs. 
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FIGURE A.5.  The IS492 homolog is present in multiple copies in V. vulnificus 1003(O).  
Genomic DNA was digested with different restriction enzymes and the probe was a DIG-labeled 
PCR product specific for the IS492 homolog.  U, uncut DNA; 1, HincII; 2, AccI; 3, ScaI; 4, 
HindIII; 5, RsaI; 6, HaeIII; 7, BamHI; 8, XmnI; 9, SalI; 10, KpnI; 11, SacI; 12, XbaI; 13, EcoRI.  
M, marker, DIG-labeled λ HindIII digest (Boehringer).  Numbers to the right of the blot refer to 
the size in Kb of the marker fragments.  
U       1        2        3        4       5       6       7        8       9      10      11      12     13      M 
27.5 
23.1 
9.4 
6.5 
4.4 
2.3 
2.0 
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 FIGURE A.6.  Both O and T strains of 10 CPS serotypes contain VVRs.  Experimental primers were specific for the VVR 
sequence.  Internal control primers were specific to a rRNA gene (rrn).  Strain numbers and their respective CPS serotypes are given 
in Table 2.1.  O, opaque; T, translucent; C, V. vulnificus 1003(O) and BG(T1) (positive controls); N, negative control; M, 100 bp 
marker (New England Biolabs). 
VVR 
rrn 
   M    O   T    O   T    O   T    M    O   T    O    T    O   T    M   O   T     O   T    O   T    M   O   T     O   T    N    M 
   1           2          3                  4          5          6                  7           8           9                 10         C 
       V. vulnificus Capsular Serotypes 
 
 
 
 
 
 
 
 
 
    A B C 
27.5 
23.1 
9.4 
6.5 
4.4 
2.3 
2.0 
M     O     T      O     T        M     O    T 
 
 
 FIGURE A.7.  Southern blots show multiple copies of the IS492 homolog and VVRs, 
but only one copy of ORF4 in V. vulnificus 1003 phase variants.  Copies of the IS are similar in 
their locations to those of the VVRs.  Genomic DNA was digested with XbaI; the probes used 
were DIG-labeled PCR products specific for A. the IS492 homolog, B. the VVR sequences, and 
C. ORF4.  O, 1003(O); T, 1003 BG(T1); M, marker, DIG-labeled λ HindIII digest (Boehringer).  
Numbers to the left of the blots refer to the size in Kb of the marker fragments.  
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 FIGURE A.8.  Nucleotide alignment of SI mini-cassettes.  Mini-cassettes 3, 4, and 5 
show the highest identity; mini-cassettes 2 and 6 show high identity to each other; mini-cassette 
1 is the shortest and shows low identity to the others.    
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   C3-349            1 -  349   (  349 bps)   Homology 
 
       Sequence  2:   C2-350            1 -  350   (  350 bps)       69% 
       Sequence  3:   C4-355            1 -  355   (  355 bps)       82% 
       Sequence  4:   C5-350            1 -  350   (  350 bps)       82% 
       Sequence  5:   C6-354            1 -  354   (  354 bps)       68% 
       Sequence  6:   C1-260            1 -  260   (  260 bps)       40% 
 
Parameters set:  Mismatch =  2;   Open Gap =  4;   Extend Gap =  1 
 
 
 
C3-349         (   1)   GCTTAATCACCTAAAATCAGT-GGTTTATGGTTTTTCTTTGTTCCC-TTG 
C2-350         (   1)   GtTTAATCACgTAAAATaAGT-tGcTTgcacTcTTT-TTTGTTCaC-gca 
C4-355         (   1)   GCTTAATCACCTAAAATCAGT-GGTTTATGGTTTTTCTTTGTTCCC-TcG 
C5-350         (   1)   GCTTAAcCACtTAAAATCAGT-GGTTTATGGTTTTTCTTTGTTCCCgTTG 
C6-354         (   1)   GtTTAATCACgTAAAATCAGTtGGTTgcatGcTTTTCTTTGcTttC-TcG 
C1-260         (   1)   GC---AcCAggTgAAAaatGa-GaccTtTcaaaaTagTcaGcTtaC-TTa 
 
C3-349         (  49)   GCTGATTGGTTTTGTGCTTGTCGGCAAGTTGGCTTCA-GTGGGTGCTGTT 
C2-350         (  48)   GCTttcaaGTTTTtccCTTGTCGGCAAGcTaaaTTCA-GTGGtcGCTGTT 
C4-355         (  49)   GCTtgTTaGTTTcGaGtTTGTCGGCAAGTTGGCTTtt-tTGaacGCTGcT 
C5-350         (  50)   GCTGATTGGTTcTGTGCTTGTCGGCAAGTgGGtTTCA-GTGGGTGCTGTT 
C6-354         (  50)   GCTttcTaaTTTTGgtCTTGTCGGCAAGTTGaCTTCAaGTGatcGtTGTT 
C1-260         (  46)   GCTttTgtcTTggGTGCTT------------------------TGtaGgT 
 
C3-349         (  98)   TTTGGGACATCCATTCTTGGGCGCTACAAATTCTGAGAATTGCCTCAATC 
C2-350         (  97)   TTcaGGACtcCtATTCgcGGGCGCgAaAAATTCaGAGAATTGCCTCAtTg 
C4-355         (  98)   TTTcGGACActtATTCTgtGGCGCTggAAATTCaGAGAATTGCCTCAtTC 
C5-350         (  99)   TTctGGACAaCCATTCTTGGGtGCTACAAA-TCTGAGAAcTGCCTCAATC 
C6-354         ( 100)   TTctGGACtTCgATTCgTGGGCGCTAaAAgTTtaGAGAgTTGCCTCAtTg 
C1-260         (  72)   TTTGtGA-------TtTTataCGtTgCAtggcaacAcAATccgCagcATC 
 
C3-349         ( 148)   AATTTTCG-GT-AAGT--GCGAGGTTAGGTC-GGCGGGCTCAATTAGAAA 
C2-350         ( 147)   AA-aTcCa-GT-gtGTtgGCGAGGagAGtga-aGtGttCTCAAT------ 
C4-355         ( 148)   AATTcTCG-GgcAAGc--GCGAGGTTgGGgC-GG-tGGCTCAATcAGAAA 
C5-350         ( 148)   AATTTTCG-GgcAAGT--GCGAGGTTAGGgCcGGCtGGaTtAATcAGAAA 
C6-354         ( 150)   AAaTccaGaGT-gtag--GCGAGGTgAGtga-aGtGattTtgATTtcAAA 
C1-260         ( 115)   AAT-----------------------------------aTCAtTcgGgAA 
 
C3-349         ( 193)   TTC---------GTTTTTAGGTTTCCAAGTTT-------GAGTGGT---- 
C2-350         ( 187)   TTC---------aaTgTTAGagTTCCAgtTTT-------cgGTttTttac 
C4-355         ( 193)   TcC---------aTTTcTAGGcTTtCAAacTTcaaactaGAtTtGc---- 
C5-350         ( 195)   gTt---------GaTcTTAGtTTTtgctcTTg-------GA-Taac---- 
C6-354         ( 196)   TTtaaagcctcgGTTTTTcGGTTTCtcA---------------cGT---- 
C1-260         ( 130)   gTC---------aTaTT---------gAcTTT-------GgaTacT---- 
 
C3-349         ( 223)   -CAGAATCCCGA-GTCGTGATCAT-CAAAACTATGAGT---AATTTCGGT 
C2-350         ( 221)   gCtaAAaCtCaAtGTtagtAaaAT-CAAAttTATGAGT---tAaTTCaGT 
C4-355         ( 230)   -CAaAATtCCtA--aCcTGAatAT-CAAAACTATGAtT---cATTTCaGT 
C5-350         ( 224)   -CgaAATtCgaA-agtaTGtTttT-CAAAtCTATGAGT---cATTTCaGT 
C6-354         ( 227)   -tAaAActCaaA-GTCagcAcagT-tAAAAtTATGAGT---tAaTTCaGc 
C1-260         ( 151)   -tAG----CtGg-GTtGTGgTtgTtCtggtgTATtAGTgcgAccTTaG-- 
 
C3-349         ( 267)   TTTCTACGCTTTGGCTTTTGTTTGTAAATCATA-GTCGAGTTAA-----T 
C2-350         ( 267)   TTTtTA-GCTTctGgTTTTGgTTtTcAATggTAaGTCGAGTTAAgc---T 
C4-355         ( 273)   TTTCTAaGtTTTGGCTTTTGTTTcTgAATCAaA-GTCGAGTTAA-----T 
C5-350         ( 268)   TTTCTAgGtTTTGGCTTTTGTTTGTgAgcCtaA-GctaAGTTAA-----c 
C6-354         ( 271)   TTTtTAgctTcTaGtTTTgGTTTtcAAAgataA-GTCGAGTTAAgc---T 
C1-260         ( 193)   TTTCTAtGCccgttaTTTgGcTaaTAgcTaAgA-tTC---TTAAgggctT 
 
C3-349         ( 311)   CTTGGTTCTATTAAAACGTAACCCATTGAAGTTTAAGCA 
C2-350         ( 313)   CTTGGTT-TcgTAAAACtTAACCCtTTGAgtcTTAAaCA 
C4-355         ( 317)   CTTGtTcCcAgaAAAACGTAACCCATTGAAGcTTAAGCA 
C5-350         ( 312)   CTTGGTTaTggTAAAACGTAACCCATTGAAGcTTAAGCA 
C6-354         ( 317)   CTTGGTaC-cgTAAAACtTAACCCtTTGAgtcTTAAaCA 
C1-260         ( 239)   CTTGGcTgctcgggAtCGT-----------------GCA 
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 FIGURE A.9.  Results of PCR for VVRs and ORF4.  Lanes 1 – 10 show the presence or absence of VVRs while lanes 11 –21 
show the presence or absence of ORF4.  Note the larger ORF4 PCR products produced in V. vulnificus GMB4(T) compared to strain 
1003(O) and pBG-ORF4.  PCR components were as described in Chapter 2 and reactions were run on a 2% agarose gel.  Primers for 
VVRs were VVR-For and VVR-Rev; primers for ORF4 were 2066-Ext and 2272-Rev (Table 2.2).  Templates used were genomic 
DNA, unless specified otherwise: 1, 11, positive control, V. vulnificus 1003(O); 2, 12, negative control; 3, 20, V. cholerae ATCC 
14035; 4, 21, V. parahaemolyticus 17802; 5, E. coli; 6, Salmonella enterica diarizonae; 7, Citrobacter freundii; 8, Bacillus subtilis; 9, 
B. subtilis phage SP82; 10, Streptomyces lividans TK23.05; 13, V. vulnificus GMB4(T); 14, pBG-ORF4; 15 – 19, plasmids from E. 
coli STBL2(pBG5.2b) transformants.  DNA samples 5 – 10 were a gift from E. C. Achberger, while S. lividans DNA was a gift from 
M. Ducote.  M, marker, 100 bp ladder (New England Biolabs).     
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 FIGURE A.10.  Nucleotide alignment of IS492 from P. atlantica and the IS492 
homolog from V. vulnificus 1003. 
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   i-IS492Pa.txt   531 - 1233   (  703 bps)   Homology 
 
       Sequence  2:   713               1 -  702   (  702 bps)       77% 
 
Parameters set:  Mismatch =  2;   Open Gap =  0;   Extend Gap =  2 
 
 
 
i-IS492Pa.txt  ( 531)   TTCTTAAAG-GCAGTGAG-AATAGGTTTGATGGT-CATGGCGAGTTCTTT 
713            (   1)   TT-TTtgAGtGCAGTcA-agATAGGTTTGATtGaagAT-GCaAG-TgTTc 
 
i-IS492Pa.txt  ( 578)   T-GGTAGAATTTGCAGGCGGTTTTTTTCCATTGTTTGCA-TGACGAGCAA 
713            (  47)   gaGGaAGgATTTGaAGtCGaTTcTTTTCCATcGTTTGaAtTGA-tAGtAA 
 
i-IS492Pa.txt  ( 626)   TTGATTTCGCCTTGCAACTAAATCACTCAT-AGCCTGCATAGTA-TCTGG 
713            (  96)   TTGgTTTCGtCTaGtgACTAAgTCgCTCATtAaaC-GtAT-GTttTCact 
 
i-IS492Pa.txt  ( 674)   TTTTAGTTGAGATAACT-TAGGC-TGAATAGCTTCACCATAATGAGCAAT 
713            ( 144)   TTTTAaTTGcG-TgAgTtTtGGttTG-ATtGCTTCggCgTAgTGgGCAAT 
 
i-IS492Pa.txt  ( 722)   CAATTG-AGCATCTAGTTTGTCTGTT-TTAGCTCG-CTGACCTATCGCCC 
713            ( 192)   -AAgcGccGCATCTAGacgGTC-GTTtTTAGCTttatTG-CCaAgaGCaC 
 
i-IS492Pa.txt  ( 769)   CAGCAAAGCGTTTA-ATGTG-AATGGGATTGGCGACAACGA-AGGGTAAA 
713            ( 239)   CAG-AAAaCtTTTtgATGTGtAATGGG-TTaGCGAtgAC-AtAaGGcAgA 
 
i-IS492Pa.txt  ( 816)   TTAGCATTTGCACACGCGATA--ATAAACGGCATTTCTAATCGGCCAGTT 
713            ( 286)   TTgGCATTTtCACACGC--TAagATgAAtGGCATTTCcAATCGaCCgGTT 
 
i-IS492Pa.txt  ( 864)   GCTTCAATGACGATACGCCCAGGCGAATGCTGTT--GGATTTT-TTTAAT 
713            ( 334)   GCTTCAATaACaATcCGttC-tG-G-ATGaTaTTtaGtAaTagtgcgAAT 
 
i-IS492Pa.txt  ( 911)   GGCTTCTTTGATACCCTTTTCATCGTTAGAAACAGTGA-AATAAATATCG 
713            ( 381)   GGCTTgTTTGATgCCtTTTTCgTCaTTtGtgAC-GTtAaAATAgATATCG 
 
i-IS492Pa.txt  ( 960)   TGAGGGCGGATATAAATATCCAA-TTGAAACTTGCCCGTATCGACACCGA 
713            ( 430)   aGAGGGCGGATATAgATAT-CAAgTTGtgtCTTaCCCGTATCaACgCCGA 
 
i-IS492Pa.txt  (1009)   CGTTAACGCTTTGATTTGTTTTTGGATTCATAATAAGCTAACTCTTGCTT 
713            ( 479)   CaTTAAtGtTTTGAagTGTaTTTGtATTCATAATAAGCTAACTCTTGCTT 
 
i-IS492Pa.txt  (1059)   GC-ATAATGCGGG-TTGAGACCCAGTAGACTATTCGAGTGTTTTGCTTGG 
713            ( 529)   GCgA-AATGCGGGcTcGAGgCCCAGaAGACTATTCGAGTGTgaTGCTTGG 
 
i-IS492Pa.txt  (1107)   AGTCCTTTGTGGTGTTCTTTCTTGTTATCGGTCTCTCAACT-GAGGAGCC 
713            ( 578)   AGTtCTaTcTGaTGTTCgTTCTTGTTATCGGTCTCTCAA-TaGAGGAGCC 
 
i-IS492Pa.txt  (1156)   ATCGCTCAATCGAACTACCACAAA-AGAAGGCTTTAGTTGCTGCTAAAGC 
713            ( 627)   AgCGtTCAATCGAACTAtCAgAtAgAGAA--CTTTAGTTGCaGCTAAAG- 
 
i-IS492Pa.txt  (1205)   T-TGGGTCTCACTTTA-CCTCACCCCGATTA 
713            ( 674)   TcTGGGTCTCACcTTAcCCTgA-ttC-ATTA 
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   i-IS492Pa.txt   531 - 1039   (  509 bps)   Homology 
 
       Sequence  2:   509               1 -  509   (  509 bps)       73% 
 
Parameters set:  Mismatch =  2;   Open Gap =  0;   Extend Gap =  2 
 
 
 
i-IS492Pa.txt  ( 531)   TTCTTAAAG-GCAGTG-AGAATAGGTTTGATGGT-CATGGCGAGTTCTTT 
509            (   1)   TT-TTtgAGtGCAGTcaAG-ATAGGTTTGATtGaagAT-GCaAG-TgTTc 
 
i-IS492Pa.txt  ( 578)   -TGGTAGAATTTGCAGGCGGTTTTTTTCCATTGTTTGCA-TGACGAGCAA 
509            (  47)   gaGGaAGgATTTGaAGtCGaTTcTTTTCCATcGTTTGaAtTGA-tAGtAA 
 
i-IS492Pa.txt  ( 626)   TTGATTTCGCCTTGCAACTAAATCACTCAT-AGCCTGCATAGTATCT--G 
509            (  96)   TTGgTTTCGtCTaGtgACTAAgTCgCTCATtAaaC-GtAT-GT-TtTcac 
 
i-IS492Pa.txt  ( 673)   GTTTTAGTTGAGATAACTT-AGGCT-GAATAGCTTCACCATAATGAGCAA 
509            ( 143)   tTTTTAaTTGcG-TgAgTTttGGtTtG-ATtGCTTCggCgTAgTGgGCAA 
 
i-IS492Pa.txt  ( 721)   TCAATTGA-GCATCTAGTTTGTCTGTTT-TAGCTCGC-TGACCTATCGCC 
509            ( 191)   T-AAgcGccGCATCTAGacgGTC-GTTTtTAGCTttatTG-CCaAgaGCa 
 
i-IS492Pa.txt  ( 768)   CCAGCAAAGCGTTT-AATGTG-AATGGGATTGGCGACAACGA-AGGGTAA 
509            ( 238)   CCAG-AAAaCtTTTtgATGTGtAATGGG-TTaGCGAtgAC-AtAaGGcAg 
 
i-IS492Pa.txt  ( 815)   ATTAGCATTTGCACACGCGATAAT--AAACGGCATTTCTAATCGGCCAGT 
509            ( 285)   ATTgGCATTTtCACACGC--TAAgatgAAtGGCATTTCcAATCGaCCgGT 
 
i-IS492Pa.txt  ( 863)   TGCTTCAATGACGATACGCCCAGGCGAATGCTGT-TGG-ATTTTTT-TAA 
509            ( 333)   TGCTTCAATaACaATcCGttC-tG-G-ATGaTaTtTaGtAaTagTgcgAA 
 
i-IS492Pa.txt  ( 910)   TGGCTTCTTTGATACCCTTTTCATCGTTAGAAACAGTGA-AATAAATATC 
509            ( 380)   TGGCTTgTTTGATgCCtTTTTCgTCaTTtGtgAC-GTtAaAATAgATATC 
 
i-IS492Pa.txt  ( 959)   GTGAGGGCGGATATAAATATCCAA-TTGAAACTTGCCCGTATCGACACCG 
509            ( 429)   GaGAGGGCGGATATAgATAT-CAAgTTGtgtCTTaCCCGTATCaACgCCG 
 
i-IS492Pa.txt  (1008)   ACGTTAACGCTTTGATTTGTTTTTGGATTCAT 
509            ( 478)   ACaTTAAtGtTTTGAagTGTaTTTGtATTCAT 
 
 
 
 FIGURE A.11.  Nucleotide alignment of IS492 from P. atlantica and the 509 bp 
encoding the transposase of the IS492 homolog from V. vulnificus 1003. 
 
 
 
 
 
 
 
 180
ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   i-IS492Pa.txt   908 - 1233   (  326 bps)   Homology 
 
       Sequence  2:   357orf2          22 -  346   (  325 bps)       83% 
 
Parameters set:  Mismatch =  2;   Open Gap =  0;   Extend Gap =  2 
 
 
 
i-IS492Pa.txt  ( 908)   AATGGCTTCTTTGATACCCTTTTCATCGTTAGAAACAGTGA-AATAAATA 
357orf2        (  22)   AATGGCTTgTTTGATgCCtTTTTCgTCaTTtGtgAC-GTtAaAATAgATA 
 
i-IS492Pa.txt  ( 957)   TCGTGAGGGCGGATATAAATATCCAA-TTGAAACTTGCCCGTATCGACAC 
357orf2        (  71)   TCGaGAGGGCGGATATAgATAT-CAAgTTGtgtCTTaCCCGTATCaACgC 
 
i-IS492Pa.txt  (1006)   CGACGTTAACGCTTTGATTTGTTTTTGGATTCATAATAAGCTAACTCTTG 
357orf2        ( 120)   CGACaTTAAtGtTTTGAagTGTaTTTGtATTCATAATAAGCTAACTCTTG 
 
i-IS492Pa.txt  (1056)   CTTGCATAATGCGGGT-TGAGACCCAGTAGACTATTCGAGTGTTTTGCTT 
357orf2        ( 170)   CTTGCgaAATGCGGGctcGAGgCCCAGaAGACTATTCGAGTGTgaTGCTT 
 
i-IS492Pa.txt  (1105)   GGAGTCCTTTGTGGTGTTCTTTCTTGTTATCGGTCTCTCAACT-GAGGAG 
357orf2        ( 220)   GGAGTtCTaTcTGaTGTTCgTTCTTGTTATCGGTCTCTCAA-TaGAGGAG 
 
i-IS492Pa.txt  (1154)   CCATCGCTCAATCGAACTACCACAAA-AGAAGGCTTTAGTTGCTGCTAAA 
357orf2        ( 269)   CCAgCGtTCAATCGAACTAtCAgAtAgAGAA--CTTTAGTTGCaGCTAAA 
 
i-IS492Pa.txt  (1203)   GCT-TGGGTCTCACTTTA-CCTCACCCCGATTA 
357orf2        ( 317)   G-TcTGGGTCTCACcTTAcCCTgA-ttC-ATTA 
 
 
 FIGURE A.12.  Nucleotide alignment of IS492 from P. atlantica and the 357 bp ORF2 
of the IS492 homolog from V. vulnificus 1003. 
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ALIGNED SEQUENCE PRINTOUT 
 
 
Reference molecule:   i-IS492Pa.txt  1040 - 1233   (  194 bps)   Homology 
 
       Sequence  2:   204               1 -  193   (  193 bps)       86% 
 
Parameters set:  Mismatch =  2;   Open Gap =  0;   Extend Gap =  2 
 
 
 
i-IS492Pa.txt  (1040)   AATAAGCTAACTCTTGCTTGC-ATAATGCGGGTT-GAGACCCAGTAGACT 
204            (   1)   AATAAGCTAACTCTTGCTTGCgA-AATGCGGGcTcGAGgCCCAGaAGACT 
 
i-IS492Pa.txt  (1088)   ATTCGAGTGTTTTGCTTGGAGTCCTTTGTGGTGTTCTTTCTTGTTATCGG 
204            (  50)   ATTCGAGTGTgaTGCTTGGAGTtCTaTcTGaTGTTCgTTCTTGTTATCGG 
 
i-IS492Pa.txt  (1138)   TCTCTCAACT-GAGGAGCCATCGCTCAATCGAACTACCACAAA-AGAAGG 
204            ( 100)   TCTCTCAA-TaGAGGAGCCAgCGtTCAATCGAACTAtCAgAtAgAGAA-- 
 
i-IS492Pa.txt  (1186)   CTTTAGTTGCTGCTAAAGCT-TGGGTCTCACTTTAC-CTCACCCCGATTA 
204            ( 147)   CTTTAGTTGCaGCTAAAG-TcTGGGTCTCACcTTACcCTgA-ttC-ATTA 
 
 
 FIGURE A.13.  Nucleotide alignment of IS492 from P. atlantica and the 204 bp 
portion of the IS492 homolog from V. vulnificus1003. 
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TABLE A.1.  Annotation of the 6436 bp sequence of the V. vulnificus SI discussed in Chapter 
2. 
  
  
Location Name or description 
  
  
   C 3 – C509 Transposase; IS492 homolog 
   357 – 669  ORF2 
   714 – 835  VVR9 
  805 – 1198  Var1/ORF3 
1198 – 1319  VVR1; VCR homolog 
1320 – 1579  Mini-cassette 1 
1580 – 1700  VVR2 
1740 – 2775  ORF4; transposon inserted between 2061 and 2062 in GMB4(T) 
2830 – 2950    VVR10; VCR homolog 
2951 – 3300  Mini-cassette 2 
3301 – 3422  VVR8 
3423 – 3771  Mini-cassette 3 
3772 – 3893  VVR7 
3894 – 4248  Mini-cassette 4 
4249 – 4370  VVR6; VCR homolog 
4371 – 4720  Mini-cassette 5 
4721 – 4842  VVR5 
4849 – 5584  ORF1; bases 5585 – 5922 are between end of ORF1 and start of VVR4 
5823 – 5942  VVR4; VCR homolog 
5943 – 6296  Mini-cassette 6 
6297 – 6419  VVR3 
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TABLE A.2.  Restriction maps are different between true VVRs (V. vulnificus repeats) and 
VCR (V. cholerae repeat) homologs in the SI of V. vulnificus 1003. 
            
            
 VVR number and restriction site positions 
            
            
 True VVRs  VCR homologs 
            
            
REa 2 3 5 7 8 9  1 4 6 10 
            
            
AciI 28 28 28 28 28 28  0 0 0 0 
 48 48 48 48 48 48  0 48 0 0 
 61 0 0 0 0 0  0 0 0 0 
 77 78 77 77 0 77  76 75 76 76 
 93 95 94 94 94 94  0 0 0 0 
 0 0 0 0 0 0  113 0 113 0 
AflIII 0 0 0 0 0 0  28 28 28 28 
BbvI 112 114 113 113 113 113  0 78 0 0 
BslI 0 0 0 0 0 0  106 103, 
104 
106 105 
BstUIb 29 29 29 29 29 29  29 29 29 29 
Fru4HI 27 27 27 27 27 27  0 0 0 0 
 0 0 0 77 0 0  0 75, 
78 
0 0 
 93 95 94 94 94 94  0 0 0 0 
 112 114 113 113 113 113  113 0 113 0 
HinfI 20 20 20 20 20 20  0 0 0 0 
HphI 63 63 63 63 63 63  0 99 59 0 
MluI 0 0 0 0 0 0  28 28 28 28 
TfiI 20 20 20 20 20 20  0 20 0 20 
Tru9Ib 0 0 0 0 0 0  0 12 12 12 
 0 0 0 0 0 0  64 0 64 64 
 107 109 108 108 108 108  108 106 108 107 
TseI 112 112 113 113 113 113  0 78 0 0 
            
            
a RE, restriction enzyme; 0, no restriction site. 
b Restriction enzymes BstUI at position 29 and Tru9I at position 106-109 are the only two 
enzymes whose restriction sites are shared by all 10 VVRs at or near the same position.   
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TABLE A.3.  Location and sequence of VVRs in the SI of V. vulnificus 1003. 
   
   
VVR Position (bp) Sequence (5’ to 3’) 
   
   
1 1198 – 1319 TAACAAAGCGTTCAAGAGGGACTTGGCACGCGTGGCATTTTCAATTTGCGTTGAGTTTAGTGGT
TAAGTTGTCATGCGGTTACTTTTGTATTGCGTGCCTGCGCCCCTTAACGCGGCGTTAT 
2 1580 – 1700  TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCGGTGAGTATTGGCGG
TGAATGTGGTCTGCGGAAGTTGGTTTAGGCGGCATTCACCCCTTAACGCAGCGTTAG 
3 6297 – 6419  TAACAAGGCGTTCAAGTGGGATTCATGCCGCGTGGCATTTTTGGTATGCGGTGAGTTTTAGTGGT
GAAAGTGGTTCTGCGGAAGGTTGGTTTAGGCGGCATTCACCCCTTAACGCAGCGTTAG 
4 5823 – 5942  TAACAAACAGTTTAAGAGGGATTCAGCACGCGTGGCATTTTTAGTATGCGGTGGTTTTGGTGTT
GAAGTGCCATGCGGCAGCTTGGTCATTGCGTGCTTCACCCCTTAACTGGGCGTTAT 
5 4721 – 4842  TAACAAGGCGTTCAAGTGGGATTCGTGCCGCGTGGCATTTTTGGTATGCGGTGAGTTTCGGTGG
TGAAAGTGGCCTGCGGAAACTTGGTTTAGGCGGCACTCACCCCTTAACGCAGCGTTAT 
6 4249 – 4370  TAACAAAGCGTTTAAGTGGGATTTGGCACGCGTGGCATTTTCGGTATGCGTTGGGTTCGGTGATT
AAGTCGCTGTGCGGTAGCTTTTGTATTGCGTGCCTGCACCCCTTAACGCGGCGTTAT 
7 3772 – 3893  TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCGGTTGTTTTTGGTGGT
GAAAGTGGTCTGCGGCAGGTTGGTTTATGCGGCATTCACCCCTTAACGCAGCGTTAT 
8 3301 – 3422 TAACAAGGCGTTCAAGAGGGATTCATGCCGCGTGGCATTTTTGGTATGCGGTGAGTTTTGGTGG
TGAAAGTGGTCTTCGGAAGGTTGGTTTGGGCGGCATTCACCCCTTAACGCAGCGTTAT 
9   714 – 835  TACAAGGCCGTTTAAGTGGGATTCATGCCGCGTGGCATTTTTGGTATGCGGTGATTTTTGGTGGT
GAAAGTGGTCTGCGGAAAGCTGGTTTATGCGGCATTCACCCCTTAACGCAGCGTTAT 
10 2830 – 2950  TAACAAACTGTTTAAGAGTGATTCGCAACGCGTGGCATTTTTACTATGCGTTGTGTTTAGTGTTT
AAGGTGGTATGCGGAGGCATCGGTATAGCGTTACTCACACCTTAACAGGGCGTTAT 
 
 
  
  
   
 
 
 
 
 
TABLE A.4.  Nucleotide identity between six mini-cassettes from the SI of V. vulnificus 1003. 
       
       
Mini-
cassettea
1 2 3 4 5 6 
       
1 -      
2 41 -     
3 40 69 -    
4 41 66 82 -   
5 45 65 82 76 -  
6 43 83 68 67 64 - 
       
       
a Identity was determined by pairwise alignments. 
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